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  II 
ABSTRACT	  
 
Non-specific chronic low back pain has serious personal and socio-economic 
consequences. International guidelines recommend multimodal cognitive behavioural 
management (CBT). The effectiveness of CBT might be enhanced by directly 
targeting central nervous system pain processing. Transcranial direct current 
stimulation (tDCS) is a novel approach aiming to influence pain by altering cortical 
excitability.  
 
An evaluation of existing reviews indicated the need for an up-to-date review of 
clinical and experimental pain trials. 
 
A systematic review including 14 trials (published 2006-2012) evaluating tDCS for the 
reduction of clinical and experimental pain identified a low level of evidence for its 
effectiveness. Only 1 trial had a low risk of bias. A meta-analysis of trials on clinical 
pain identified a small pain reducing effect that just reached clinical importance. 
 
To investigate the effectiveness of tDCS alone and in combination with CBT, a 
double-blind RCT was conducted; preceded by a feasibility study confirming 
practicability of trial procedures and patient acceptability of tDCS. Results indicated 
that tDCS alone or in combination with CBT did not significantly influence pain or 
disability.  
 
An updated meta-analysis, including this trial’s results, lowered the pain reducing 
effect of tDCS below clinical importance, and increased the level of evidence for its 
effectiveness to "high".  
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1. CHAPTER	  
 
	  	  	  	  	  INTRODUCTION	  
 
The research presented in this thesis investigates the effectiveness of transcranial 
direct current stimulation (tDCS) for the reduction of chronic non-specific low back 
pain (CNSLBP). CNSLBP is a prevalent condition, associated with personal and 
socio-economic risks and consequences, and with a range of management options. 
International guidelines recommend a multimodal approach to management. The 
efficacy of management programmes might be enhanced by interventions that target 
central nervous system pain processing, which is known to be altered in chronic pain 
states. tDCS is an intervention that electrically influences the function of areas of the 
brain from the outside of the skull and might influence pain processing non-
invasively. This initial chapter provides background to CNSLBP and available 
management approaches; introducing tDCS as a new intervention. The main trial 
reported in this thesis was conducted in Germany, hence information presented in 
this introductory chapter describes the situation internationally with a focus on  
CNSLBP in Germany. 
 
1.1	  Low	  back	  pain	  (LBP)	  
 
LBP is defined as "pain, muscle tension, or stiffness localised below the costal 
margin and above the inferior gluteal folds, with or without pain referred to the leg(s)" 
(van Tulder et al., 2006, p.171). It is one of the most prevalent and expensive 
diseases in Western industrialised countries (Becker et al., 2010) and was the most 
frequent type of pain reported in a survey in the United States in 2002 (Deyo et al., 
1994). A recent systematic review investigating the global prevalence of low back 
pain (Hoy et al., 2012), included 165 studies from 54 countries and estimated the 
mean point prevalence (percentage of persons currently experiencing LBP) of 
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activity-limiting LBP as 12% and the mean lifetime prevalence (percentage of 
persons that experience LBP once or more in their lifetimes) of LBP as 39%. The 
global mean lifetime prevalence was lower than anticipated by the authors due to 
very low rates reported in studies conducted in China, Nepal, Cuba, and Pakistan 
(Hoy et al., 2012). Publications from the United States indicated a much higher point 
prevalence of 20-30% (Deyo et al., 2006) and a 1 month prevalence of 30-68% was 
reported for different European countries (Nachemson, 2004). Estimates in Germany 
were particularly high, with reported values of 37% point prevalence, 76% 1-year 
prevalence, and 86% lifetime prevalence (Schmidt et al., 2007). Higher prevalences 
were consistently reported for high-income countries (Volinn, 1997; Hoy et al., 2012).  
 
The mean total costs per back pain patient in Germany (including acute and chronic 
LBP) were estimated as approximately €1300 per year (Wenig et al., 2009) and 
€1000 for 6 months (Becker et al., 2010) including direct (e.g. health care utilisation) 
and indirect costs (e.g. production losses due to days off work). Wenig et al. 
extrapolated their results to the German adult population and calculated the total 
annual costs of LBP as €48.96 billion, which equates to 2.2% of the German gross 
domestic product, indicating the major impact of LBP on the German economy 
(Wenig et al., 2009).  
 
The majority of LBP is benign (Henschke et al., 2009) and 74-89% of acute LBP 
patients recover after 3-6 months (Chou and Shekelle, 2010). However, LBP can 
have a severe impact on a patient‘s quality of life. For example, approximately 11% 
experience high intensity pain and a further 11% perceive high disability due to LBP 
(Schmidt et al., 2007; Walker et al., 2004). In a recent cross sectional study in the 
Netherlands (Soer et al., 2013), 178 patients with acute LBP rated the mean 
perceived quality of life using the European Quality of Life instrument (EuroQol-D5) 
(Centre for Health Economics, 1990) as 0.43 (standard deviation (SD) =0.29), with 0 
indicating no quality of life and 1 indicating maximum imaginable quality of life.  
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1.2	  Chronic	  low	  back	  pain	  (CLBP)	  
 
Approximately 9-28% of LBP patients develop chronic pain (Grotle et al., 2005; 
Gurcay et al., 2009; Henschke et al., 2008; Balague et al., 2011). This variability  in 
rates for the transition to CLBP can be explained by inconsistencies in the definition 
of CLBP. The most widely used definition for CLBP is ongoing LBP for more than 3 
months (Rozenberg, 2008; Bogduk, 2004; Airaksinen et al., 2006). This definition, 
based only on duration, has been criticised as too simplistic because it neglects the 
psychosocial aspects associated with CLBP (Cedraschi et al., 1999) and does not 
accommodate subgroups of recurrent (Dunn and Croft, 2005) or fluctuating (Tamcan 
et al., 2010) pain. More recent tools developed to identify patients at risk for CLBP 
(The Keele Start Back Screening Tool) (Hill et al., 2008) and chronic musculoskeletal 
pain (Örebro Musculoskeletal Pain Screening Questionnaire) (Linton and Boersma, 
2003) include psychosocial aspects such as fear avoidance beliefs, depression, 
bothersomeness and disability. However, published prevalence rates are still based 
on duration of LBP. Differences in reported prevalence rates also depend on the 
instrument used, e.g. measuring the duration of pain results in higher prevalence 
rates than measuring the duration of work absenteeism (Chou and Shekelle, 2010; 
Ozguler et al., 2000). In a survey of approximately 5000 households in the United 
States, the point prevalence of CLBP has been reported as 3.9% (95% confidence 
interval (CI), 3.4%-4.4%) in 1992 and as 10.2% (95% CI, 9.3%-11.0%) in 2006 
highlighting the rising tendency of CLBP (Freburger et al., 2009). 
 
The mean direct and indirect costs for CLBP in Germany in 2003 / 2004 have been 
recorded as twice as high as the costs for acute LBP in a patient sample with 41% 
CLBP and 59% LBP (Becker et al., 2010) and also twice as high as the costs for age 
and gender matched participants without CLBP (Hong et al., 2013). In addition, 
CLBP has been identified as the disease with the highest overall degree of resource 
use in Canadians under the age of 60 (Rapoport et al., 2004). Annual costs for CLBP 
patients in Germany have been estimated as >€7000, mainly derived from absence 
from work and lost productivity data (Juniper et al., 2009).  
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Further to the economic impact of CLBP, patients exhibit high levels of psychological 
distress, including reduced quality of life (Morone et al., 2011; van Hooff et al., 2011; 
Frettloh et al., 2009), depression (Demyttenaere et al., 2007; Hagen et al., 2006; 
Rush et al., 2000; Currie and Wang, 2004), and sleep disorders (Hill et al., 2008; 
Hagen et al., 2006; O’Donoghue et al., 2009); and are at a high risk of 
musculoskeletal co-morbidities, such as arthropathies or rheumatism (Gore et al., 
2012). 
 
1.2.1	  Chronic	  non-­‐specific	  low	  back	  pain	  (CNSLBP)	  
 
Approximately 85-90% of LBP patients presenting to primary care have no 
diagnosable pathology and are referred to as non-specific low back pain (NSLBP) 
(Hart et al., 1995; Manek and MacGregor, 2005). NSLBP is defined as "tension, 
soreness and/or stiffness in the lower back region for which there is no identifiable 
specific cause" (Balague et al., 2011, p.482). The majority of CLBP has no defined 
source and is therefore generally referred to as CNSLBP (Airaksinen et al., 2006; 
Balague et al., 2011). The European Guidelines for the Management of CNSLBP 
defined the condition as "non-specific low back pain that persists for more than 12 
weeks" (Airaksinen et al., 2006, p.S208). The literature does not clearly distinguish 
between CLBP and CNSLBP regarding prevalence, costs, burden of the disease, 
and management, but implies that CLBP is generally non-specific (Hong et al., 2013; 
Henschke et al., 2009; Juniper et al., 2009). Hence, prevalence and socio-economic 
burden reported in Section 1.2 also refer to CNSLBP. This lack of distinction between 
CLBP and CNSLBP is indicated by the inclusion criteria for CLBP trials that cover all 
types of ongoing LBP rather than specific pathologies (Hong et al., 2013), exclusion 
criteria that include patients with spinal pathologies (Moon et al., 2013), and 
interventions that target central nervous system processing rather than local or 
systemic pathologies (Henschke et al., 2010; Juniper et al., 2009).  
 
For the purpose of this thesis and to promote a clearer distinction between CLBP 
caused by ongoing pathologies (e.g. rheumatoid arthritis, spondylolisthesis, or spinal 
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stenosis) and non-specific CLBP, the term CNSLBP will be used throughout. It is 
defined as pain, tension, soreness, or stiffness in the lower back region (below the 
costal margin and above the inferior gluteal folds, with or without referred leg pain) 
without identifiable cause that persists for a minimum of 12 weeks (Airaksinen et al., 
2006, p.S208). 
 
1.2.2	  Pathogenesis	  of	  CNSLBP	  
 
The pathogenesis of CNSLBP is not fully understood, but multidimensional risk 
factors have been identified for the transition from NSLBP to CNSLBP: 
 
• Physical factors: severe pain at onset (Fransen et al., 2002; Hilfiker et al., 
2007; Valat et al., 1997) and high levels of disability (Fransen et al., 2002). 
 
• Psychological factors: depression, psychological distress, passive coping 
strategies and fear-avoidance beliefs (Pincus et al., 2002; Ramond et al., 
2011; Hilfiker et al., 2007; Carragee et al., 2005; Gatchel et al., 1995; Nicholas 
et al., 2011) as well as pessimistic thoughts about the prognosis (Campbell et 
al., 2013). 
 
• Occupational factors: heavy labour, unavailability of light duties, low levels of 
job satisfaction and poor working conditions (Linton, 2000; Valat et al., 1997; 
Hilfiker et al., 2007; Fransen et al., 2002; Carragee et al., 2005; Gatchel et al., 
1995). 
  
• Social and economic factors: level of schooling, language problems, a low 
income, and an unfavourable family status (Abasolo et al., 2012; Valat et al., 
1997). 
  
• Acute pain itself is also a risk factor for the transition to chronic pain as the 
processing of repeated sensory stimuli leads to a sensitisation of the central 
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nervous system, and subsequently chronic pain (Apkarian et al., 2009; 
Campbell et al., 2013; Seifert and Maihofner, 2009). 
 
1.2.2.1	  Central	  nervous	  system	  processing	  of	  CNSLBP	  
 
In the absence of a peripheral pathology, central sensitisation is the main mechanism 
responsible for the development and maintenance of NSCLBP (Latremoliere and 
Woolf, 2009; Woolf, 2011). Central sensitisation is defined as the “augmented 
responsiveness of the central neurons to input from low-threshold 
mechanoreceptors“ (Meyer et al., 1995, p.13-44). A cascade of events is responsible 
for this altered responsiveness of the central nervous system. The 2 main 
mechanisms are an increased release of excitatory neurotransmitters at spinal level, 
influencing pain perception via the spinothalamic pathway, and an altered top-down 
pain control system from the brain that includes facilitation of nociception and 
reduced pain inhibition (Apkarian et al., 2009; Zhang et al., 2005) (Figure 1.1). At the 
synapses of the spinal dorsal horn, substances such as cytokines, prostaglandins, 
glutamates, substance P, and calcitonin gene-related peptides result in a prolonged 
excitatory state of second order neurones (Bradley, 2008). Analgesia induced as a 
descending mechanism from the brain involves a network of cortical and subcortical 
pathways as well as the endogenous opioid system and the release of adrenergic 
agents (Millan, 2002). 
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The central role of the brain in the maintenance of CNSLBP is reflected by the extent 
of neuroplastic changes reported. The literature distinguishes between structural 
changes that refer to adaptive anatomical changes in volume and location of brain 
regions, and functional changes that describe alterations of the activity of brain 
regions (Davis and Moayedi, 2012). A recent systematic review of reported structural 
and functional changes in chronic pain indicated that the localisation of observed 
changes is independent of the type of pain and that structural and functional changes 
occur in overlapping areas of the brain (May, 2011). Brain areas mutually affected by 
different types of chronic pain are illustrated in Figure 1.2. Additional areas can be 
affected that are specific for the localisation and type of pain. Reported structural 
changes  include reduced grey matter in brain areas associated with pain processing 
(e.g. dorsolateral prefrontal cortex (DLPFC), primary motor cortex (M1), thalamus, 
brainstem, primary somatosensory cortex (S1), and posterior parietal cortex) 
(Apkarian et al., 2004; Buckalew et al., 2008; May, 2008; Schmidt-Wilcke et al., 2006; 
Seminowicz et al., 2011) as well as shifts of the representational areas of the lower 
back on S1 (Flor et al., 1997) or of areas attributed to lumbar spine stabilising 
muscles on M1 (Tsao et al., 2008).  
 
Functional changes in the brain suggest that pain processing for CLBP patients is 
altered compared to healthy controls. Central sensitisation can be observed in 
Figure 1.1 Ascending and descending pain pathways  
 
Footnotes: PAG=periaqueductal grey 
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functional magnetic resonance imaging (MRI) as an increased excitability of pain 
processing regions (Diers et al., 2007; Flor et al., 1995; Kobayashi et al., 2009). 
Recent trials suggest that functional changes are reversible (Flor and Diers, 2009; 
Tsao et al., 2010; Seminowicz et al., 2011) and that structural losses of grey matter 
are not due to irreversible neuro-degeneration as previously hypothesised (Apkarian 
et al., 2004). It might be possible, therefore, to reverse functional changes with 
successful treatment (Rodriguez-Raecke et al., 2009; Seminowicz et al., 2011). 
 
 
 
 
 
 
 
Figure 1.2 Illustration of functional (A) and structural (B) brain changes in chronic pain (May, 2011).  
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1.2.2.2	  Management	  of	  CNSLBP	  
 
1.2.2.2.1	  Multimodal	  pain	  management	  programmes	  
 
International guidelines for the management of CNSLBP recommend cognitive 
behavioural multimodal pain management programmes (CBT) (Koes et al., 2010; 
Airaksinen et al., 2006; Lambert, 2010; Savigny et al., 2009) combining work 
conditioning, behavioural therapy, relaxation techniques and general fitness training. 
The multimodal nature of this approach is required to target the multidimensional risk 
factors for NSCLBP (Section 1.2.2). Central nervous system pain processing 
(Section 1.2.2.1) is addressed by supporting patients' coping with pain and by 
influencing fear avoidance beliefs, function, and disability (Morone et al., 2011). 
Multimodal pain management programmes are expensive but were evaluated as 
cost-effective in relation to the estimated direct and indirect costs associated with 
CNSLBP and in comparison with (for example) surgical management (Rolli Salathe 
et al., 2012). A recent systematic review on physical interventions for CLBP identified 
moderate evidence for the short-term effectiveness of multimodal management 
compared to other kinds of active intervention on pain intensity and work readiness 
(4 randomised controlled trials) (van Middelkoop et al., 2011). However, the pooled 
effect size for pain reduction was low (12 mm on a 0-100 mm VAS for pain) and, at 
both 12 and 24 months post intervention, reduction in pain and change in work 
readiness were reported as not statistically significant in included RCTs. Additional 
approaches to influence the central nervous system, such as graded motor imagery 
or sensory discrimination training have been proposed, to improve effect sizes and 
long-term benefits of multimodal pain management programmes (Moseley and Flor, 
2012; Wand and O’Connell, 2008; Wand et al., 2011). 
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1.2.2.2.2	  Pharmaceutical	  pain	  management	  
 
Unimodal management such as medication are insufficient to improve clinical 
symptoms in CNSLBP. For example, Kovacs et al. reported that usual unimodal 
medical management did not significantly reduce pain in 28% and disability in 37% of 
CNSLBP patients (n=830) (Kovacs et al., 2012). However, pharmaceutical 
interventions are frequently used as an adjuvant intervention in multimodal pain 
management programmes (Dufour et al., 2010; Paolucci et al., 2011; Morone et al., 
2011; Artner et al., 2012). 
 
Two recent overviews of recommendations from international guidelines found that 
guidelines agree on the use of non-steroid anti-inflammatory drugs (NSAIDs), 
opioids, muscle relaxants, and antidepressants for CNSLBP (Dagenais et al., 2010; 
Pillastrini et al., 2011). Due to the common and often severe side effects of these 
drugs (Benyamin et al., 2008; Mago et al., 2008; Roelofs et al., 2008; van Tulder et 
al., 2003), the authors highlighted that medication should be used only for short-term 
pain relief and be accompanied by non-pharmaceutical interventions (Pillastrini et al., 
2011). Another pharmaceutical option is injection therapy, using mainly 
corticosteroids and local anaesthetics. A systematic review evaluating injection 
therapy for subacute and CLBP concluded that there was no strong evidence for or 
against the use of any type of injection therapy (Staal et al., 2008). 
 
1.2.2.2.3	  Neurosurgical	  pain	  management	  
 
In severe cases of chronic pain, neurosurgical pain management is an option to 
influence central nervous system pain processing when all other management 
approaches have failed. The activity of central nervous system neurones that are 
affected in the processing of pain can be altered by changing the electrical load of 
their cell membranes (Hallett, 2000). Electrical stimulators are surgically implanted 
into either the spinal cord or the brain. Spinal cord stimulators (Figure 1.2) have been 
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evaluated as effective, but this conclusion was based on 2 randomised clinical trials 
(RCTs) and 23 observational studies that included patients with failed back syndrome 
(i.e. CNSLBP that did not improve with any available types of management including 
back surgery) (Frey et al., 2009). Deep brain stimulation (DBS) with electrical 
stimulators implanted into the somatosensory thalamus and the periventricular grey 
matter regions (Figure 1.2) had a clinically significant effect (defined as 51% pain 
reduction or more) on the perceived pain intensity of 42 out of 68 CNSLBP patients 
(Kumar et al., 1997) and 80% of patients with failed back syndrome (Bittar et al., 
2005; Rasche et al., 2006). Due to the invasive surgical procedure required for DBS, 
it is increasingly replaced by the less invasive motor cortex stimulation (MCS) (Figure 
1.2) (Levy et al., 2010) that was developed in the 1990s (Tsubokawa et al., 1991). 
MCS is easier to perform, safer and potentially more effective than DBS (Nizard et 
al., 2012). A systematic review and meta-analysis found a pain relieving effect of 
MCS on various types of chronic pain with a mean responder (a patient who 
demonstrated a global response according to the included study’s definition) rate of 
64% (Lima and Fregni, 2008). Patient populations in the reviewed studies included 
spinal cord injuries but no patients with CNSLBP. The advantage of surgically 
implanted electrical stimulators is the avoidance of the systemic adverse effects from 
long-term drug management, but adverse effects including infections, hardware 
problems and seizures have been reported (Fontaine et al., 2009). 
 
 
 A                                                           B                                                             C 
Figure 1.2 Location of stimulation electrodes for DBS (A), MCS (B), and Spinal Cord Stimulation (C) 
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1.2.2.2.4	  Non-­‐invasive	  brain	  stimulation	  	  
 
Recent research has aimed to replicate the pain reducing effect of MCS without 
surgical intervention, by either applying electrical currents through the skull or 
producing a magnetic field that results in an electrical current flow (Hallett, 2000). 
The use of electrical currents was based on historical documents that described how, 
as early as 2750 BC, ancient Egyptians took advantage of the unique characteristics 
of the Torpedo fish. The fish produced electrical shocks that the Egyptians used to 
cure pain e.g. in patients with gout. Hellwag documented, in 1802, how he cured a 
patient with severe headache using galvanic currents (Hellwag, 1802). In the 1950s 
and 1960s, investigators discovered that transcranial electrical stimulation could alter 
the activity of the brain of animals (Burns, 1954; Creutzfeldt et al., 1962; Goldring and 
O’Leary, 1951) but these studies could not be reproduced in humans, and the limited 
technology available at that time was unable to quantify the effects. The application 
of transcranial electrical stimulation was re-visited in the 1990s in animal studies 
(Moriwaki, 1991). It was first applied in humans in 2000 (Nitsche and Paulus, 2000), 
when effects of tDCS could be measured using transcranial magnetic stimulation 
(TMS) or functional magnetic resonance imaging (fMRI). The first trials evaluating the 
effect of tDCS in patients with chronic pain were published in 2006 (Fregni et al., 
2006a, 2006b). These 2 trials acted as a trigger for a series of trials on tDCS for 
different types of pain. 
 
A recent systematic review, published by the Cochrane collaboration, evaluated the 
effect of non-invasive brain stimulation techniques, including tDCS and repeated 
TMS (rTMS), on chronic pain (O’Connell et al., 2010). High frequency single-dose 
rTMS of the M1 resulted in a combined mean effect of 15% pain reduction that just 
reached recommended minimum relevant clinical change. tDCS over M1, similarly, 
resulted in a small but statistically significant reduction of chronic pain. However, the 
authors concluded that available evidence was either of unclear or of high risk of bias 
and included trials with heterogeneous features (I2=71%). Hence, research of high 
methodological quality was required to evaluate the use of tDCS or rTMS as 
interventions for chronic pain conditions.  
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When directly compared, the following advantages of tDCS over rTMS have been 
reported in the literature:  
 
• No serious side effects of tDCS have been reported (Poreisz et al., 2007; 
Nitsche et al., 2003b, 2003c). Reported minor side effects have included mild 
burning, tingling, itching, and stinging at the site of stimulation (Borckardt et 
al., 2011); headaches and tiredness (Nitsche et al., 2003c); or, infrequently, 
nausea or insomnia (Poreisz et al., 2007). rTMS has also been regarded as a 
safe intervention, however, the occurrence of seizures as a serious adverse 
event has been reported (Loo et al., 2008). 
 
• The equipment is smaller, portable, less costly, and easier to handle (Priori et 
al., 2009). Hence, with regards to clinical practice, more clinics could afford 
tDCS as a treatment method and more clinicians would be able to apply the 
technique. Theoretically, self-application by patients would also be possible, in 
a manner similar to transcutaneus electrical nerve stimulation (TENS). 
 
• A sham-paradigm has been established for tDCS that includes a brief period 
of stimulation that is unable to produce a clinical or neurophysiologic effect 
(Nitsche et al., 2003b). The sham stimulation mimics the sensations perceived 
by the patient during the real (verum) stimulation. This might include tingling 
underneath the electrodes or a mild burning sensation. Two publications have 
reported that sham and verum stimulation are indistinguishable (Gandiga et 
al., 2006; Poreisz et al., 2007). Blinding patients in TMS trials is more difficult 
as TMS produces a clicking noise and a typical skin sensation below the coil 
that produces the magnetic field (Loo et al., 2000). 
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1.3	  tDCS	  
 
tDCS is a weak (1-2 mA) direct current produced by a small battery driven device. It 
is applied to the skull via sodium chloride (NaCl) solution soaked sponge electrodes. 
Current flows from the cathode to the anode, thereby inducing positively or negatively 
charged currents at the site of the stimulation (Nitsche et al., 2008). Stimulation of 
M1, for example, modulates the membrane resting potential of local neurones and, 
thereby, induces local excitability changes (Nitsche et al., 2003b). Cortical excitability 
increases under anodal stimulation (positive electrode positioned over M1) and 
decreases during cathodal stimulation (Liebetanz et al., 2002). Motor-evoked 
potentials (MEP) and fMRI confirmed these observations (Bergmann et al., 2009; 
Boros et al., 2008; Kwon et al., 2008). In a Positron Emission Tomography (PET) 
study, Lang et al. (2005) demonstrated that the current induced by tDCS over M1 
affected the structures directly underneath the electrodes as well as neuronal activity 
in remote structures including the thalamic nucleus (Lang et al., 2005). Hence, 
stimulation of accessible superficial structures could also affect more remote 
structures known to be critical for pain processing.  
 
1.3.1	  Proposed	  neurophysiological	  mechanisms	  of	  tDCS	  over	  M1	  for	  the	  reduction	  
of	  pain	  
 
Although neurophysiological explanations for the effectiveness of tDCS over M1 are 
not fully understood, this target area was supported by neurophysiological evidence 
that anodal stimulation increased cortical excitability (Kwon et al., 2008; Liebetanz et 
al., 2002; Kirimoto et al., 2011), that cortical excitability was reduced in patients with 
chronic pain (Mhalla et al., 2010), and that surgically implanted M1 stimulators 
showed pain reducing effects in the past (Lima and Fregni, 2008). M1 is a superficial 
area of the brain positioned on the cortical convexity of the precentral gyrus and, 
therefore, easily accessible (Antal et al., 2011). Furthermore, based on fMRI data, 
M1 has been consistently associated with pain processing (Bingel et al., 2002; Singer 
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et al., 2004), mainly due to the strong thalamic projections found in animal models 
(Hirayama et al., 1990; Yamashiro et al., 1994). 
 
Authors attributed the pain reducing effect to various mechanisms, including 
activation of the endogenous opioid system (DosSantos et al., 2012), influence on 
the emotional appraisal of pain (Garcia-Larrea and Peyron, 2007), and descending 
pain inhibition (Garcia-Larrea and Peyron, 2007; Medeiros et al., 2012; Knotkova et 
al., 2013). Evidence for an activation of the endogenous opioid system is based on 
evidence from an invasive MCS study using PET to indicate increased cebrebral 
blood flow in areas associated with high opioid receptor density, such as the 
periaqueductal grey (Maarrawi et al., 2007). However, only 8 patients were assessed 
in this trial and cerebral blood flow is an indirect measure for endogenous opioid 
release. 
 
Descending pain inhibition or top-down pain control is the most discussed working 
mechanism and was demonstrated in an animal study on rats with experimentally 
induced sciatica pain (Pagano et al., 2010). It is based on the hypothesis that altered 
cortical excitability results in the modulation of a widespread neural network that 
includes the thalamic nuclei, limbic system, brainstem nuclei, and spinal cord 
(Holsheimer et al., 2007). Prolonged non-invasive brain stimulation has been 
reported to result in ongoing effects comparable to long-term depression and long-
term potentiation (Nitsche and Paulus, 2000) explaining the long-lasting effects of 
therapeutic stimulation (Fregni et al., 2006a, 2006b; Mori et al., 2010). Long-term 
depression and long-term potentiation rely on the modulation of the serotonergic 
system (Zhong et al., 2008). The influence of tDCS on the serotonergic system has 
been investigated by pharmaceutically modulating the serotonergic system using 
Citalopram, a selective serotonin re-uptake inhibitor. Citalopram increased and 
prolonged the facilitatory effect of anodal stimulation and reversed the inhibitory 
effect of cathodal stimulation, indicating an interaction of tDCS and the serotonergic 
system as well as proposing an enhanced therapeutic effect when combining anodal 
stimulation with Citalopram (Nitsche et al., 2009). 
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Further neurophysiological systems have been reported to play a role in pain 
reduction following tDCS, such as the glutamatergic, GABAergic, dopaminergic, and 
cholinergic systems (Medeiros et al., 2012; Tremblay et al., 2013; Stagg et al., 2009).  
 
The interaction between the glutamatergic system and the GABAergic system 
following tDCS stimulation has been investigated intensively by Stagg et al. (2009). 
Glutamate and GABA are the two principal neurotransmitters mediating respectively 
excitatory and inhibitory signals in the CNS (Ciranna, 2006). Reductions of GABA 
levels result in increased glutamatergic activity (Stagg et al., 2009), thereby allowing 
for brain plasticity to occur (Sanacora et al., 2008; dos Santos et al., 2012). Evidence 
from magnetic resonance spectroscopy indicates that anodal tDCS reduces GABA 
and increases glutamatergic neuronal activity (Stagg et al., 2009), explaining the 
excitatory effects of anodal stimulation. Pharmacological studies using NMDA 
receptor (glutamatergic) blocking medication, such as ketamine, confirm this effect of 
tDCS on the glutamatergic system (Nitsche et al., 2003a).  
 
Top-down pain control ist therefore hypothesised to rely on the excitation of the pain 
inhibitory network through various pathways including the immediate activation of 
local and distant brain areas associated with pain inhibition as well as the 
involvement of various neurotransmitter systems that might explain the reported long-
term effects of tDCS. Further details on neurophysiological working mechanisms are 
provided in the Discussion chapter (Section 8.8). 
 
1.3.2	  tDCS	  parameters	  (duration	  and	  frequency)	  
 
The duration and frequency of tDCS applications influence the duration of observed 
neurophysiological changes. Nitsche and Paulus (2001) demonstrated that 5-7 
minutes stimulation of 1 mA anodal tDCS changed MEP amplitudes for up to 5 
minutes. When stimulation was continued for 13 minutes, amplitude changes were 
maintained for up to 90 minutes with stable effects during that period of time. Effects 
gradually reduced, returning to baseline after 150 minutes (Nitsche and Paulus, 
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2001). Monte-Silva et al. (2010) postulated that repeating the stimulation could 
prolong M1 excitability changes. The longest effects were observed when the second 
stimulation was applied while excitability changes from previous stimulations were 
still ongoing (Monte-Silva et al., 2010). In a rat model, a lasting effect of tDCS on 
chronic inflammation was demonstrated for ≥24 hours after an 8-day period of 
stimulation (Laste et al., 2012). Trials that applied tDCS to patients with chronic pain 
reported that significant pain reducing effects (compared to sham stimulation) 
occurred after 2-3 days of daily stimulation (Antal et al., 2010; Fregni et al., 2006b) 
and were maintained for ≥3 weeks post stimulation (Fregni et al., 2006a, 2006b). 
Stimulation parameters used in trials evaluating chronic pain were commonly 20 
minutes of stimulation on 5 consecutive days. However, trials investigating the 
clinical use of tDCS for the reduction of pain employed small sample sizes (maximum 
of 11 patients per group) (Fregni et al., 2006a, 2006b) and mixed parallel group and 
crossover-design within 1 trial (Antal et al., 2010). These trials were described as 
exploratory (Antal et al., 2010) or proof of principle (Fregni et al., 2006b) and their 
pain reducing results can be regarded as propositions for future research, but 
effectiveness remains to be evaluated in large scale, methodologically sound, 
randomised controlled trials. Furthermore, the most effective stimulation parameters 
remain to be investigated. 
 
1.3.3	  tDCS	  combined	  with	  other	  treatment	  modalities	  
 
Recent research suggests that the pain reducing effect of traditional interventions 
was enhanced by applying tDCS as an adjuvant intervention. For example, when 
used as a priming technique to an rTMS protocol, tDCS modulated pain thresholds in 
healthy volunteers (Moloney and Witney, 2013). The combination of tDCS and TENS 
resulted in a pain reducing effect in patients with chronic pain that was significantly 
larger than the effect of each intervention alone (Boggio et al., 2009a), and tDCS 
applied in combination with a multidisciplinary programme improved the perceived 
level of pain of patients with fibromyalgia (Riberto et al., 2011). As with the trials on 
tDCS alone, clinical trials showed methodological limitations such as small sample 
sizes and inappropriate study designs. For example, in a crossover trial, Boggio et al. 
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applied all conditions to participants (n=8) with only a 48-hour interval between 
interventions to wash out intervention effects. Since neurophysiological effects might 
have been ongoing (Section 1.3.2), this trial design could provide erroneous results 
(Boggio et al., 2009a). Riberto et al. used a sample size calculation based on the 
outcome measure VAS for pain but reported a secondary outcome measure (SF-36) 
as the main result (Riberto et al., 2011). Hence, the trial was not adequately powered 
to evaluate the effectiveness of tDCS as an adjuvant intervention for pain reduction. 
 
 
Chapter Summary  
 
This chapter introduced CNSLBP with its serious personal and socio-economic 
consequences. International guidelines recommended multimodal management. 
Based on the knowledge that pain processing within the central nervous system is 
altered in patients with CLBP, interventions that target pain processing might 
enhance the effect of multimodal management programmes. tDCS is a non-invasive 
option, with no known serious side effects. However, its effectiveness, as a single 
intervention or combined with multimodal management for the reduction of CNSLBP 
is unclear. Researchers used different stimulation parameters for different types of 
pain. To gain a comprehensive overview of the current available evidence, it was 
important to initially summarise all published reviews on tDCS for the reduction of 
pain.  
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2. CHAPTER	  
	  
OVERVIEW	  OF	  PUBLISHED	  REVIEWS	  OF	  TDCS	  FOR	  THE	  
REDUCTION	  OF	  PAIN	  
 
Chapter 1 introduced CNSLBP with its associated serious socio-economic 
consequences and significant impact on patients' quality of life. tDCS was introduced 
as an evolving intervention designed to target pain processing within the brain. The 
recent scientific interest in this intervention is illustrated by the number of publications 
in this field within a short period of time (16 entries in PubMed between 2006 and 
2008). Germany hosted its third International Conference on TMS and tDCS in 
Goettingen in 2008 and a new scientific journal (Brain Stimulation, published by 
Elsevier) was launched in the same year. Hence, before planning new research in 
this area, it was important to critically appraise existing research to gain an overview 
of the current level of evidence and to identify gaps requiring further investigation. 
Consequently, a literature review was conducted to initially synthesise published 
reviews (and subsequently clinical trials) to evaluate the effectiveness of tDCS for the 
reduction of pain. This chapter describes the process followed to identify and critically 
appraise published reviews and discusses the findings of individual reviews as well 
as drawing overall conclusions from this evidence.  
	  
2.1	  Introduction	  
 
At commencement of the research reported in this thesis (September 2009), tDCS 
for the reduction of pain was a rapidly evolving area of research. In September 2010, 
the Cochrane Collaboration published a systematic review and meta-analysis on 
different non-invasive brain stimulation techniques, including 6 trials on tDCS for the 
reduction of various types of chronic pain (O’Connell et al., 2010). No trial was 
included that evaluated the effectiveness of tDCS for CNSLBP. An initial scoping 
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search of the literature further identified non-systematic reviews that focussed on the 
neurophysiological impact of brain stimulation or its effectiveness for different clinical 
or experimental conditions. Reviews focussed on different aspects of the topic and 
reported different conclusions for similar research questions. Consequently, a 
comprehensive overview of the existing reviews was required to summarise key 
findings on a) the focus and content of existing reviews and b) the methodological 
quality of published reviews, to subsequently summarise the current evidence  and 
evaluate the overall level of evidence for the effectiveness of tDCS for the reduction 
of pain. The objective of this overview of reviews was therefore to identify, critically 
appraise, and summarise existing reviews on tDCS for the reduction of pain. 
 
2.2	  Methods	  	  
 
The overview of reviews was prepared following the guidelines in Chapter 22 of the 
Cochrane Handbook on Overviews of Reviews  (Becker and Oxman, 2008). 
 
2.2.1	  Eligibility	  criteria	  	  for	  review	  inclusion	  
 
• Participants of trials included in reviews satisfied the following criteria: 
Patients had a clinical pain condition or were healthy participants exposed to 
a type of experimental pain. Both clinical and experimental types of pain were 
included because a scoping search of the literature revealed that only a small 
number of trials on clinical pain conditions had been published on tDCS and 
no trials were available that focussed exclusively on tDCS for the reduction of 
LBP. Reviews identified in the scoping search typically focussed on both 
healthy participants and participants experiencing clinical pain (Nitsche et al., 
2008; Rosen et al., 2009). Experimental pain research has the advantage of 
using standardised pain procedures and greater reproducibility (Cavallone et 
al., 2013). Results from experimental pain trials can inform trials on clinical 
pain and thereby contribute to the overall evidence on tDCS for pain 
reduction. A comprehensive overview of the current level of evidence on 
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tDCS for the reduction of pain therefore required the inclusion of all types of 
pain. 
 
• Interventions applied in trials included in reviews satisfied the following 
criteria: tDCS was defined as an electrical stimulation using direct current, 
applied to the outside of the skull (Nitsche et al., 2008). Reviews were 
excluded if they focussed on TMS or other types of transcranial electrical 
stimulation that used pulsed or alternating currents. 
 
• Control groups in trials included in reviews satisfied the following 
criteria: Included trials had to include a sham or placebo group. Hence, 
reviews that reported only case studies were excluded. 
 
• Outcome measures in trials included in reviews satisfied the following 
criteria: The primary outcome of interest was pain intensity, measured on a 
VAS, a numerical rating scale (NRS), or using a pain evaluation 
questionnaire. Reviews were excluded if they primarily focussed on the 
neurophysiology of tDCS or on outcome measures other than pain. 
 
• Types of review: An initial scoping search demonstrated that the majority of 
published reviews were narrative in nature. To gain a comprehensive 
overview of the topic, systematic and non-systematic reviews were included 
that focussed on effectiveness of brain stimulation for pain and included ≥1 
trial on tDCS for the reduction of pain.  
 
• Language of publication of reviews: Review articles had to be published in 
English or German language.  
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2.2.2	  Search	  methods	  	  
 
The search for reviews evaluating the effectiveness of tDCS for the reduction of pain 
was conducted on 15th September 2010 to inform the design of a systematic review 
of clinical trials on tDCS for the reduction of pain (Chapter 3) and updated on 30th 
March 2012. Results reported in this chapter are based on the updated literature  
search. The search strategy included 3 search steps. Initially, a search was 
performed in databases specific to systematic reviews recommended by 
internationally respected resources for the conduct of systematic reviews (Cochrane 
Handbook (Becker and Oxman, 2008); Centre for Reviews and Dissemination 
(Centre for Reviews and Dissemination, 2009)): 
 
• Cochrane Database of Systematic Reviews 
• Database of Abstracts of Reviews of Effects  
• National Institute for Health and Clinical Excellence  
• Health Technology Assessment  
• Campbell Library of Systematic Reviews 
• Scottish Intercollegiate Guidelines Network. 
 
Search terms were ("tDCS" OR "brain stimulation") AND "pain". These broad terms 
were used since it was anticipated that only a small number of reviews would be 
identified. The second search was conducted in general health related databases: 
 
• EMBASE 2006 to 2012 Mar 30 
• Ovid MEDLINE(R) Process & Other Non-Indexed Citations and Ovid 
MEDLINE(R) 2006 to present 
• PsycArticles Full Text  2006 to present 
• CAB Abstracts 2006 to 2012 Week 13 
• PsycINFO 2006 to March Week 4 2012 
• PubMed 2006 to present 
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The search terms included a combination of MeSH terms such as pain and brain, 
natural language terms such as tDCS and non-invasive, and phrases such as 
"transcranial direct current stimulation". The searches were limited to review articles 
published later than 01.01.2006 since the first 2 trials on tDCS for pain reduction 
were published in 2006. The search history for Ovid is reported in Appendix 2.1.  
 
Additionally reference lists of included articles were screened and hand searches 
conducted of the contents of pain and neurophysiology related journals (BMC 
Neuroscience, Brain, Brain Stimulation, Clinical Journal of Pain, Clinical 
Neurophysiology, Clinical Neuroscience Research, European Journal of Neurology, 
European Journal of Pain, International Journal of Neuroscience, Journal of Clinical 
Neurophysiology, Journal of Clinical Neuroscience, Journal of Neuroscience, Journal 
of Pain and Symptom Management, Neurophysiology, Neuroscience, Pain, Pain 
Medicine, The Journal of Pain), as well as the publication list of a tDCS related 
website (Transcranial Technologies, 2012). 
 
The titles and abstracts of all reviews identified in the 3 search steps were screened 
using the pre-defined eligibility criteria (Section 2.2.1). Subsequently, the full text of 
articles meeting the eligibility criteria at the title / abstract stage were retrieved and 
evaluated.   
 
2.2.3	  Assessment	  of	  methodological	  quality	  	  
 
All eligible reviews were analysed using the critical appraisal tool for the assessment 
of the methodological quality of systematic reviews (AMSTAR, Appendix 2.2) (Shea 
et al., 2007b) as recommended by Smith et al. (Smith et al., 2011) and referenced in 
the Cochrane Handbook (Becker and Oxman, 2008). The tool comprises 11 items 
and has good face and content validity (Shea et al., 2007b), external validity (Shea et 
al., 2007a) and reliability (Shea et al., 2009) for measuring the methodological quality 
of systematic reviews. Each item offers the options "yes", "no", "cannot answer" or 
"not applicable", with a higher number of "yes" scores indicating higher 
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methodological quality. The methodological quality of individual trials included in the 
reviews was not reviewed, but the AMSTAR tool does include an item that evaluates 
whether trial methodological quality was assessed as part of the review process. 
 
2.2.4	  Data	  extraction	  and	  management	  	  
 
Important information on characteristics and results of included reviews were 
extracted and entered into a data extraction table with pre-specified headings 
designed to focus on the research question and to provide information in a structured 
and clear format (Smith et al., 2011). This information included: author(s), year of 
publication, brain stimulation techniques reviewed, clinical conditions of patients or 
experimental pain paradigms applied in included trials, authors (year) of included 
trials and key results from the review. 
	  
2.2.5	  Data	  analysis	  
 
It was anticipated after the scoping search, that only 1 meta-analysis on tDCS for the 
reduction of pain would be identified. Hence, a statistical synthesis of meta-analysis 
results was not anticipated to be possible. Data were synthesised in a narrative 
manner, stating the contents and the results from individual reviews, along with 
methodological quality.  
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2.3	  Results	  	  
 
2.3.1	  Database	  and	  hand	  search	  results	  	  
 
One review was identified in review specific databases (O’Connell et al., 2010). The 
search in health related databases identified 104 entries, and hand searching added 
4 further reviews (Arul-Anandam et al., 2009; Brunoni et al., 2012; Lima and Fregni, 
2008; Zaghi et al., 2009). Of these 108 entries, 82 were excluded according to the 
pre-defined inclusion criteria when title and abstract were screened. Full text 
screening excluded 7 further articles: one was the report on the included Cochrane 
review (O’Connell et al., 2011) and 6 articles did not review any clinical trials on the 
use of tDCS for the reduction of pain (Borckardt et al., 2009; Brunoni et al., 2012; 
Cruciani et al., 2009; Lefaucheur, 2008; Nitsche et al., 2008; May and Jurgens, 
2010). Nineteen reviews were included. The selection process was illustrated as a 
flowchart adapted from the PRISMA statement (Liberati et al., 2009) (Figure 2.1). 
Lists of included and excluded reviews are provided in Appendix 2.3. 
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Figure 2.1 Flowchart for review selection process (Moher et al., 2009) 
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Records excluded 
according to exclusion 
criteria: 
- duplicates (n=20) 
- publication not a review  
  (n=27) 
- authors did not review  
  trials on pain (n=29) 
- authors did not review  
  trials on tDCS (n=3) 
- language (n=2) 
  
Full-text articles excluded 
according to exclusion 
criteria: 
- authors did not review  
  trials on tDCS and pain 
- dual publication (n=1) 
Records identified 
through database 
searching (OVID) 
(n=101) 
Additional records 
identified through 
hand searching 
(n=3) 
Records screened  
(title and abstract) 
(n=108) 
Full-text articles 
assessed for eligibility 
(n=26) 
Reviews included 
(n=19) 
Additional records 
identified in PubMed  
(n=4) 
  27 
 
2.3.2	  Methodological	  quality	  of	  included	  reviews	  
 
Only the Cochrane review scored "yes" on all 11 items of the AMSTAR tool  
(O’Connell et al., 2010) (Table 2.1) and was therefore regarded as of high 
methodological quality. Two further reviews reached 7 and 5 "yes" scores (Lima and 
Fregni, 2008; Zaghi et al., 2011). The remaining reviews ranged between 0-2 items 
scored as "yes". The 3 highest ranking publications were the only reviews with a 
systematic approach following a clearly stated research question and providing 
details for a comprehensive literature search as well as the characteristics of the 
included studies (Lima and Fregni, 2008; O’Connell et al., 2010; Zaghi et al., 2011). 
All other reviews adopted a non-systematic narrative style, with no a priori statement 
of design, a non-systematic (or not reported) literature search, no duplicate study 
selection / data extraction, not including a list of included and excluded trials, not 
using the publication status as an inclusion criteria, not assessing the likelihood of 
publication bias, and no assessment of the methodological quality of included trials 
(Table 2.1). The inclusion of these elements is strongly recommended by guidelines 
for the reporting of systematic reviews (Centre for Reviews and Dissemination, 2009; 
Green et al., 2008; Liberati et al., 2009) since only reviews of high methodological 
quality can provide reliable conclusions on the current level of evidence for tDCS for 
pain reduction (Shea et al., 2009). 
 
 
Table 2.1 Quality of included reviews  
 
Author; Year 1 2 3 4 5 6 7 8 9 10 11 No of Yes 
Antal & Paulus 
2007       
No No No No No No No No N/A No No 0 
Antal & Paulus  
2010 No No No No No No No No N/A No Yes 1 
Arul-Anandam et al.  
2009 
No No No No No No No No N/A No No 0 
Been et al. 
2007 No No No No No No No No N/A No No 0 
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Fregni et al.  
2007 
 
No 
 
No 
 
Yes 
 
No 
 
No 
 
Yes 
 
No 
 
No 
 
N/A 
 
No 
 
No 
 
2 
Fregni & Pascual-  
Leone  
2007 
No No Yes No No Yes,  online No No N/A No 
Yes,  
online 2(4) 
Jensen 
2008 
No No No No No No No No N/A No No 0 
Jensen 
2009 
No No No No No Yes No No No No No 1 
Knotkova 
& Cruciani  
2010 
No No No No No No No No No No No 0 
Lefaucheur 
2008 No No No No No No No No No No No 0 
Lefaucheur 
2009 No No No No No No No No No No No 0 
Lima & Fregni 
2008 No No Yes Yes Yes Yes No No Yes Yes No 7 
Nitsche & Paulus  
2011 
No No No No No Yes No No N/A No No 1 
O'Connell et  al. 
2010 
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 11 
Rosen et al. 
2009 
No No No No No No No No No No No 0 
Short et al. 
2009 No No No No No No No No No No Yes 1 
Williams et  
al. 2009 
No No No No No No No No No No Yes 1 
Zaghi et al. 
2009 
No No No No No No No No Yes No No 2 
Zaghi et al. 
 2011 
No No Yes Yes No Yes No No Yes Yes No 5 
Footnotes: 1=Was an 'a priori' design provided?; 2=Was there duplicate study selection and data extraction?; 3=Was a 
comprehensive literature search performed?; 4=Was the status of publication (i.e. grey literature) used as an inclusion 
criterion?; 5=Was a list of studies (included and excluded) provided?; 6=Were the characteristics of the included studies 
provided?; 7=Was the scientific quality of the included studies assessed and documented?; 8=Was the scientific quality of the 
included studies used appropriately in formulating conclusions?; 9=Were the methods used to combine the findings of studies 
appropriate?; 10=Was the likelihood of publication bias assessed?; 11=Was the conflict of interest stated?; N/A=not applicable. 
 
	  
 	  
Table 2.1 continued 
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2.3.3	  Analysis	  of	  the	  characteristics	  of	  included	  reviews	  	  
 
Of the 19 included reviews, 2 were published in German and 17 in English. Four 
were published in 2007, 3 in 2008, 7 in 2009, 3 in 2010, and 2 in 2011, indicating an 
ongoing scientific interest in tDCS as a treatment option for pain reduction. Three 
reviews focused on tDCS alone (Arul-Anandam et al., 2009; Knotkova and Cruciani, 
2010; Nitsche and Paulus, 2011), while most reviews included other invasive or non-
invasive brain stimulation techniques (Table 2.2). Six reviews included trials on 
chronic pain as well as experimental pain (Antal and Paulus, 2007, 2010; Been et al., 
2007; Lefaucheur, 2009; Nitsche and Paulus, 2011; Rosen et al., 2009). Some 
reviews evaluated the effect of tDCS on pain as well as other clinical conditions such 
as Parkinson's disease (Been et al., 2007; Williams et al., 2009), stroke (Arul-
Anandam et al., 2009; Been et al., 2007; Jensen et al., 2008; Williams et al., 2009), 
depression (Arul-Anandam et al., 2009; Been et al., 2007), and tinnitus (Jensen et 
al., 2008), or focussed exclusively on specific chronic pain conditions such as 
neuropathic pain (Knotkova and Cruciani, 2010), central pain (Zaghi et al., 2009) or 
fibromyalgia (Short et al., 2009). Twelve reviews included only the same 2 trials 
(Fregni et al., 2006a, 2006b) on tDCS for the reduction of chronic clinical pain, both 
published in 2006 (Arul-Anandam et al., 2009; Antal and Paulus, 2010; Lefaucheur, 
2009; Fregni et al., 2007; Fregni and Pascual-Leone, 2007; Jensen et al., 2008; Lima 
and Fregni, 2008; Williams et al., 2009; Short et al., 2009; Antal and Paulus, 2007; 
Been et al., 2007; Jensen et al., 2009). The Cochrane review included 6 trials 
(O’Connell et al., 2010) and an additional trial was identified by one of the 2 most 
current reviews (Nitsche and Paulus, 2011). The most current reviews (Nitsche and 
Paulus, 2011; Zaghi et al., 2011) included chronic pain trials published between 2006 
and 2010 and experimental pain trials published between 2008 and 2010. The 3 
reviews with the highest methodological quality also included trials up to 2010 (Lima 
and Fregni, 2008; O’Connell et al., 2010; Zaghi et al., 2011). 
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2.3.4	  Analysis	  of	  the	  results	  of	  included	  reviews	  
 
The review of the highest methodological quality by O'Connell et al. (2010) was a 
systematic review and meta-analysis of randomised controlled and crossover trials 
on different non-invasive brain stimulation techniques including tDCS for the 
reduction of chronic clinical pain, conducted within the framework of the Cochrane 
Collaboration (O’Connell et al., 2010). The results demonstrated that the combined 
effect of trials on tDCS applied over M1 showed a small pain reduction compared to 
sham tDCS (standardised mean difference -0.59, 95% CI -1.10 to -0.08). The authors 
further concluded that there was significant heterogeneity of included trials and that 
the existing evidence was insufficient to draw valid conclusions regarding the effect 
of tDCS for the reduction of pain. Only 1 of the 5 trials included in the meta-analysis 
was assessed as low risk of bias. All other trials showed substantial methodological 
weaknesses due to unclear allocation concealment, unclear carry-over effects, 
potential for selective outcome-reporting and unclear strategies for the management 
of missing data. Hence, results from the systematic review were based on the limited 
evidence available at the time and conclusions might change depending on future 
research. 
 
A second systematic review and meta-analysis by Lima et al. (2008) evaluated the 
effects of invasive (surgically implanted stimulators) and non-invasive (rTMS and 
tDCS) electrical stimulation methods that targeted M1 for the relief of chronic pain 
(Lima and Fregni, 2008). The results showed that both approaches (invasive and 
non-invasive) reduced pain but that invasive stimulation of M1 induced a larger pain 
reduction compared to non-invasive stimulation (rTMS and tDCS) (responder rate: 
64% for invasive stimulation with 95% CI 58.7 to 69.2 and 40% for non-invasive 
stimulation with 95% CI, 33.9 to 46.0). The evaluation of tDCS studies only, showed 
an improved mean responder rate of 74% (95% CI, 52.1 to 90.7). However, this 
result was based on 2 tDCS trials, only (Fregni et al., 2006a, 2006b). The update of 
this review (Zaghi et al., 2011) included 3 further tDCS trials and resulted in a 
combined pooled effect size of -0.86 cm (95% CI -1.54 to -0.19 cm on a 0 to 10 cm 
VAS for pain for tDCS and rTMS. Clinically minimum relevant change 
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recommendations for pain in chronic pain populations range from 1.5 to 4 cm on a 0-
10 cm VAS (Maughan and Lewis, 2010; Ostelo et al., 2008), hence pain reduction 
cannot be regarded as clinically meaningful. The remaining narrative reviews on 
chronic pain agreed that tDCS was an effective future method for the treatment of 
chronic clinical pain (Arul-Anandam et al., 2009; Fregni et al., 2007; Antal and 
Paulus, 2007, 2010; Lefaucheur, 2008, 2009; Short et al., 2009; Jensen et al., 2008; 
Fregni and Pascual-Leone, 2007; Been et al., 2007; Rosen et al., 2009; Williams et 
al., 2009; Knotkova and Cruciani, 2010; Nitsche and Paulus, 2011; Jensen et al., 
2009). 
 
Reviews that included trials on experimental pain concluded that cathodal tDCS 
reduced the perceived intensity of experimentally induced pain in healthy participants 
(Lefaucheur et al., 2008; Rosen et al., 2009) and altered neurophysiological 
measures for pain such as laser-evoked (Rosen et al., 2009; Antal and Paulus, 2007, 
2010; Lefaucheur et al., 2008; Nitsche and Paulus, 2011) and somatosensory-
evoked potentials (Been et al., 2007). Five reviews concluded that tDCS was a safe 
technique with few side effects (Antal and Paulus, 2007; Been et al., 2007; Knotkova 
and Cruciani, 2010; Lefaucheur, 2009; Nitsche and Paulus, 2011). Further 
advantages identified for tDCS were that it is inexpensive (Arul-Anandam et al., 
2009; Jensen et al., 2008; Knotkova and Cruciani, 2010; Zaghi et al., 2009), easy to 
apply (Jensen et al., 2008), mobile (Arul-Anandam et al., 2009; Knotkova and 
Cruciani, 2010) and had a reliable placebo condition (Antal et al., 2010; Jensen et al., 
2008) supporting it as a future pain management and research tool. 
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Table 2.2 Contents and characteristics of included reviews 
 
Author /  
year 
Stimulation 
techniques  
Clinical 
conditions  
Experi-
mental pain  
tDCS+pain trials included  Key results on tDCS and pain 
Antal & 
Paulus 
2007 
tDCS 
rTMS 
chronic pain, 
migraine 
LEPs (Fregni et al., 2006a; Csifcsak et al., 
2006) 
- tDCS potential future therapy 
- no safety risks 
Antal & 
Paulus 
2010 
rTMS 
tDCS 
chronic pain LEPs (Antal et al., 2008; Fregni et al., 
2006a; Fregni et al., 2006b; Terney et 
al., 2008) 
- tDCS seemed capable to reduce chronic pain and 
experimental pain perception 
- reliable placebo condition for tDCS at 1 mA 
Arul-
Anandam et 
al.2009 
tDCS chronic pain, 
depression, 
stroke 
none (Fregni et al., 2006a; Fregni et al., 
2006b) 
- tDCS inexpensive, mobile, may have long-lasting 
effects 
- tDCS may emerge as a therapeutic modality, 
particularly for major depressive disorders 
- evidence base small, more studies needed 
Been et al. 
2007 
 
 
 
 
tDCS 
CVS 
stroke, chronic 
pain, 
Parkinson's 
disease, 
depression, 
migraine 
SEPs (Fregni et al., 2006a; Fregni et al., 
2006b;) 
- tDCS safe method 
- tDCS implied neurophysiological effects on M1 
and S1 
- tDCS reduced chronic pain 
Fregni et al.  
2007 
rTMS 
tDCS 
chronic pain none (Fregni et al., 2006a) - reviewed one trial on tDCS and introduced tDCS 
as a new method for the treatment of chronic pain 
Fregni & 
Pascual-
Leone 2007 
rTMS 
tDCS 
chronic pain none (Fregni et al., 2006a) -tDCS reduced pain in one clinical trial 
-indicated therapeutic potential 
Jensen 
2008 
rTMS 
tDCS 
chronic pain, 
stroke, tinnitus 
none (Fregni et al., 2006a; Fregni et al., 
2006b) 
-tDCS altered cortical activity 
-tDCS reduced chronic pain 
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Table 2.2 - continued 1 
 
Jensen  
2009 
 
 
DBS, MCS 
rTMS,  
tDCS 
chronic pain none (Fregni et al., 2006a; Fregni et al., 2006b) - tDCS held promise for treating chronic 
refractory spinal cord injury pain 
- advantages: not invasive, easy to apply, 
inexpensive, reliable placebo condition, 
modulatory effects may be stronger than rTMS 
Knotkova & 
Cruciani  
2010 
tDCS neuropathic 
pain 
none (Fregni et al., 2006a; Fregni et al., 2006b; Fenton et 
al., 2009; Roizenblatt et al., 2007) 
- analgesic effect of tDCS on neuropathic pain  
- evidence justified clinical use 
- easy to apply, portable, not expensive, safe 
Lefaucheur 
2008 
 
 
 
rTMS 
tDCS 
chronic pain LEPs (Antal et al., 2008; Boggio et al., 2008; Csifcsak et 
al., 2006; Fregni et al., 2006a; Fregni et al., 2006b; 
Silva et al., 2007; Terney et al., 2008) 
-tDCS altered LEP response 
-tDCS reduced experimental pain perception 
-experimental pain reduction was increased by 
additional medication  
-tDCS reduced chronic pain, but experience 
limited to 2 studies 
Lefaucheur 
2009 
rTMS,TECS 
tDCS, ECS 
chronic pain none (Fregni et al., 2006a) -explained neurophysiological mechanisms of 
action 
-tDCS was safe within published safety limits 
Lima& Fregni 
2008 
 
MCS 
rTMS 
tDCS 
chronic pain none (Fregni et al., 2006a; Fregni et al., 2006b) -meta-analysis shows good responder rates for 
invasive and non-invasive techniques 
-weighted responder rate was 45.3% (95% CI, 
39.2–51.4) for tDCS+rTMS 
Nitsche& 
Paulus 2011 
 
tDCS chronic pain LEPs (Antal et al., 2010; Mori et al., 2010; Fenton et al., 
2009; Boggio et al., 2009a; Bachmann et al., 2010; 
Csifcsak et al., 2009; Fregni et al., 2006a; Fregni et 
al., 2006b) 
- further research should focus on stimulation 
protocols 
- tDCS is safe technique 
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Table 2.2 - continued 2 
O'Connell et 
al. 2010 
 
 
 
 
rTMS 
tDCS 
CES 
chronic pain none (Fregni et al., 2006a; Fregni et al., 2006b; Boggio 
et al., 2009; Fenton et al., 2009; Mori et al., 2009; 
Valle et al., 2009) 
-meta-analysis of trials  of active stimulation over M1 
superior to sham stimulation (SMD -0.59, 95% CI -
1.10 to -0.08) 
-heterogeneity does not allow an estimation of the 
effect size 
-no firm conclusions regarding effectiveness for pain 
reduction 
Rosen et al. 
2009 
 
rTMS 
tDCS 
chronic pain LEPs (Antal et al., 2008; Fregni et al., 2006a; Fregni et 
al., 2006b; Roizenblatt et al., 2007; Terney et al., 
2008) 
-tDCS altered LEP response 
-tDCS reduced chronic clinical pain 
-tDCS reduced experimentally induced pain 
Short et al. 
2009 
 
rTMS 
tDCS 
ECT 
fibromyalgia  none (Fregni et al., 2006b; Roizenblatt et al., 2007) -tDCS may be effective to reduce fibromyalgia pain 
- further research needed 
- combination of different stimulation techniques as a 
future option 
Williams et al. 
2009 
 
rTMS 
tDCS 
chronic pain, 
stroke 
Parkinson's 
disease 
none (Fregni et al., 2006a; Fregni et al., 2006b) -tDCS reduced pain in 2 clinical trials 
Zaghi et al. 
2009 
MCS, 
rTMS 
tDCS 
central pain none (Fregni et al., 2006a; Fregni et al., 2006b; Cecilio 
et al., 2008) 
-all treatment modalities appeared to induce clinical 
gains 
-tDCS most cost-effective 
Zaghi et al. 
2011 
rTMS 
tDCS 
chronic pain none (Fregni et al., 2006a; Fregni et al., 2006b; Boggio 
et al., 2009; Fenton et al., 2009; Mori et al., 2009) 
-update of the SR and meta-analysis by Lima & 
Fregni 2008, 
-combined pooled effect for rTMS and tDCS -0.86 
(95%CI -1.54,-0.19) 
- yearly cost of tDCS approx $11,740 
 
 
Footnotes: CES= cranial electrotherapy stimulation; ECS=epidural cortical stimulation; ECT= electroconvulsive therapy; LEPs=laser evoked potentials; M1=primary motor cortex; 
MCS=motor cortex stimulation; rTMS=repetitive transcranial magnetic stimulation; SEP=somatosensory-evoked potential; SR=systematic review; SMD=standard mean difference; 
TECS=transcranial electrical stimulation using pulsed currents; tDCS=transcranial direct current stimulation
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2.4	  Discussion	  
 
Nineteen reviews were included in this overview of reviews. Three of these used a 
systematic approach (Lima and Fregni, 2008; Zaghi et al., 2011; O’Connell et al., 
2010), but only 1 was assessed as high methodological quality (O’Connell et al., 
2010). However, the results of Connell et al. (2010) were based on 6 clinical trials, 
only, and did not include trials on experimental pain although results from 
experimental pain research might provide valuable information about the 
effectiveness of tDCS in a more standardised setting. The cut-off date for the 
literature search of the Cochrane review was between November 2009 (for 
MEDLINE) and January 2010 (for CINAHL). As tDCS is a new technique for the 
reduction of pain with high scientific interest, new trials might have been published 
since these cut-off dates that might change the results from the meta-analysis. 
 
The results of the 2 further systematic reviews were based on the same trials as the 
Cochrane review but the authors had not conducted an assessment of the 
methodological quality of the included trials (Lima and Fregni, 2008; Zaghi et al., 
2011). Both reviews reported a meta-analysis but Lima & Fregni only included 2 trials 
(Zaghi et al., 2011; Lima and Fregni, 2008) and Zaghi et al. (2011) stated the effect 
size for a combination of rTMS trials with tDCS trials and provided no information on 
the effect of tDCS alone (Lima and Fregni, 2008). A combination of the results of the 
3 meta-analyses was therefore not feasible. All other reviews were of narrative 
nature and scored low in the methodological quality assessment. These narrative 
reviews contributed 1 RCT additional to those included in the systematic reviews 
(Zaghi et al., 2011) and 2 case studies on chronic clinical pain (Antal et al., 2010). 
The RCT was published after the cut-off date of the Cochrane review and had not 
been formally evaluated for risk of bias. All authors concluded that tDCS was a 
promising future treatment approach for the reduction of chronic pain and underlined 
the advantages of tDCS such as its low cost, portability and safety as well as the 
option for a reliable placebo condition for research purposes.  
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Six reviews included a total of 4 trials on experimentally induced pain or pain-
representing neurophysiological measurements and concluded that tDCS was 
effective in the reduction of experimental pain as well as in altering the responses to 
laser-evoked and somatosensory-evoked potentials (Antal and Paulus, 2007, 2010; 
Been et al., 2007; Lefaucheur et al., 2008; Nitsche and Paulus, 2011; Rosen et al., 
2009). Different stimulation sites and parameters affected different types of 
experimentally induced pain with M1 emerging as the most widely used target. 
However, none of the trials on experimental pain were assessed for risk of bias. 
Hence, the risk that reported effects over- or underestimated the true effect has not 
been evaluated.  
 
None of the included reviews had evaluated the overall level of current evidence by, 
for example, using GRADE (Grading of Recommendations Assessment, 
Development and Evaluation (Schunemann et al., 2008). Despite the agreement on 
the potential efficacy and safety of tDCS, the available evidence from systematic and 
non-systematic reviews was therefore insufficient to recommend tDCS as a tool for 
the reduction of chronic pain or experimentally induced pain. Only 1 available review 
had conducted a risk of bias assessment of the included trials that indicated 
methodological shortcomings in all but 1 of the included trials. The authors 
considered this risk of bias and the heterogeneity of included trials as so severe that 
they did not recommend the use of tDCS for the reduction of chronic pain despite the 
pain reducing effect of tDCS over M1 found from their meta-analysis (O’Connell et 
al., 2010).  
 
Narrative reviews indicated ongoing scientific interest in the topic with 1 further RCT 
published after the cut-off date of the Cochrane review. This RCT, as well as all trials 
on experimental pain, still require formal assessment of methodological quality. Trials 
included in the Cochrane review focussed on patients experiencing pain due to 
fibromyalgia, spinal cord injury, chronic pelvic pain, and multiple sclerosis. Two case 
studies included in the narrative reviews stated an effect on cancer pain and on 
vulvodynia. Trials on experimental pain included pain paradigms induced by laser-
evoked potentials and somatosensory-evoked potentials. It remained unclear 
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whether tDCS had been applied to other clinical conditions or different pain 
paradigms in the meantime. The reviews further showed that different stimulation 
locations, durations and intensities had been used in published trials, but they did not 
recommend any stimulation paradigm that was used most frequently or had been 
shown to be most effective. It remained unclear whether different types of chronic 
pain required different stimulation paradigms and whether experimental pain 
responded to the same stimulation paradigms as chronic pain. 
 
This overview of reviews had 2 limitations. For time and resource reasons, only 1 
researcher had conducted the search, quality assessment, and data extraction. This 
potential risk of bias was addressed by the à priori definition of a standardised 
procedure, with clear inclusion / exclusion criteria and a pre-designed data extraction 
process following international guidelines (Becker and Oxman, 2008; Centre for 
Reviews and Dissemination, 2009). The second limitation was the exclusion of 
reviews published in a language other than German or English. Two reviews were 
identified from the literature search with an English abstract but a French full text. 
Both focussed on invasive MCS only and were published by the research group of 
Lefaucheur et al. (Lefaucheur et al., 2009; Nguyen et al., 2009).  
 
This overview of reviews therefore strongly supports the need for a high quality and 
up-to-date systematic review, that focuses on the effectiveness of tDCS for the 
reduction of pain, includes all currently available publications on different types of 
clinical and experimental pain, evaluates the methodological quality or risk of bias of 
included trials, evaluates the stimulation paradigm that is most effective, and uses 
GRADE to evaluate the overall level of evidence. 
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Chapter summary: 
A comprehensive search and evaluation of published reviews on the effectiveness of 
tDCS for the reduction of pain was conducted. Assessment of the methodological 
quality of 19 included reviews indicated that a systematic review and meta-analysis 
conducted by the Cochrane Collaboration showed the highest methodological quality 
and 2 further reviews met the requirements of a systematic review. Results from the 
Cochrane review indicated a small effect for tDCS on clinical pain reduction but did 
not include trials on experimental pain. Experimental pain trials were included in 6 
reviews but trials were not evaluated for methodological quality. Reviews did not 
report the most effective or most frequently used stimulation paradigm. Reported 
advantages of tDCS over other brain stimulation techniques included low cost, 
safety, portability, and a reliable placebo condition for research purposes.  
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3. CHAPTER	  
 
TRANSCRANIAL	  DIRECT	  CURRENT	  STIMULATION	  FOR	  THE	  
REDUCTION	  OF	  CLINICAL	  AND	  EXPERIMENTALLY	  INDUCED	  
PAIN	  -­‐	  A	  SYSTEMATIC	  REVIEW	  AND	  META-­‐ANALYSIS	  
 
Chapter 2 provided an overview of existing reviews on the use of tDCS for the 
reduction of pain. Critical appraisal of the reviews identified 3 reviews that had used 
a systematic approach and only 1 that had conducted a risk of bias assessment of 
included trials. None of the reviews had evaluated the overall level of evidence. The 
3 systematic reviews included only a small number of trials, and trials on 
experimental pain were not formally assessed for methodological quality. 
Furthermore, the included reviews had not provided information on the most 
frequently used or most effective tDCS paradigm for the reduction of pain to inform 
the design of a clinical trial. The overview of reviews therefore identified a need to 
conduct an up-to-date systematic review of the literature on tDCS for the reduction 
of pain, including clinical and experimentally induced pain, to inform the design and 
protocol for a randomised controlled trial. Hence, a systematic review was 
conducted. This chapter describes the process of the systematic review and 
discusses the findings regarding tDCS for the reduction of clinical pain and 
experimentally induced pain.  
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3.1	  Introduction	  
 
The overview of published reviews on tDCS for the reduction of pain demonstrated 
that the first clinical trials were conducted in 2006. Twenty-six review articles (of 
which 19 were included in the overview of reviews) were published between 2006 
and 2012 (Section 2.3.1). This comparably large number of reviews, based on 4 
trials evaluating experimental pain and 7 trials evaluating clinical pain, illustrated the 
scientific interest in the topic. Reviews focused on the neurophysiological pain 
reducing mechanisms of tDCS, on tDCS amongst other stimulation techniques such 
as surgically implanted stimulators, or repetitive magnetic stimulation (rTMS). None 
of the reviews exclusively evaluated the effectiveness of tDCS for the reduction of 
pain (Section 2.3.4).  
 
Three of the included review articles used a systematic approach, but only 1 was 
assessed as high methodological quality (O’Connell et al., 2010). It focused on 
various non-invasive brain stimulation techniques and included 6 trials on tDCS for 
the reduction of clinical pain published prior to 11th of January 2010. The authors 
conducted a meta-analysis on the results of 5 trials on tDCS over M1 for the short-
term (immediately post intervention) reduction of clinical pain resulting in a small 
combined standardised mean effect of -0.59 (95% CI -1.10,-0.08) on a 0-10 cm VAS 
for pain (compared to sham stimulation). Despite the thorough methodological 
approach, the systematic review had some shortcomings: 
 
• Evaluation of the level of evidence according to the GRADE approach 
(Guyatt et al., 2008) as recommended by the Cochrane Handbook 
(Schünemann et al., 2008), was not conducted. Consequently the overall 
level of evidence from the systematic review remained unclear.  
 
• Trials using tDCS for the reduction of experimental pain were excluded. 
Experimental pain plays an important role in the understanding of pain and 
for the development of pain reducing interventions (Petersen-Felix and 
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Arendt-Nielsen, 2002). It has some advantages over clinical pain for research 
purposes as it can be standardised regarding its duration, intensity, 
frequency, and location, and applied to healthy volunteers who are less 
susceptible to confounding factors (Cavallone et al., 2013; Petersen-Felix 
and Arendt-Nielsen, 2002). Hence, it was important to evaluate whether 
tDCS had a pain reducing effect on experimental pain and whether this could 
be achieved using the same stimulation parameters as trials on chronic pain 
to inform future research on tDCS.  
 
• The cut-off date for the literature search was January 2010. 
 
In summary, the evaluation of evidence from published reviews was not up-to-date, 
the methodological quality of the majority of reviews was low, and there was 
insufficient evidence to either support the effectiveness of tDCS for the reduction of 
clinical pain, or to indicate whether tDCS reduced experimentally induced pain in a 
research setting. Additionally, it remained unclear whether any specific stimulation 
approach regarding mode of stimulation (anodal / cathodal), site of stimulation (e.g. 
M1, S1), duration, intensity or frequency of stimulation was most effective for either 
type of pain.  
 
Hence, the objective of this review was to provide up-to-date evidence on the 
effectiveness of tDCS on both clinical and experimentally induced pain, based on 
sound methodology. A secondary objective was to identify the most effective 
stimulation parameters regarding stimulation site, mode, intensity, duration and 
frequency for the reduction of both types of pain. Addressing both objectives will 
inform the design of a clinical trial on tDCS for the reduction of CNSLBP.  
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3.2	  Methods	  
 
A protocol was developed prior to conducting the review to minimise the potential 
for introducing bias (Appendix 3.2). Structure and contents of the protocol were 
adapted from Chapter 4 of the Cochrane Handbook for Systematic Reviews of 
Interventions (Higgins and Green, 2008), the handbook "Systematic Reviews" 
published by York University (Centre for Reviews and Dissemination, 2009), and the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement (Liberati et al., 2009) as internationally recognised guidelines for the 
conduct and reporting of systematic reviews. The systematic review and meta-
analysis adhered to the protocol throughout, and no amendments were required.  
 
3.2.1	  Eligibility	  criteria	  for	  trial	  inclusion	  
 
• Types of articles:  
The review included RCTs, controlled trials, and other designs such as 
crossover trials, defined as trials that allocate participants to a sequence of 
interventions in a randomised order (Higgins and Deeks, 2008). These other 
designs were included because, from the existing reviews, it was not 
anticipated that many RCTs would be available and the systematic review 
was designed to provide a comprehensive overview of existing trials on tDCS 
for pain reduction. Non-controlled trials and case studies were excluded. No 
language or publication status restrictions were imposed. 
 
• Types of participants:   
Trial participants were adults (≥18 years), since there were no publications on 
the neurophysiological effect of tDCS on the juvenile brain. Trials included 
participants with clinical pain or healthy participants, who were experimentally 
exposed to a pain paradigm. Trials on patients with primary symptoms other 
than pain, such as depression, stroke, or Parkinson’s disease were excluded. 
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Animal trials were not included because the transferability of brain stimulation 
results to humans is not fully understood (Brunoni et al., 2011b). 
 
• Types of interventions:  
tDCS defined as an electrical stimulation applied to the outside of the skull 
using direct currents (Nitsche et al., 2008). Furthermore, identified reviews 
used terms such as "motor cortex stimulation" and specified them later as 
non-invasive and electrical (Lima and Fregni, 2008), or mentioned "non-
invasive brain stimulation" to subsequently distinguish between magnetic and 
electrical techniques (Rosen et al., 2009; Williams et al., 2009). These terms 
were therefore included in the search strategy. Trials on invasive brain 
stimulation methods, on magnetic stimulation (e.g. rTMS) and on electrical 
stimulation that used pulsed or alternating currents were excluded. 
 
• Types of comparisons:  
 Acceptable comparator interventions were sham-stimulation (placebo) or a 
 control group, so that conclusions could be drawn about the effectiveness of 
 tDCS. 
 
• Types of outcome measures:  
The outcome of interest was pain severity immediately post intervention as a 
primary or secondary outcome measure. The time-point immediately post 
intervention was chosen to allow comparability with the results of the overview 
of reviews. The type of pain measurement tool was not pre-determined (e.g. 
VAS for pain, NRS for pain). If a self-report tool (e.g. questionnaire) was used, 
pain had to be a main focus of the questionnaire to enable comparison with 
the results of other trials (e.g. Roland-Morris Disability Questionnaire (Roland 
and Morris, 1983) or Oswestry Disability Questionnaire (Fairbank et al., 1980), 
Brief Pain Inventory (Serlin, 1995), McGill Pain Questionnaire (Melzack, 
1975)). 
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3.2.2	  Search	  methods	  
3.2.2.1	  Information	  Sources	  
 
Two researchers independently conducted a systematic search of electronic 
databases relevant for the medical and allied health professions literature. The cut-
off date for the literature search was 30th Sept 2010. OVID was used to search the 
databases: MEDLINE, EMBASE, CAB Abstracts (Centre for Agricultural Bioscience 
International), and PsychINFO. Searches were performed in the Cochrane Register 
of Controlled Trials (CENTRAL), CINAHL, and PeDRO. 
 
To identify non-published trials and, thereby reduce publication bias, trials in 
progress were searched in the Clinical trial register of the U.S. National Institute of 
Health (www.clinicaltrials.gov), the Current Controlled Trials Register, U.K. 
(www.controlled-trials.com), the NHS National Research Register 
(https://portal.nihr.ac.uk/Pages/NRRArchive.aspx), the European Trial Register 
Eudract (https://eudract.emea.europa.eu), and key authors were contacted by 
email. 
 
Conference proceedings of relevant events known to the researchers and detailed 
on the ZETOC website (http://zetoc.mimas.ac.uk) were screened. Reference lists of 
previously identified reviews and of the newly acquired trial publications were hand 
searched. The contents of all journals in which identified trials were published 
(Arthritis and Rheumatism, Brain Stimulation, Clinical Journal of Pain, European 
Journal of Neurology, Journal of Pain and Symptom Management, 
Neuropsychologia, Pain, Pain Medicine, The Journal of Pain) as well as key journals 
for neurophysiology and neuroscience (BMC Neuroscience, Brain, Clinical 
Neurophysiology, Clinical Neuroscience Research, International Journal of 
Neuroscience, Journal of Clinical Neurophysiology, Journal of Clinical 
Neuroscience, Journal of Neuroscience, Neurophysiology, Neuroscience) were 
searched.  
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3.2.2.2	  Literature	  Search	  
 
Medical subject heading (MeSH) terms and natural language terms were combined 
in the search strategy. The search strategy included terms referring to the 
population studied, the intervention this review was focussed on, the control 
intervention and the outcome studied. The following search terms were combined: 
 
Population:  
adult AND (pain OR healthy)  
 
Intervention:  
(transcranial direct current stimulation OR tDCS OR electric(al) OR direct current) 
AND (brain OR motor cortex OR M1 OR somatosensory cortex OR S1 OR 
prefrontal cortex OR DLPFC) AND stimulation AND non-invasive  
 
Comparison:  
sham OR placebo OR control 
 
Outcome:  
pain OR numerical rating scale OR visual analogue scale  
 
Search filter or limitations were set to "humans". The search was limited to the 
timeframe of 2006 to current (30th Sept 2010) (according to the existing reviews the 
first clinical trials on tDCS were published in 2006). An example for the search 
strategy in Medline (Ovid format) is shown in Table 3.1. 
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Table 3.1 Search history Medline (Ovid ) 
 Searches Results Search Type 
1 (tDCS or direct current).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
tx, ct, bt, nm, an, hn, ui, tc, id] 
14666 Advanced 
2 (brain or cortex or M1 or S1).mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, tx, ct, bt, nm, an, hn, ui, tc, id] 
3344001 Advanced 
3 stimulation.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, tx, ct, bt, nm, 
an, hn, ui, tc, id] 
1619454 Advanced 
4 (non-invasive or non invasive or noninvasive).mp. [mp=ti, ab, sh, 
hw, tn, ot, dm, mf, tx, ct, bt, nm, an, hn, ui, tc, id] 
318937 Advanced 
5 (sham or placebo or control).mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, tx, ct, bt, nm, an, hn, ui, tc, id] 
6692365 Advanced 
6 (pain or numerical rating scale or verbal rating scale or visual 
analogue scale or VAS or NRS).mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, tx, ct, bt, nm, an, hn, ui, tc, id] 
1575621 Advanced 
7 1 and 2 and 3 and 4 and 5 and 6 155 Advanced 
8 limit 7 to humans [Limit not valid in HMIC,Journals@Ovid,CAB 
Abstracts, Your Journals@Ovid,PsycINFO; records were retained] 
154 Advanced 
9 (RCT or randomised or randomized).mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, tx, ct, bt, nm, an, hn, ui, tc, id] 
1433110 Advanced 
10 8 and 9 109 Advanced 
11 remove duplicates from 10 79 Advanced 
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3.2.2.3	  Study	  Selection	  
 
Articles identified in the search were selected independently by 2 reviewers (Higgins 
and Deeks, 2008) to minimise bias. Both reviewers had subject as well as 
methodological knowledge. In the first stage of study selection, the eligibility criteria 
(Section 3.2.1) were applied to the title and abstract of identified articles. In the 
second stage, the full text publications of potentially eligible articles were obtained 
and criteria reapplied.  
Strength of inter-reviewer agreement regarding study eligibility was expressed using 
Cohen's Kappa coefficient, a statistical test that determines the statistical agreement 
of 2 raters on nominal / categorical data (Cohen, 1960). In the case of disagreement 
between the 2 reviewers that was not resolved by discussion, a third reviewer with 
expertise in systematic review methodology was approached. The third reviewer 
decided whether the article was included (Higgins and Deeks, 2008). 
 
3.2.3	  Data	  extraction	  and	  management	  
 
Data from included trials were collected by 2 independent reviewers and entered into 
a table with pre-specified headings (Higgins and Deeks, 2008) designed to meet the 
research objectives. The data extraction table comprised the following data items: 
 
• Author, date and country of the trial study population 
• Study population (healthy volunteers or pain patients, type of pain condition / 
 experimental pain paradigm, number of participants, age range) 
• Stimulation parameters (site of stimulation, duration, intensity, mode, 
 frequency) 
• Control paradigm used (placebo / sham / no intervention) 
• Type of pain related outcome measures, mean effects, and  
 statistical procedures  
• Observed side effects. 
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To facilitate the combination of results in meta-analyses, it was required that pain 
measurements (means and standard deviations post intervention, change over time 
and standard errors, or confidence intervals for mean values or for change over 
time) were reported. Trial authors were contacted via email when important data 
were missing (Higgins and Deeks, 2008).  
 
	  
3.2.4	  Assessment	  of	  risk	  of	  bias	  in	  included	  trials	  
 
Included trials were critically appraised for potential risk of bias by 2 independent 
researchers using the Cochrane risk of bias assessment tool (Higgins et al., 2008), 
as recommended by the PRISMA statement (Liberati et al., 2009). The risk of bias 
assessment was important for the evaluation of the internal validity of trial results 
and to estimate the overall level of evidence for tDCS for pain reduction (Higgins et 
al., 2008). The tool comprised the domains: Sequence generation, allocation 
concealment, blinding of participants, blinding of therapist, incomplete outcome 
data, selective outcome reporting, and other sources of bias. Each domain can be 
rated as high, low, or unclear risk of bias. When a domain was rated as "unclear" 
due to inadequate reporting, the trial authors were contacted via email and asked to 
clarify research procedures. Strength of inter-rater agreement was expressed using 
Cohen's Kappa coefficient (Cohen, 1960). In the case of continuing disagreement 
after discussion, a third researcher decided the risk of bias for the domain. Each risk 
of bias component was considered with regard to the key outcome measures 
(Higgins et al., 2008; Juni et al., 1999). If blinding of the therapist was impossible for 
technical reasons and therefore rated as of high risk of bias, but patient blinding was 
maintained, the trial was included in the meta-analysis. The domain "incomplete 
outcome data" was considered to induce a risk of bias if data were statistically 
analysed per-protocol and losses to follow-up were 20% or higher (Fewtrell et al., 
2008), or if participant withdrawal patterns indicated the risk of a systematic bias.  
 
To support the decision to include or exclude trials from the main meta-analysis, a 
summary risk of bias rating was conducted: Trials with a rating of “high risk of bias” 
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in one or more domains were assessed as of overall high risk of bias, trials with a 
rating of “unclear risk of bias” in one or more domains were assessed as of overall 
unclear risk of bias. The justification for inclusion or exclusion in the main meta-
analysis was detailed in an additional column of the risk of bias table specifying high 
risk of bias and external validity issues. 
 
3.2.5	  Summary	  Measures	  
 
Summary measures were means and standard deviations post intervention, change 
over time and standard errors, or confidence intervals for mean values or for change 
over time for any type of pain intensity measurement, including NRS, VAS, verbal 
rating scales or questionnaires. 
 
3.2.6	  Synthesis	  of	  results	  
 
All trials were included in the descriptive analysis. Meta-analyses across trials that 
had comparable outcome measures and comparable interventions in terms of nature, 
stimulation sites, mode, and duration were conducted using a random effects model 
allowing for population and intervention parameters (e.g. type of clinical pain, 
stimulation paradigm to vary between trials (Schmidt et al., 2009). Studies with high 
risk of bias domains can lead to invalid conclusions (Higgins et al., 2008). Trials with 
a high risk of bias in a minimum of 1 domain were therefore excluded from the meta-
analysis. 
 
The software used for the meta-analyses was Review Manager Version 5.0. 
Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. The 
meta-analyses were performed by entering the mean pain intensity and standard 
deviations post-intervention for the tDCS and the sham group into the Review 
Manager Software. Where standard deviations were not reported, they were 
estimated from reported confidence intervals (Higgins and Deeks, 2008). When 
numerical data were unavailable, data were extracted from published graphs.  
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3.2.7	  Risk	  of	  bias	  across	  trials	  
 
Results from the risk of bias assessment across trials were summarised narratively. 
Heterogeneity defined as inconsistency across studies was explored by I2. "I2 
describes the percentage of the variability in effect estimates that is due to 
heterogeneity rather than sampling error (chance)" (Deeks, 2008, p.276). 
 
3.2.8	  Additional	  analyses	  (sensitivity	  analysis)	  
 
A second meta-analysis including all trials independent of the results from the risk of 
bias assessment was conducted to evaluate whether risk of bias judgements for 
individual trials would influence the combined effect of tDCS on pain (Deeks, 2008; 
Higgins et al., 2008).  
 
3.2.9	  Overall	  level	  of	  evidence	  
 
The overall level of evidence for tDCS for the reduction of pain was evaluated using 
GRADE (Schunemann et al., 2008). The GRADE approach is used to formulate an 
overall conclusion on the level of evidence based on the methodological quality of 
included trials (Schünemann et al., 2008). Evidence based on RCTs with a low risk of 
bias is regarded as high while evidence from observational studies is regarded as 
low (Guyatt et al., 2008). Following specific criteria (e.g. imprecision of results 
indicated by wide confidence intervals), the level of evidence from low risk of bias 
RCTS can be downgraded by 1 or 2 levels. Accordingly, the level of evidence from 
observational studies can be upgraded when specific criteria are fulfilled (Guyatt et 
al., 2008).  
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3.3	  Results	  
 
3.3.1	  Study	  Selection	  
 
A total of 88 studies were identified during the electronic and hand search process. 
After screening titles / abstracts, 15 studies were retrieved as full text articles 
(Figure 3.1). Full text screening excluded 1 study (Roizenblatt et al., 2007), because 
it investigated the same study population as Fregni et al. (Fregni et al., 2006b), 
resulting in a total number of 14 included trials. The inter-rater agreement of studies 
to be included in the systematic review during title / abstract and full text screening 
was kappa 0.946 (p<0.0005). Disagreement (following discussion) was on 1 article 
out of 88. 
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Figure 3.1 Flowchart for study selection process (Moher et al., 2009) 
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Excluded due to high risk 
of bias  
or heterogeneity of 
outcome parameters 
(n=10) 
Records identified through 
database searching (n=86) 
Additional records identified 
through hand search (n=2) 
Records after duplicates removed (n=79) 
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(title and abstract) 
(n=79) 
Full-text articles assessed 
for eligibility 
(n=15) 
Trials included in  
meta-analysis 
(n=4) 
Trials included in 
qualitative synthesis 
(n=14) 
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3.3.2	  Risk	  of	  bias	  within	  studies	  	  
 
The risk of bias assessment resulted in a considerable number of "unclear" ratings. 
Most ratings of "unclear" were due to inadequate reporting (Table 3.2). Four authors 
were contacted to request clarification on details from 8 trials. Three authors 
responded and provided additional information and data. The risk of bias domains 
that most frequently received the ratings 'high' or 'unclear' referred to insufficiently 
described allocation concealment (all trials), unclear or invalid randomisation 
procedures (Antal et al., 2008, 2010; Bachmann et al., 2010; Csifcsak et al., 2009; 
Fenton et al., 2009; Terney et al., 2008; Valle et al., 2009) and not reporting missing 
data strategies (Antal et al., 2010; Boggio et al., 2009a, 2009b; Terney et al., 2008). 
Since only 1 trial had an accessible trial protocol (Fenton et al., 2009), selective 
outcome reporting for all other trials was rated as unclear. The key domain "other 
sources of bias" included methodological aspects such as differences between 
groups at baseline, parametrical statistical tests that were conducted on small 
sample sizes (Antal et al., 2010; Bachmann et al., 2010; Boggio et al., 2009a; 
Fenton et al., 2009; Valle et al., 2009) and further statistical issues (Antal et al., 
2010). The inter-rater agreement for the risk of bias assessment was kappa 0.950 
(p<0.0005). The third rater was approached to decide on 3 out of 98 conflicting 
evaluations that could not be resolved by discussion. 
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Table 3.2 Risk of bias assessment of included trials 
  1  2  3 a 3 b 4 5 6 Sum-
mary 
RoB 
RoB and external validity 
justification for inclusion in main 
meta-analysis 
Antal et al.   
 2008 
1st reviewer 
2nd 
reviewer 
U 
U 
U 
U 
L 
L 
U 
U 
L 
L 
U 
U 
L 
L 
U No high risk component.  
Antal et al.  
2010 
1st reviewer 
2nd 
reviewer 
3rd reviewer 
H 
H 
U 
U 
L 
L 
L 
L 
U 
U 
U 
U 
H 
U 
H 
H High risk of bias: No adequate 
randomization procedure. Numbers 
in each group too small. Data from 
crossover and sham-controlled 
study groups entered into the same 
data analysis. 
Bachmann 
et al. 2010  
1st reviewer 
2nd 
reviewer 
H 
H 
U 
U 
L 
L 
H 
H 
U 
U 
U 
U 
H 
H 
H High risk of bias due to small 
sample size and invalid sequence 
generation (pseudo randomised).  
Boggio et 
al. 2008  
1st reviewer 
2nd 
reviewer 
L 
L 
U 
U 
L 
L 
U 
U 
H 
H 
U 
U 
U 
U 
H High risk due to 4 drop-outs (20%) 
not accounted for.  
Boggio et 
al. 2009a  
1st reviewer 
2nd 
reviewer 
L 
L 
U 
U 
L 
L 
H 
H 
L 
L 
U 
U 
U 
U 
U Only high risk component refers to 
therapist blinding.  
Boggio et 
al. 2009b  
1st reviewer 
2nd 
reviewer 
L 
L 
U 
U 
L 
L 
H 
H 
U 
U 
U 
U 
H 
H 
H Small sample size, preliminary 
study. Two drop-outs (25%), 
reasons (scheduling issues) 
provided. 
Cfiszak et 
al. 2009  
1st reviewer 
2nd 
reviewer 
3rd reviewer 
U 
U 
U 
U 
L 
L 
L 
L 
L 
L 
U 
U 
U 
L 
H 
H  No randomization procedures 
reported. Small sample size for 
NAS as outcome measure. 
Fenton et 
al. 2009  
1st reviewer 
2nd 
reviewer 
U 
U 
U 
U 
L 
L 
L 
L 
L 
L 
H 
H 
H 
H 
H Small sample size, pilot study. 
Randomization procedure unclear. 
Raw data spreadsheet indicates 2 
drop-outs (22%) that were not 
reported (originally 9 patients 
participated in study). Protocol 
available, planned primary outcome 
"patient global assessment" not 
reported. 
Fregni et al. 
2006a  
1st reviewer 
2nd review 
3rd reviewer 
L 
L 
U 
U 
L 
L 
U 
U 
L 
U 
L 
U 
U 
U 
U 
U No high risk component. Allocation 
concealment clarified by author. 
Sample size calculation based on  
very large effect size.  
Fregni et al. 
2006b  
1st reviewer 
2nd 
reviewer 
L 
L 
U 
U 
L 
L 
H 
H 
L 
L 
U 
U 
L 
L 
U Only high risk component refers to 
therapist blinding (not possible). 
Allocation concealment clarified by 
author. Baseline pain scores higher 
in treatment group but not 
statistically significant. 
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Table 3.2 - continued 1 
Mori et al. 
2009  
1st reviewer 
2nd reviewer 
L 
L 
U 
U 
L 
L 
U 
U 
L 
L 
U 
U 
L 
L 
L No high risk component. Allocation 
concealment clarified by author. 
Sample size calculation based on  very 
large effect size. 
Soler et 
al.  
2010  
1st reviewer 
2nd reviewer 
L 
L 
U 
U 
L 
L 
U 
U 
U 
U 
U 
U 
L 
L 
U No high risk component. 
Terney et 
al. 2008  
1st reviewer 
2nd reviewer 
U 
U 
U 
U 
L 
L 
U 
U 
H 
H 
U 
U 
H 
H 
H Questionable intervention effect for 
group tDCS+placebo (pain reduction at 
time-point A2 only) 
Valle et 
al.  
2009  
1st reviewer 
2nd reviewer 
H 
H 
U 
U 
L 
L 
U 
U 
L 
L 
U 
U 
H 
H 
H Inappropriate randomisation procedure 
and small sample size. 
 
 
Footnotes: 1 Sequence generation; 2 Allocation concealment; 3a Blinding of participants; 3b Blinding of therapist; 4 Incomplete 
outcome data; 5 selective outcome reporting;  6 Other sources of bias. H= high risk of bias; U=unclear risk of bias; L= low risk of 
bias. Summary: high risk of bias = 1 or more of the key domains were rated as high; unclear =1 or more of the key domains 
were rated as unclear.  
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3.3.3 Data	  extraction	  
 
Methods: Of the 14 included trials, n=6 investigated the effect of tDCS on 
experimental pain and n=8 focused on clinical pain. The reported experimental pain 
paradigms were laser-evoked pain, mechanical and thermal pain, images of human 
pain and electrical pain stimuli.  
 
Participants: Clinical pain syndromes included a variety of chronic conditions such 
as chronic pelvic pain, fibromyalgia, and neuropathic pain due to spinal cord injury 
or multiple sclerosis (total number of participants n=167). Experimental pain trials 
only included healthy participants (n=89). 
 
Interventions: All trials investigating clinical pain employed anodal (positively 
charged electrode over the target area) stimulation over M1 (2 trials additionally 
applied tDCS to the DLPFC) with a duration of 20-30 minutes, and intervention 
repetitions from a single session to ten sessions on consecutive working days. 
Experimental pain trials varied greatly regarding the stimulation site and 
parameters. Two trials focused on anodal stimulation, 1 trial on cathodal stimulation 
and 3 trials applied both modes of stimulation. The M1 was stimulated in 5 of the 
trials, 2 of which also stimulated the visual cortex (V1) and the DLPFC. One trial 
investigated the stimulation of the S1 only. Duration of stimulation ranged from 5-15 
minutes. 
 
Outcomes: Outcome measures in all clinical pain trials included a NRS or VAS, 
while outcomes in all experimental pain trials were reported through numerical 
scales as well as pain thresholds and emotional discomfort (Tables 3.3 and 3.4).  
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Table 3.3 Characteristics of trials on experimental pain 
Authors, 
date 
(country) 
Type of  
pain  
Number 
of 
partici-
pants 
Age (mean 
or range)   
Stimulation 
mode   
Control  Site  Intensity 
 (mA)  
Duration 
(min) 
Side 
effects 
Pain related outcome 
measures 
Antal et al. 
2008 
(Germany, 
Hungary) 
laser-
evoked 
pain 
10 18-30 anodal 
cathodal 
sham S1 1 15 not reported NRS 
Bachmann 
et al. 2010 
(Germany) 
thermal + 
mechanical 
pain 
threshold 
8 25-41 anodal 
cathodal 
sham M1 1 15 not 
reported 
heat pain threshold, cold 
pain threshold, mechanical 
pain Threshold, wind-up 
Boggio et 
al. 2008 
(USA, 
Brazil) 
electrical 
stimulation  
20 21 anodal sham M1 
DLPFC 
V1 
2 5  headache 
tingling 
perception threshold, 
pain threshold 
Boggio et 
al. 2009a 
(USA, 
Brazil) 
images of 
human 
pain 
23  21 anodal sham M1  
DLPFC 
V1 
2 5  headache 
dizziness 
tingling 
emotional discomfort 
Csifcsak et 
al. 2009 
(Germany, 
Hungary, 
Denmark) 
laser-
evoked 
pain  
16 20-30 anodal 
cathodal 
sham M1 
 
1 10 not reported NRS 
Terney et  
al. 2008 
(Germany, 
Hungary) 
laser-
evoked 
pain 
12 20-31 cathodal 
+  
pergolide 
placebo 
medication 
M1 1 15 not reported NRS 
           
Footnotes: DLPFC= dorsolateral prefrontal cortex; LEPs= laser-evoked potentials; M1= primary motor cortex; NRS= Numerical Analogue Scale; S1= somatosensory cortex 
 
  58 
 
Author, year 
(country) 
Type of  
pain  
No. 
of pa-
tients  
Age (mean 
or range) 
Mode  Control  Site  Intensity  
(mA) 
Duration Side 
effects 
Pain  outcome measures 
Antal et al.  
2010  
(Germany) 
fibromyalgiap
ost-stroke, 
LBP, 
trigeminal 
neural. 
23 28-70 yrs anodal sham M1 1 20 min,  
5 days 
no adverse VAS, SICI  
(paired-pulse TMS) 
Boggio et al. 
2009 
(USA, Brazil, 
Australia) 
chronic pain 8 63.3 anodal 
+ 
TENS 
sham, 
sham TENS  
M1 2 30 min headache VAS 
Fenton et al. 
2009 
(USA, Brazil) 
chronic pelvic 
pain 
7 38 anodal sham 
M1 
1 20 min,  
2 days 
headache, neck pain, 
burning sensation, 
redness 
VAS 
Regional Pain Scale for 
FMS 
Fregni et al. 
2006 (USA, 
Brazil, Germany) 
fibromyalgia 32 53.4 anodal sham M1  
DLPFC 
2 20 min,  
5 days 
sleepiness, 
headache, local 
redness, itching 
VAS, 
analgesics 
use, tender points 
Fregni et al. 
2006 (USA, 
Brazil, Spain, 
Germany) 
spinal cord 
injury 
17 35.7 anodal sham M1 2 20 min,  
5 days 
headache,  
itching under electrodes 
VAS 
Mori et al.  
2009 (Italy) 
multiple 
sclerosis  
19 44.8 anodal sham M1 2 20 min,  
5 days 
no adverse effects VAS, SF-MPQ 
Valle et al. 2009 
(Brazil) 
fibromyalgia 41 54.8 anodal sham M1 
DLPFC 
2 20mins, 
10 days 
minor skin redness and 
tingling 
VAS, Fibromyalgia  
questionnaire 
Soler et al. 2010 
(Spain, USA) 
spinal cord 
injury 
20 45 anodal 
+visual 
illusion 
sham 
sham 
illusion 
M1 2 20 min, 
10 days 
mild headache, 
tiredness 
NRS, NPSI, BPI 
Footnotes: BPI= br                       
neuropathic pain sy                  
stimulation; VAS= vis    
Table 3.4 Characteristics of trials on clinical pain 
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3.3.4	  Synthesis	  of	  the	  results	  
 
3.3.4.1	  Descriptive	  analysis	  of	  trials	  on	  experimental	  pain	  
 
The overall high risk of bias in 4 out of 6 trials on tDCS for the reduction of 
experimental pain was mainly due to inadequate randomisation procedures, 
insufficient allocation concealment, and selective outcome reporting (Table 3.2). 
None of the trials on experimental pain had published a trial protocol. Trial reports 
did not define primary outcome measures but reported altered pain or sensory 
thresholds as main results, depending on statistical significance.  
 
Experimental pain was induced by different methods (Table 3.3) but always to the 
dorsal surface of the hand. Both anodal and cathodal stimulation demonstrated 
pain-relieving effects compared to sham stimulation. Sham stimulation in all trials 
was a brief period of stimulation that mimicked the typical initial burning sensation 
underneath the electrodes but had in previous research not resulted in 
neurophysiological change (Nitsche et al., 2003b). All trials reported some pain 
reduction with the stimulation paradigm chosen. Cathodal stimulation resulted in a 
statistically significant pain reduction when applied over S1 (Antal et al., 2008) and 
significantly reduced the laser intensities required to induce a mild pain sensation 
(Csifcsak et al., 2009), as well as the mechanical pain threshold (Bachmann et al., 
2010) when applied over M1. Small, but statistically significant effect sizes in pain 
reduction were achieved by Terney et al. (2008) after sham and cathodal stimulation 
of M1, measured 40 minutes post stimulation. Anodal stimulation of M1 
demonstrated significantly increased perception thresholds and increased pain 
thresholds in 1 trial (Boggio et al., 2008) that was not observed by other authors 
(Bachmann et al., 2010) and demonstrated no effect on pain reduction when applied 
over S1 (Antal et al., 2008). Anodal stimulation further reduced emotional discomfort 
when applied over DLPFC (Boggio et al., 2009b). Additionally, trials on experimental 
pain showed significantly altered neurophysiological measures such as the P2 and 
N2 components of evoked potentials as surrogate markers for pain perception 
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(Antal et al., 2008; Csifcsak et al., 2009; Terney et al., 2008). Owing to the variety of 
stimulation sites and parameters as well as outcome measures (e.g. pain 
thresholds, emotional discomfort, pain intensity) it was not feasible to combine data 
from the experimental pain trials.  
 
3.3.4.2	  Descriptive	  analysis	  and	  meta-­‐analyses	  of	  trials	  on	  clinical	  pain	  
 
Although trial populations included various clinical pain conditions, all trials applied 
anodal stimulation and used M1 as the site of stimulation. A numerical or visual 
rating scale was the primary or secondary outcome measure of all trials, thereby 
allowing synthesis of data in a meta-analysis.   
 
All 8 trials demonstrated a pain relieving effect. Six trials were conducted by the 
same research group (Boggio et al., 2009a; Fenton et al., 2009; Fregni et al., 
2006a, 2006b; Soler et al., 2010; Valle et al., 2009) inducing a risk for reporting 
bias. Four trials (Antal et al., 2010; Boggio et al., 2009a; Fenton et al., 2009; Valle et 
al., 2009) were excluded from the meta-analysis owing to a high risk of bias in 1 or 
more domains. In 2 cases, this referred to a very small sample size (n=7 (Boggio et 
al., 2009a)) and (n=8 (Fenton et al., 2009)) and methodological issues, such as 
insufficient allocation concealment and losses to follow-up (>20%) that were either 
not reported or not accounted for. Two trials (Antal et al., 2010; Valle et al., 2009) 
used a non-random sequence generation (order of entrance) and 1 trial entered 
data from 2 different trial designs (crossover trial and sham-controlled trial) into the 
same data analysis (Antal et al., 2010). Hence, 4 trials with a total of 107 patients 
were included in the meta-analysis. The pooled effect size (mean difference; 
random effects model) was -2.29 with a 95% confidence interval of -3.5 to -1.08, 
p=0.0002 (Figure 3.2).  
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Table 3.5 Reported outcomes of trials on experimental pain 
Author, 
year 
(country) 
Pain related outcome measures Neurophysiological outcome measures 
Antal  
et al. 2008 
(Germany, 
Hungary) 
 
 
 
 
 
Laser-induced pain pre and post tDCS over S1.  
Percentage change from baseline   
           
                     mean  (SD) 
cathodal    - 12.5% (2.14) 
sham         +  3.0%  (3.57) 
anodal       +  1.0%  (3.93) 
LEPs pre and post stimulation over S1. 
Percentage change from baseline. 
 
LEP N2        mean (SD)       LEP P2 mean (SD)  
cathodal       -32% (7.58)                   -13% (9.18) 
sham            -17% (7.58)                   + 7% (9.18) 
anodal          -11% (7.58)                   -11% (9.18) 
 
Bachmann  
et al. 2010 
(Germany) 
 
 
 
Cold pain threshold (F-value 0.42) and heat pain 
threshold (F-value 0.21) not significantly different 
after anodal, cathodal, or sham tDCS over M1.  
 
 
Boggio  
et al. 2008 
(USA, Brazil) 
 
  
 
 
 
Electrical pain threshold pre and post tDCS. 
Percentage change from baseline after anodal 
stimulation. 
        
                    mean 
M1                +8%  
DLPFC       +13% 
sham              0%  
 
 
 
Boggio  
et al. 2009b 
(USA, Brazil)   
 
 
 
 
 
 
 
 
Emotional discomfort / pain associated with images 
of human pain at baseline and post anodal 
stimulation. 
          
                mean NRS  (SD) 
Baseline    4.8            (0.84) 
M1              5.8            (1.09) 
V1               5.75          (1.09) 
DLPFC       4.45          (0.93) 
sham          5.05          (1.09) 
 
 
 
 
Csifcsak  
et al. 2009 
(Germany, 
Hungary, 
Denmark)  
 
 
 
 
 
 
 
 
 
Mean laser intensities to induce mild pain  
before and after stimulation over M1. 
 
cathodal          mean (mJ) 
before               523 
after                  556 
anodal 
before               510 
after                  495 
sham 
before               510 
after                  508 
 
 
LEPs before and after tDCS over M1. 
 
LEP N2       mean μV (SD)      LEP P2 mean μV (SD)  
cathodal   
before            -13.9      (7.2)                      20.04   (9.25) 
after                 -8.2      (6.2)                      15.56   (7.55) 
anodal 
before            -13.3      (6.8)                      19.38   (8.11) 
after               -10.6      (6.4)                      15.87   (6.82) 
sham 
before           -12.24      (8.7)                     16.03   (6.44) 
after                  -9.1      (6.2)                     15.23   (5.80) 
 
Terney  
et al. 2008 
(Germany, 
Hungary) 
 
 
 
   
 
 
 
Laser-induced NRS values before and after tDCS 
over M1. 
 
cathodal       mean NRS (SD)                           
before             4.39           (1.39) 
after                3.98           (1.66) 
sham 
before             3.28           (1.15) 
after                3.19           (1.32) 
 
 
LEPs before and after tDCS over M1. 
 
LEP N2       mean μV (SD)      LEP P2 mean μV (SD)  
cathodal  
before        -11.04      (5.82)              15.14      (6.96) 
after             -9.36      (6.59)              12.27      (7.11) 
sham 
before        -13.12      (7.52)              12.94      (3.51) 
after           -11.83      (7.92)              10.06      (3.21) 
Footnotes: LEP= laser evoked potentials; M1= primary motor cortex; NRS= numerical rating scale; S1= primary sensory cortex; SD= 
standard deviation; tDCS= transcranial direct current stimulation; V1= visual cortex. 
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Figure 3.2 Meta-analysis of 4 trials with a low or unclear risk of bias 
	  
3.3.4.3	  Heterogeneity	  
 
Although 3 of the 4 trials included in the meta-analysis adopted homogeneous 
methodological approaches (same research group), the diversity of clinical pain 
syndromes could introduce heterogeneity of intervention effects. However, the 
estimated heterogeneity across studies was I2=31%, P= 0.22 and χ2= 4.36 (Figure 
3.2). According to the Cochrane Handbook this level of heterogeneity (0-40%) is 
interpreted as "might not be important" (Deeks, 2008, p.278). It has been 
recommended that at least 10 trials should be included to distinguish chance from 
potential publication bias in the case of funnel plot asymmetry (Sterne, 2008), hence 
an exploration of publication bias in a funnel plot was not conducted. 
 
3.3.4.4	  Additional	  analyses	  (sensitivity	  analysis)	  	  
 
A second meta-analysis was conducted to explore whether exclusion of the 4 trials 
with a high risk of bias had influenced the findings of the first meta-analysis. A meta-
analysis of all 8 trials resulted in an effect estimate (mean difference; random effects 
model) of -1.51 with a 95% confidence interval from -2.34 to -0.68, p=0.0004 (Figure 
3.3). The level of heterogeneity was not changed when considering all trials 
(independent of associated risks of bias) in the meta-analysis (Figure 3.3). 
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Figure 3.3 Meta-analysis of all 8 trials 
 
3.4	  Discussion	  	   	  
 
3.4.1	  Discussion	  of	  results	  for	  tDCS	  for	  the	  reduction	  of	  experimental	  pain	  
 
The evidence for tDCS for pain reduction is currently based on 6 trials investigating 
experimental pain and 8 trials investigating chronic pain. Only 1 trial was assessed 
as showing an overall low risk of bias. Reporting did not follow current guidelines for 
the reporting of clinical trials, although the revised CONSORT statement was 
published in 2001 (Moher et al., 2001), e.g. procedures for allocation concealment 
were not described for any trial, randomisation procedures were not clearly stated in 
4 cases, and only 1 trial had a published trial protocol that detailed planned trial 
procedures and, thereby, minimised the risk of selective outcome reporting.  
 
Experimental pain trials applied a wide variety of tDCS parameters (stimulation 
sites, mode, duration) and the diversity of outcome measures as well as a high 
overall risk of bias in 4 out of 6 trials made it impossible to combine the data in a 
meta-analysis. Although all authors reported either significant pain reduction or 
reduced pain related outcomes, no consistent pattern for the most effective 
stimulation approach emerged. Whilst cathodal stimulation consistently altered the 
N2 and P2 components of laser evoked potentials (Antal et al., 2008; Csifcsak et al., 
2009; Terney et al., 2008), it only reduced perceived pain in 1 trial (Antal et al., 
2008). Anodal stimulation introduced small changes in emotional discomfort (Boggio 
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et al., 2009b) and increased the threshold to electrical pain in 1 trial (Boggio et al., 
2008). This finding was reproduced for mechanical but not for thermal pain 
thresholds by other authors (Bachmann et al., 2010). Further research is required to 
establish the most effective stimulation paradigm to reduce different types of 
experimental pain. Furthermore, future research should focus on the most 
responsive outcome measure for experimental pain reduction following tDCS, e.g. 
pain intensity measured on a numerical rating scale, laser-intensity (in μV) or 
hot/cold temperature (in C°) to induce the sensation of pain.   
 
It is unclear whether results from experimental pain trials can be translated to 
clinical pain reduction. Experimental pain has some advantages over clinical pain 
for research purposes as it can be standardised with regards to duration, intensity, 
frequency, and location, and applied to healthy volunteers who are less susceptible 
to confounding factors such as psychological disorders that frequently accompany 
chronic disease (Staahl and Drewes, 2004). Recently, authors confirmed the 
importance of experimental pain research for above mentioned reasons, but 
acknowledged that findings might not be relevant to clinical and, especially, chronic 
pain populations, since experimental pain cannot reproduce the psychological, 
cognitive and social aspects of the condition (Reddy et al., 2012). The current 
systematic review indicated that anodal stimulation, the stimulation mode used in all 
trials on clinical pain, had neither a positive nor negative effect in 3 experimental 
pain trials (Antal et al., 2008; Csifcsak et al., 2009; Terney et al., 2008), suggesting 
that healthy volunteers responded differently from clinical pain patients to anodal 
stimulation. Hence, while research applying experimental pain paradigms is helpful 
to further understand the neurophysiological mechanisms underlying the effect of 
tDCS, results from tDCS on experimentally induced pain might not be transferable 
to clinical pain patients.  
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3.4.2	  Discussion	  of	  results	  for	  tDCS	  for	  the	  reduction	  of	  clinical	  pain	  
 
The evidence for the reduction of clinical pain was more consistent than the 
evidence from trials on experimental pain: all trials employed anodal stimulation of 
M1 with intensities of either 1 or 2 mA, with 2 mA delivered for 20 minutes, on 5 
consecutive days, as the most frequently used combination of stimulation 
parameters. A pooling of the effect sizes was feasible since all trials used a 
numerical scale to measure pain. However, only 4 trials met the minimum 
methodological requirements to be included into the meta-analysis and data of 
different patient populations with different types of clinical pain (fibromyalgia, pain 
due to spinal cord injury and pain due to multiple sclerosis) were combined. All pain 
conditions represented chronic pain populations and similar reductions in pain were 
reported across all trials, supporting the potential transferability of systematic review 
results to further chronic pain populations.  
 
Although effects for pain were reported as statistically significant across all trials, the 
pooled effect of -2.29 with a 95% confidence interval of -3.5 to -1.08 just reach 
clinical importance. Minimal clinically important pain reduction was reported as 15 
mm on a 0-100 mm VAS, equivalent to 1.5 cm on a 0-10 cm NRS (Ostelo et al., 
2008) and more recently as 2.4 cm on a 0-10 cm NRS (Maughan and Lewis, 2010). 
The results from the sensitivity analysis that included trials with a high risk of bias 
showed an effect size of -1.51 (95% confidence interval -2.34 to -0.68). Sensitivity 
analysis results were just within limits of the lowest minimum clinically relevant 
change recommendation (Ostelo et al., 2008). Comparing the results of both meta-
analyses showed that the high risk of bias trials did not result in larger effect sizes 
for pain reduction than trials that only had a low or unclear risk of bias. The width of 
the confidence interval was comparable for both analyses, hence, methodological 
quality of trials did not appear to influence precision of the results. 
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3.4.3	  Discussion	  of	  systematic	  review	  results	  based	  on	  current	  evidence	  	  
 
The findings of this systematic review were comparable with the conclusions from 
the systematic review and meta-analysis published by the Cochrane Collaboration 
(O’Connell et al., 2010) that reported a low level of methodological quality of 
available trials. The meta-analysis from O’Connell et al. (2010) resulted in a 
standardised mean difference of -0.59 with a 95% CI from -1.10 to -0.08 with p=0.02 
(tDCS short-term follow-up, M1 stimulation). In the current review, when using 
standardised mean differences instead of the reported mean differences, the effect 
was estimated as -0.97 (95% CI -1.49 to -0.45). This small difference was 
introduced by 1 recent trial that was included in this current meta-analysis (Soler et 
al., 2010) and 2 trials that were excluded owing to a high risk of bias (Boggio et al., 
2009a; Fenton et al., 2009).  
 
The small, but statistically significant, combined mean effect for pain reduction only 
referred to immediate results after the final stimulation. Further research, of high 
methodological quality is required that investigates longer-term effects of tDCS on 
pain reduction.  
 
Using GRADE, the quality of the evidence for tDCS as a method to reduce pain, 
based on the 4 trials included in the meta-analysis, was low. This estimate is 
interpreted as "further research is very likely to have an important impact on our 
confidence in the estimate of effect and is likely to change the estimate" (Guyatt et 
al., 2008, p.926). This interpretation was the result of downgrading the level of 
evidence by 2 levels due to limitations in the design of the included trials (3 trials 
with an unclear risk of bias) (Fregni et al., 2006a; Fregni et al., 2006b; Soler et al., 
2010) and overall imprecision of results (wide confidence intervals in trials with 
small sample sizes) in all trials.  
 
To upgrade the level of evidence for tDCS for the reduction of clinical pain and to 
allow recommendations for the future use of tDCS, a well-designed, low risk of bias 
randomised controlled trial with an adequate sample size is required that assesses 
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the effect of tDCS on pain and includes follow-up time-points for the evaluation of 
longer-term effects of the intervention.  
 
3.4.4	  Limitations	  of	  the	  systematic	  review	  
 
• When data were unavailable from the trial reports and after unsuccessful 
contact of trial authors, values for mean pain intensity and standard 
deviations were retrieved from graphs. This procedure might have introduced 
some inaccuracy in the data but allowed the inclusion of trials that would 
have otherwise been excluded. 
 
• Systematic review results only refer to short-term pain reduction immediately 
after the final stimulation. For the clinical use of tDCS it would be essential to 
evaluate longer-term results.  
 
 
Chapter summary 
 
This chapter has detailed the process and the results of a systematic review 
including a meta-analysis on tDCS for the reduction of experimental and clinical 
pain. The systematic review was published in the Clinical Journal of Pain (Journal 
Impact Factor 2.552) in 2012 (Luedtke et al., 2012b) (Appendix 3.1). 
 
Fourteen trials, 6 on experimental pain and 8 on clinical pain, were included in this 
review. Only 1 trial on clinical pain was assessed as having an overall low risk of 
bias. Seven trials had methodological shortcomings. Trials on experimental pain 
investigated different stimulation approaches and used a wide variety of outcome 
measures. Future research is required to establish an effective stimulation paradigm 
and to identify reliable and responsive outcome measures. A meta-analysis of all 
trials on clinical pain indicated that pain reduction just reached a minimal clinically 
important difference. The stimulation paradigm applied in the majority of trials was 2 
mA for 20 minutes, on 5 consecutive days. The transferability from experimental trial 
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results to clinical pain has still to be established. Hence, to promote a 
recommendation for the clinical effectiveness of tDCS for the reduction of pain, 
future research should focus on clinical pain conditions. 
 
The overall level of evidence was rated as "low". Based on the current level of tDCS 
no recommendation can be made for its use in clinical practice. In conclusion, there 
was a need for a well designed randomised controlled trial, with an adequate 
sample size, to assess the effectiveness of tDCS for the reduction of clinical pain.  
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4.	  CHAPTER	  	  
 
EFFECTIVENESS	  OF	  ANODAL	  TRANSCRANIAL	  DIRECT	  
CURRENT	  STIMULATION	  IN	  PATIENTS	  WITH	  NON-­‐SPECIFIC	  
CHRONIC	  LOW	  BACK	  PAIN:	  DESIGN	  AND	  METHODS	  FOR	  A	  
RANDOMISED	  CONTROLLED	  TRIAL	  
 
Previous chapters have presented the theoretical background and the current 
evidence on tDCS for the reduction of pain. The systematic review and meta-
analysis of the available evidence concluded that there was a low level of evidence 
for tDCS as an intervention for pain reduction. Experimental pain trials did not 
demonstrate conclusive results regarding optimum stimulation parameters and 
outcome, and the transferability of results to clinical pain was questioned. To assess 
the effectiveness of tDCS for the reduction of clinical pain, methodologically sound 
RCTs, with adequate power were required. This chapter details the design and 
methods for an RCT investigating the effect of tDCS alone and in combination with 
CBT on NSCLBP.  
 
4.1	  Trial	  objectives	  
 
The main objectives of this trial were:  
• To investigate the immediate effectiveness of tDCS on NSCLBP. 
• To investigate whether tDCS as an adjunct further improved the immediate 
effectiveness of a CBT in patients with NSCLBP. 
 
A secondary objective was: 
• To assess after how many days of stimulation a pain reducing effect occurred. 
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4.2	  Trial	  design	  
 
A single-centre, double blind, sham-controlled, stratified parallel group RCT, with 2 
study arms, was designed and conducted in Germany. The trial design and its 
reporting followed the internationally recognised recommendations published by the 
CONSORT group (Schulz et al., 2010), the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH, 1996), the World Medical Association's Declaration of Helsinki 
(WMA, 2008) and the Cochrane Collaboration (Sterne, 2008). A well-conducted 
RCT is considered to be the gold standard for evaluating the effect of an 
intervention (Barton, 2000; Grossman and Mackenzie, 2005; Kaptchuk, 2001; 
Manchikanti et al., 2003) and was therefore the design of choice to investigate the 
effectiveness of tDCS in NSCLBP. Randomisation of participants to sham (Section 
4.5.2) and verum tDCS (Section 4.5.1) was required to ensure that the measured 
effects were the result of the stimulation mode and not influenced by selection or 
sampling bias (selection of participants likely to respond to tDCS) (Altman and 
Bland, 1999b). The sham arm of the trial controlled for the potential placebo (e.g. 
montage of electrodes, attention of researcher) (Manchikanti et al., 2003). 
Participants and researcher were blind to the group allocation throughout the data 
collection period and during the analysis of the data, to avoid reporting and observer 
bias (Hrobjartsson and Boutron, 2011; Psaty and Prentice, 2010). 
 
All participants received 5 consecutive days of tDCS (verum or sham) (Section 4.5), 
followed by a 4-week CBT programme, which was the standard care for NSCLBP 
patients at the study centre. International guidelines recommended CBT as the most 
effective available management for NSCLBP (Section 1.1.3.3.1). It was neither 
feasible nor ethical to deprive patients of their recommended management. Hence, 
tDCS was applied as an adjunct to CBT to investigate whether tDCS further 
improved the effectiveness of the CBT. Outcomes were measured prior to the first 
stimulation, 24 hours after the final stimulation, at the end of the CBT and at 4, 12, 
and 24 weeks follow-up (Section 4.8.2). This study design (Figure 4.1) was 
developed to enable testing of the immediate effect of tDCS alone, and the 
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immediate and longer-term effect (final follow-up at 24 weeks post intervention) of 
tDCS as an adjuvant prior to a CBT.  
 
 
 
 
Figure 4.1 Trial design flowchart  
	  
	  
	  
	  
  
sham 
Baseline	  assessment	   
Post-­‐intervention	  assessment	  2 
Follow-­‐up	  assessments	  	  
4	  weeks,	  12	  weeks	  and	  24	  weeks 
	  Post-­‐intervention	  assessment	  1 
tDCS 
	  
Cognitive-­‐behavioural	  programme	  
(CBT) 
5	  days	  daily 
4	  weeks 
Screening	  and	  randomisation	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4.3	  Eligibility	  criteria	  for	  participants	  
 
4.3.1	  Inclusion	  criteria	  
 
Eligible participants were adults aged 18-65 years, with NSCLBP (as defined in 
Section 1.3), who met the eligibility criteria for a CBT at a back pain clinic in 
Germany. Although back pain occurs in patients younger than 18 years (McBeth and 
Jones, 2007), its prevalence increases with age until it gradually declines from the 
age of 60-65 (Hoy et al., 2010). The upper age limit of 65 years was selected 
because it was the legal age for retirement in Germany and health insurances do not 
pay for pain management programmes beyond that age since they target the 
patient's capacity to return to work. Hence, this age restriction was important 
because all patients were required to commence a CBT programme after the 
stimulation period. The lower age limit of 18 years was required because at 
commencement of the study, there was no prior evidence that tDCS was safe in 
under 18 year olds. The first research study on the tolerability of tDCS in children 
and adolescents was published after commencement of the trial and considered only 
children and adolescents with psychiatric disorders (Mattai et al., 2011). A 
computational model, developed during the data collection period, confirmed the 
decision to exclude children. The model indicated that tDCS induced higher electrical 
fields when applied to the brain of a child. Studies on paediatric populations, 
therefore, would require different stimulation parameters (Minhas et al., 2012). 
 
Eligibility for the CBT programme required the patient to understand and speak 
German so that they could benefit from the cognitive elements within it. The patient 
had to be a member of a participating health insurance company that covered the 
costs of the CBT. Health insurance is compulsory in Germany. Private and public 
health insurance companies participated in the CBT scheme covering a wide range 
of patients of different socio-economic background. Bias due to health insurance 
membership was therefore not expected. Patients had to be motivated to return to 
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work after the programme (a health insurance requirement) and had to be physically 
fit (e.g. without severe cardiorespiratory disease) to tolerate a 4-week physical 
training programme. Eligibility for the CBT was confirmed by agreement of an 
orthopaedic consultant, a psychologist, and a physiotherapist following a standard 
screening procedure (standard procedure of back pain clinic). 
	  
4.3.2	  Exclusion	  criteria	  
 
Participants who fulfilled the inclusion criteria were excluded if they had any of the 
following: 
 
• Other chronic pain syndromes: in particular other musculoskeletal pain 
syndromes (e.g. chronic neck pain), since no research was identified that 
reported whether or how 2 or more chronic pain syndromes interact within 
the central nervous system.  
 
• Spinal surgery in the past 6 months: patients were excluded if they were 
recovering from surgery because any effect of the stimulation would be 
confounded with the natural course of healing. After 6 months the majority of 
spinal surgery patients returned to work and sports, and were regarded as 
fully recovered (Oestergaard et al., 2012; Reinhold et al., 2010; Watkins et 
al., 2012).  
 
• Neurological disease: any neurological disease that might have an impact on 
the brain cortex of the participant, such as Parkinson's disease (Brown et al., 
2008; Pasquereau and Turner, 2011; Vardy et al., 2011), multiple sclerosis 
(Ceccarelli et al., 2010; Filippi et al., 2002; Valsasina et al., 2011), or epilepsy 
(O’Muircheartaigh et al., 2011; Vollmar et al., 2011). These were excluded 
because it was unknown whether central nervous system diseases affected 
the cortical response to tDCS.  
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• Psychiatric disease: especially severe depression that could reduce the 
chances to gain any benefit from either the tDCS intervention or the CBT. It 
was shown that severe depression strongly influenced the transition from 
acute to chronic pain (Epping-Jordan et al., 1998) and that highly distressed 
patients benefited less from therapy interventions (McCracken and Turk, 
2002). Although tDCS had been applied to reduce depression in the past, 
those trials used a different stimulation approach by targeting the DLPFC 
(Boggio et al., 2007; Dell’Osso et al., 2012, 2011).  
 
• Pregnant or trying to become pregnant: no published research had 
investigated whether (or how) tDCS affects the foetus. 
 
• Alcohol, drug, or medication abuse: no published research had evaluated the 
interaction of substance abuse with the response to tDCS or CBT. It was 
known that centrally effective medication influenced the effect of tDCS 
(Terney et al., 2008), therefore, substances such as alcohol that affect the 
central nervous system should not be consumed immediately prior to or after 
the stimulation. 
 
The eligibility criteria were similar to those used in recent large trials on patients with 
non-specific CLBP who were treated in pain management programmes with 
cognitive-behavioural elements (Dufour et al., 2010; Lamb et al., 2010). Additional 
exclusion criteria were applied based on those used in published tDCS trials (Antal et 
al., 2010; Fregni et al., 2006a, 2006b). Although medication intake was not specified 
as an exclusion criterion, type and dosage of preventive and acute medication was 
recorded and any change in medication was documented to allow distinction 
between stimulation and medication effects. 
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4.4	  Settings	  and	  location	  for	  data	  collection	  
 
Patients were recruited and treated at a back pain clinic in North Germany, starting 
from January 2011. The clinic was established in 2001 and specialises in the 
management of patients with ongoing spinal pain. The CBT programme is led by 
orthopaedic specialists, physiotherapists, sports scientists, and psychologists with 
expertise in chronic pain management. Based on initial feasibility work, 100 to 150 
eligible non-specific CLBP patients per year are treated at the clinic. Patients were 
referred by their health insurance company when they had been off work for more 
than 6 weeks, or, repeatedly during the past 12 months, due to NSCLBP.  
 
4.5	  Interventions	  	  
 
4.5.1	  Verum	  tDCS	  (intervention	  group)	  
 
4.5.1.1	  Stimulation	  paradigm	  
 
Participants in the verum group received 20 minutes of anodal stimulation over the 
left M1 with an intensity of 2 mA, on 5 consecutive days, administered by the 
researcher. Selection of this stimulation paradigm was based on results from the 
systematic review of the current available evidence (Section 3.4.2). The review 
indicated that all trials on chronic pain had stated a positive effect from anodal 
stimulation over M1, with some variation in intensity, duration, and number of 
stimulations (Luedtke et al., 2012b). The most frequently applied paradigm in trials 
with the lowest risk of bias was 2 mA on 5 days for 20 minutes per session (Fregni et 
al., 2006a, 2006b; Mori et al., 2009). The application of tDCS on consecutive days 
was supported by trials that resulted in a greater cumulative effect on cortical 
excitability or a greater pain reducing response than single session tDCS (Alonzo et 
al., 2013; Fregni et al., 2006a, 2006b; Reis et al., 2009). 
 
  76 
4.5.1.2	  Localisation	  of	  the	  stimulation	  site	  
 
Single-pulse TMS was used to accurately determine the position of M1 and, 
therefore, the ‘hotspot’ for the tDCS stimulation in an individual participant: A figure of 
8 coil with an outer diameter of 70 mm was placed over the left side of the skull near 
the anticipated area of M1 (Figure 4.2). The single-pulse TMS was produced with an 
initial intensity of 50% by a Magstim 200 magnetic stimulator (The Magstim 
Company, Dyfed, UK). The position of the coil was adjusted and intensity of the 
magnetic pulse increased (as necessary) until an isolated twitch of the right abductor 
digiti minimi muscle was observed by the researcher. This procedure had been 
reported as a reliable technique for the localisation of the M1 in a trial that 
investigated the reliability of motor mapping on 6 healthy volunteers on 2 separate 
days (Mortifee et al., 1994). The procedure had been used in previous trials on tDCS 
(Fregni et al., 2006a; Jurgens et al., 2012; Luedtke et al., 2012a; Nitsche et al., 
2007). 
 
 
                          
tDCS was produced by a battery driven small stimulator device and applied to the 
skull via sponge electrodes (Figure 4.4). Large size (7x5 cm = 35 cm2) sponge 
electrodes, comparable to those used in all previous trials on tDCS in patients with 
Figure 4.2 Position of the TMS coil to identify M1       Figure 4.3 Localisation of left M1 (blue) and 
                                                                                      approximate position of the abductor digiti  
                                                                                      minimi muscle (red) 
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chronic pain, were soaked in a saline solution (0.9%), then placed over the 
stimulation sites, and held in place by elastic bandages (Figure 4.5). The anode 
(positively charged electrode) was placed over the left M1, while the cathode 
(negatively charged electrode) was placed supraorbitally on the opposite side (above 
the right eyebrow). The electricity was slowly increased to 2 mA at the beginning of 
the stimulation and slowly decreased at the end of the stimulation, to reduce skin 
sensations, such as itching or burning, underneath the electrodes (Ambrus et al., 
2012). When the electrodes were securely attached, the participants chose a 
comfortable position (in most cases supine with legs elevated) for the duration of the 
stimulation.  
 
                                                                  
             
Figure 4.4 tDCS machine (NeuroConn) and stimulation sites            Figure 4.5 Attachment of the             
                                                                                                             electrodes with elastic bandages          
	  
	  
4.5.2	  Sham	  Intervention	  (comparator	  group)	  
 
The sham procedure was identical to the verum stimulation procedure (Section 4.5.1) 
except that the DC stimulator automatically switched off after 30 seconds (after 
slowly reducing the stimulation intensity). The machine display continued to indicate 
the time and the impedance in the same manner as during the verum stimulation. 
During the initial 30-second stimulation period, participants perceived skin sensations 
identical to those perceived during the real stimulation. This short stimulation did not 
result in any measurable neurophysiological changes as identified by motor evoked 
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potentials and somato-sensory evoked potentials (Kirimoto et al., 2011; Nitsche and 
Paulus, 2001) and had been used as a placebo condition in all previous trials on 
tDCS for the reduction of chronic pain (Antal et al., 2010; Boggio et al., 2009a; 
Fenton et al., 2009; Fregni et al., 2006a, 2006b; Mori et al., 2009; Soler et al., 2010; 
Valle et al., 2009). Due to the initial brief stimulation period and the associated skin 
sensation as well as the identical machine display, this method is regarded as a 
reliable placebo condition for double blind trial designs (Gandiga et al., 2006; Loo et 
al., 2010; Priori et al., 2009) (further detail on blinding is given in Section 4.12). 
	  
4.6	  Standard	  Care:	  CBT	  programme	  	  
 
A maximum of 8 patients per group received physically challenging sessions, 
including cardiovascular exercises, machine assisted muscle strength training, 
specific muscle stabilisation exercises for the trunk muscles, work hardening 
sessions, as well as information sessions on the neurophysiology of pain, pain 
coping strategies, and relaxation classes. Individual physiotherapy sessions were 
added in the case of specific needs, such as acute pain limiting the capacity for 
exercise. Patients attended 5 hours daily (Monday to Friday) for 4 weeks as 
outpatients. The CBT programme was delivered by an interdisciplinary team of 
orthopaedic consultants, physiotherapists, psychologists, and sports scientists.  
 
CBT programmes have been reported internationally as effective for the reduction of 
pain and the improvement of function and disability in patients with CLBP (Bendix et 
al., 1996; Dufour et al., 2010; Lamb et al., 2010). However, the addition of techniques 
directly influencing central nervous system pain processing, such as tDCS, might 
further contribute to the reduction of pain and associated symptoms in NSCLBP 
(Section 1.1.3.3.1). The effectiveness of this CBT programme was later evaluated by 
Heinrich et al. (2011), who found a significant reduction in pain (F=96.61; df=2.65; 
p≤0.001), disability (F=210.79; df=1.48; p≤0.001), and function (F=139.3; df=2.28; 
p≤0.001) immediately after the programme. The effects remained stable at a 12 
months follow-up (Heinrich et al., 2011).  
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4.7	  Primary	  and	  secondary	  outcome	  measures	  	  
 
NSCLBP is a condition that is influenced by a variety of contributing physical and 
psychosocial factors (Alschuler et al., 2011). Hence, it has been recommended in the 
research literature that a range of outcome measures should be used (dependent on 
the research question and the study design) to capture the influence of the 
intervention (Chapman et al., 2011; Turk et al., 2003). The Initiative on Methods, 
Measurement, and Pain Assessment in Clinical Trials (IMMPACT) defined the 
following outcome domains as important for chronic pain trials: pain, physical 
functioning, emotional functioning, participant ratings of improvement and 
satisfaction, symptoms and adverse events, as well as participant disposition (e.g. 
adherence to the treatment regimen and reasons for premature withdrawal from the 
trial) (Turk et al., 2003). This recommendation is supported by the World Health 
Organisation's International Classification of Functioning, Disability and Health (ICF) 
that highlights that a disease or impairment does not only result in impaired physical 
structures and functions but also in reduced activities and participation. It further 
stresses the importance of environmental factors (World Health Organisation, 2014). 
Hence, a range of outcome measures is required to cover all aspects of chronic pain.   
 
4.7.1	  Primary	  outcome	  measures	  
 
tDCS and CBT have different roles within the management of NSCLBP. tDCS 
directly targets pain-processing areas within the brain, aiming to reduce pain 
intensity. Pain intensity was therefore required as a primary outcome measure for the 
effectiveness of tDCS. It covers the first domain of the IMMPACT recommendations 
(Turk et al., 2003) and the domain "physical structures" of the ICF core set for LBP 
(Cieza et al., 2004). CBT targets disability, cognitions and beliefs associated with 
chronic pain and other psychosocial aspects of the pain experience and might not 
necessarily result in a reduction of pain intensity (McCracken and Turk, 2002; 
Scascighini et al., 2008; Turk, 2002). Hence, to answer the research question on the 
combined effect of tDCS and CBT, a second primary outcome measure was required 
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that reflected the effects of the CBT. Recent trials on the effectiveness of CBT were 
identified and screened for primary endpoints (Brox et al., 2009; Dufour et al., 2010; 
Fairbank et al., 2005; Johnsen et al., 2013; Kääpä, 2008; Lamb et al., 2010; Smeets 
et al., 2006b). The only outcome measure included in all trials was disability. 
Disability covers the domain "physical functioning" of the IMMPACT 
recommendations and the domain "activities and participation" of the ICF core set for 
LBP (Cieza et al., 2004). High levels of disability were consistently reported in 
patients with LBP / CLBP (Sections 1.1 and 1.2) and correlated with reduced quality 
of life (Guclu et al., 2012; Kovacs et al., 2004). Disability was, therefore, an important 
second primary outcome measure. The statistical implications associated with 2 
primary outcome measures are discussed in the section on data analysis (Sections 
4.3 and 4.13). 
 
4.7.1.1	  Visual	  analogue	  scale	  for	  pain	  (VAS)	  
 
Pain intensity was chosen as a primary outcome measure, to reflect the 
neurophysiological mechanisms of tDCS and to allow the comparison of trial results 
with previously published research. All published tDCS trials measured pain intensity 
on NRS or VAS for pain (Antal et al., 2010; Boggio et al., 2009a; Fenton et al., 2009; 
Fregni et al., 2006a, 2006b; Mori et al., 2009; Soler et al., 2010; Valle et al., 2009).  
 
In the current trial, pain intensity was measured on a VAS (0-100 mm), where 0 mm 
indicated no pain and 100 mm indicated the worst imaginable pain (Appendix 4.2). 
VAS for pain is an internationally validated (Gramling and Elliott, 1992; Jensen et al., 
1986) and reliable (Lundeberg et al., 2001) tool, easy to use and understood by 
patients (McCormack et al., 1988). The recommended minimum clinically important 
change for visual and numerical pain scales in chronic pain patients ranged from 15 
mm (Ostelo et al., 2008) to 24 mm (Maughan and Lewis, 2010). Back pain might vary 
in intensity throughout the day and, consequently, can be difficult to quantify (De 
Souza and Frank, 2000). Hence, for the purpose of this trial, participants were 
instructed to indicate the average pain level during the past 24 hours. Average pain 
ratings had been used as a primary outcome measure in all previous tDCS trials and 
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were reported to be more consistent than recalled minimum or maximum levels of 
pain, when compared to momentary pain ratings recorded throughout the day (Stone 
et al., 2010).  
 
4.7.1.2	  Disability	  
 
The 2 most frequently used and internationally validated tools to measure disability in 
previously published trials were the Roland Morris Disability Questionnaire (RMDQ) 
(Roland and Morris, 1983) and the Oswestry Disability Index (ODI) (Fairbank et al., 
1980). Both questionnaires were recommended for research use in LBP populations 
(Chapman et al., 2011; Deyo et al., 1998), and both tools have previously been 
shown to discriminate accurately between LBP patients with high and low levels of 
disability (Leclaire et al., 1997). Table 4.1 details the test properties of the ODI and 
RMDQ. Findings differed across studies. Since 1 publication evaluated the ODI as 
more sensitive to change than the RMDQ (Davidson and Keating, 2002), and other 
authors reported RMDQ to be the more sensitive to change (Beurskens et al., 1996), 
a small preliminary study was conducted to evaluate sensitivity to change of both 
outcome measures in the proposed study population. 
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Table 4.1	  Test properties of ODI and RMD	  	  
 ODI	   RMDQ	   References	  
Authors	  /	  Date	  	  
Range	  
Instructions	  
for	  patients	  
Fairbank	  /	  1980	  
0-­‐24	  Points	  
"Please	  answer	  every	  section	  and	  mark	  in	  each	  one	  only	  the	  
one	  box	  which	  applies	  to	  you."	  
Roland	  &	  Morris	  /	  1983	  
0-­‐50	  Points	  
"Check	  the	  box	  before	  each	  sentence	  that	  describes	  
you	  today.	  Leave	  the	  box	  blank	  if	  the	  sentence	  does	  not	  
describe	  you."	  
(Roland	  and	  Morris,	  1983;	  Fairbank	  et	  al.,	  1980)	  
Validated	  in	  
German	  
yes	   yes	   (Exner	  and	  Keel,	  2000;	  Mannion	  et	  al.,	  2006;	  
Osthus	  et	  al.,	  2006)	  	  	  
Test-­‐Retest	  
Reliability	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	  
Same	  day:	  ICC	  =	  0.99	  
4	  days:	  	  	  	  	  	  	  ICC	  =	  0.91	  
1	  week:	  	  	  	  	  	  ICC	  =	  0.83	  
(excellent	  to	  adequate)	  
Same	  day:	  	  	  	  	  	  ICC	  =	  0.91	  
1	  to	  14	  days:	  	  ICC	  =	  0.93	  
3	  to	  6	  weeks:	  ICC	  =	  0.86	  
(excellent	  to	  adequate)	  
(Davidson	  and	  Keating,	  2002;	  Fairbank	  et	  al.,	  
1980;	  Fairbank,	  2000;	  Gronblad	  et	  al.,	  1993;	  
Kopec	  et	  al.,	  1996;	  Osthus	  et	  al.,	  2006;	  Vianin,	  
2008)	  
Internal	  
consistency	  
Cronbach’s	  alpha	  ranged	  from	  0.71	  to	  0.87	  
(acceptable)	  
Cronbach's	  alpha	  =	  0.83	  
(acceptable)	  
(Fairbank	  and	  Pynsent,	  2000;	  Fischer	  et	  al.,	  2001;	  
Kopec	  et	  al.,	  1996;	  Mousavi	  et	  al.,	  2006;	  Strong	  et	  
al.,	  1994;	  Vianin,	  2008)	  
Sensitivity	  to	  
change	  /	  
responsiveness	  
	  
	  
High	  responsiveness	  (Vianin,	  2008)	  
Might	  not	  be	  sensitive	  to	  change	  at	  lower	  levels	  of	  disability	  
(Dawson	  et	  al.,	  2010;	  Beurskens	  et	  al.,	  1996).	  
ODI	  more	  responsive	  to	  change	  than	  RMDQ	  (Davidson	  and	  
Keating,	  2002).	  
Directly	  compared	  to	  RMDQ:	  equal	  properties	  in	  the	  
detection	  of	  improvement	  or	  worsening	  of	  patient	  symptoms	  
(Stratford	  et	  al.,	  1996).	  
Might	  not	  detect	  improvements	  in	  patients	  with	  an	  
initial	  score	  above	  20	  or	  decreases	  in	  patients	  with	  an	  
initial	  score	  below	  4.	  
Directly	  compared	  to	  ODI:	  equal	  properties	  in	  the	  
detection	  of	  improvement	  or	  worsening	  of	  patient	  
symptoms	  (Stratford	  et	  al.,	  1996).	  
(Beurskens	  et	  al.,	  1996;	  Davidson	  and	  Keating,	  
2002;	  Dawson	  et	  al.,	  2010;	  Fairbank,	  2000;	  
Stratford	  et	  al.,	  1996;	  Vianin,	  2008)	  
MCRC	   0%	  
6-­‐17	  points	  
30%	  
2-­‐5	  points	  
(Bombardier	  et	  al.,	  2001;	  Jordan	  et	  al.,	  2006;	  
Kovacs	  et	  al.,	  2007;	  Maughan	  and	  Lewis,	  2010;	  
Ostelo	  et	  al.,	  2008)	  
Footnotes:	  ICC=intraclass	  coefficient;	  MCRC=minimum	  clinically	  relevant	  change;	  ODI=Oswestry	  Disability	  Index;	  	  RMDQ=Roland	  Morris	  Disability	  Questionnaire	  
  83 
4.7.1.2.1	  Evaluation	  of	  ODI	  and	  RMDQ	  
 
Both outcome measures were evaluated during a 3-month preliminary study prior to 
commencement of the trial, to determine which tool was easiest to use and most 
responsive to change in a sample taken from the anticipated study population. The 
validated German versions of the ODI (Mannion et al., 2006) and the RMDQ (Exner 
and Keel, 2000) were completed pre- and post-intervention, by 27 consecutive 
NSCLBP patients who were participating in a CBT programme during the 3-month 
preliminary phase. Responsiveness to change was analysed by calculating 
standardised response mean (mean change divided by standard deviation of change 
scores) for each outcome measure (Beurskens et al., 1996; Davidson and Keating, 
2002; Monticone et al., 2011; Stratford et al., 1996). The results (Table 4.2) indicated 
that both tools had comparable standardised response mean values of 1.29 and 1.17 
for RMDQ and ODI, respectively. However, the RMDQ was rated as 0 in 7 out of 27 
post-CBT-patients (floor-effect), indicating that these patients were fully recovered 
after the CBT. Only 2 of these patients also scored 0 on the ODI post-CBT, while the 
remaining 5 still showed some disability according to the ODI (Figures 4.6 and 4.7) 
(Appendix 4.1). This result is in line with the publication by Davidson & Keating 
(2002), which indicated that the ODI was more sensitive to identify lower levels of 
disability.  
 
Furthermore, the written patient instructions provided by the ODI questionnaire were 
more easily understood by patients, as identified by comparing the number of “?” that 
patients wrote on the questionnaires (3 "?" on RMDQ compared to 0 "?" on ODI). 
The RMDQ required patients to tick the sentences that described their “pain today”. 
Sentences that patients felt did not describe their back pain had to be left blank. This 
made it difficult to distinguish between patients who were completely free of disability 
and those who did not fill out the questionnaire, since the submitted questionnaires 
showed only un-ticked sentences in both situations. Hence, the ODI was chosen as 
the second primary outcome measure to assess changes due to the CBT.  
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The ODI (Appendix 4.2) is a self-rating scale that evaluates the degree of disability in 
a number of areas of activities of daily living. It also evaluates how the level of pain 
interferes with 10 categories of physical activity. Patients tick the statement they find 
most suitable within each category. The sum score of all categories is multiplied by 2 
to indicate a percentage level of disability (Fairbank et al., 1980). Percentages can be 
interpreted as: 0-20%=minimal disability, 21-40%=moderate disability, 41-60% 
severe disability, 61%-100% crippled / bedbound / exaggerated symptoms (Fairbank 
et al., 1980). The ODI has been widely used and validated internationally in chronic 
low back pain populations (Beurskens et al., 1996; Holm et al., 2003; Leclaire et al., 
1997). 
	  
Table 4.2: 3-month evaluation of RMDQ and ODI  
 RMDQ_pre RMDQ_post 
Difference pre-
post ODI_pre ODI_post 
Difference pre-
post 
mean 8.37 3.59 4.78 14.07 8.07 6 
SD 4.02 3.92 3.69 5.48 4.61 5.12 
SRM   1.29   1.17 
 
 
Footnotes: ODI=Oswestry Disability Index; RMDQ=Roland Morris Disability Questionnaire; SD= standard deviation; 
SRM=standardised response mean. 
 
 
	  	   	   	   	   	   	   	   	   	   	  
Figure 4.6 Boxplots of values for ODI pre and                  Figure 4.7 Boxplots of values for RMDQ 
post CBT                                                                            pre and post CBT        
Footnotes: CBT=cognitive-behavioural therapy; ODI=Oswestry disability index; RMDQ=Roland-Morris disability questionnaire 
Time Time 
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4.7.2	  Secondary	  outcome	  measures	  
 
To explore the effects of tDCS and CBT on all aspects of NSCLBP, secondary 
outcome measures were selected according to their evidence base for evaluating 
NSCLBP and their measurement properties. Secondary outcome measures were 
further selected to cover the remaining recommended outcome domains for chronic 
pain trials (emotional functioning, improvement and satisfaction) (Turk et al., 2003) 
and ICF core set for LBP recommendations (Cieza et al., 2004). A search of the 
literature on tDCS and CBT trials was conducted to identify established and clinically 
relevant secondary outcome measures that were subsequently evaluated for 
measurement properties. tDCS trials mainly reported on the aspects of quality of life 
(Fregni et al., 2006a; Mori et al., 2009; Valle et al., 2009), global improvement (Fregni 
et al., 2006a, 2006b; Soler et al., 2010), depression (Fregni et al., 2006b; Mori et al., 
2009) and disease specific outcome measures as secondary endpoints. Published 
CBT trials, additionally to pain and disability, typically measured fear avoidance 
beliefs (Brox et al., 2009; Lamb et al., 2010), quality of life (Dufour et al., 2010; Huge 
et al., 2006; Lamb et al., 2010), and depression and anxiety (Kääpä, 2008; Smeets et 
al., 2006a). These identified outcome measures are in line with recent 
recommendations on outcome measures for CLBP based on a systematic review of 
the literature (Chapman et al., 2011). Authors recommended VAS for pain, ODI or 
RMDQ for function and SF-36 for quality of life supported by additional psychological 
outcome measures, such as fear avoidance beliefs and depression. Based on 
previously used outcome measures, published recommendations, ICF domains, and 
measurement properties, the following secondary outcome measures were chosen 
for this trial (Table 4.3) (Appendix 4.3):  
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• ICF domain of physical functioning: 
   - Funktionsfragebogen Hannover (FFBH) 
   (Hannover Functional Ability Questionnaire) 
   - Bothersomeness  
   - RAND 36-Item Health Survey subscales  
     Physical functioning     
        Role limitations due to physical health 
 
• ICF domain of emotional functioning: 
   - RAND 36-Item Health Survey subscales  
     Energy / fatigue,                        
     Emotional well-being 
     Role limitations due to emotional problems 
   - Fear Avoidance Beliefs Questionnaire (FABQ)  
   - Hospital Anxiety and Depression score (HADS)  
 
• ICF domains of improvement and satisfaction: 
   - Patient Perceived Satisfactory Improvement (PPSI) 
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Table 4.3 Psychometric properties of secondary outcome measures 
 FfBH	   Bothersomeness	   RAND36	   FABQ	   HADS	   PPSI	  
Authors / 
Date 	  
(Kohlmann and 
Raspe, 1996)	  
(Dunn and Croft, 2005)	   (Hays et al., 1993; 
Ware and Sherbourne, 
1992)	  
(Waddell et al., 1993)	   (Zigmond and 
Snaith, 1983)	  
(ten Klooster et 
al., 2006)	  
Description	   12 items on the 
patient's capacity to 
perform daily life 
activities.  
Responses rated on 
a 3-point scale:                 
- no can't perform 
activity 
- yes, with difficulties 
- yes	  
Single question: "How 
bothersome is your 
pain today?"  
5 response options:    
- not at all     
- slightly         
- moderately  
- very much  
- extremely 	  
36 item scale on 
general health. 
Subscales on Physical 
Functioning, Role 
limitations due to 
physical health and 
emotional problems, 
Energy / fatigue, 
Emotional well-being, 
Pain, and General 
health  
Public domain version 
of SF-36. In contrast to 
SF-36, no sum-score is 
evaluated.	  
Fear-avoidance beliefs 
in patients with low 
back pain.  
Two subscales: 
physical activity and 
work	  
14 item scale with 
subscales on 
anxiety and 
depression in 
patients with health 
problems	  
5-point Likert-
type scale 
ranging from 
"much worse" to 
"much better"	  
Validated 
in German	  
Originally developed 
in German	  
no	   SF-36 
(Bullinger, 1995)	  
(Pfingsten et al., 2000; 
Staerkle et al., 2004)	  
(Herrmann and 
Buss, 1994)	  
no	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Table 4.3 - continued 1 
 FfBH	   Bothersomeness	   RAND36	   FABQ	   HADS	   PPSI	  
Construct 
Validity 
Internal 
consistency	  
Cronbach's alpha 0.87-
0.90 
(Magnussen et al., 
2010; Roese et al., 
1996)	  
Correlation with VAS 
on pain and disability 
(Dunn and Croft, 2005)	  
Cronbach's alpha 
overall: 0.791 
Each subscale: >0.70-
0.75 except social 
function dimension: 
0.55-0.631 
(Alonso et al., 1998; 
Zhang et al., 2012)  
All numbers refer to   
SF-36	  
Cronbach’s alpha 
0.882 to 0.783  
(Matsudaira et al., 
2013; Monticone et al., 
2011)  
Correlation with RMDQ 
and Tampa Scale of 
Kinesio-phobia  
(Crombez et al., 1999; 
Kovacs et al., 2004)	  
Cronbach’s alpha for 
subscale HADS-
Anxiety:  
.68 to .93 
 
HADS-Depression: 
 .67 to .90  
 
(Bjelland et al., 2002) 
Correlation 
with VAS on 
pain 
(ten Klooster et 
al., 2006)	  
Test-retest 
reliability	  
ICC 0.84 
(Kohlmann and Raspe, 
1996; Magnussen et 
al., 2010) 
	  
N/A	   ICC for individual 
subscales ranged from 
0.60-0.80 
>0.80 for all subscales 
except social 
functioning 
(Brazier et al., 1992; 
Steffen and Seney, 
2008) 
All numbers refer to   
SF-36	  
Test-retest reliability 
ICC ranges from 0.72 
to 0.97) 
(Chaory et al., 2004; 
Holm et al., 2003; 
Kovacs et al., 2006; 
Pfingsten et al., 2000; 
Staerkle et al., 2004) 	  
Pearson product- 
moment correlation 
coefficient of 0.89 
(anxiety), 0.86 
(depression) and 0.91 
(total scale) (P < 0.001) 
over 3 weeks 
(Spinhoven et al., 
1997)	  
N/A	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Table 4.3 - continued 2 
 FfBH	   Bothersomeness	   RAND 36	   FABQ	   HADS	   PPSI	  
Sensitivity 
to change	  
High responsiveness 
assessed as 
correlation with 
change in VAS and 
global change 
(Magnussen et al., 
2010)	  
80% sensitivity (61% 
specificity) to detect 
people in the highest 
category of pain and 
disability 
(Dunn and Croft, 
2005)	  
High sensitivity to 
change evaluated in 
comparison with 
Dartmouth CO-OP 
charts; 
 
Ceiling effects in 
physical and emotional 
role subscales and 
social functioning. 
Floor effect in physical 
and emotional role 
subscales. 
(Jenkinson et al., 
1995; Koh et al., 2006) 
All numbers refer to   
SF-36	  
Satisfactorily as 
evaluated by minimum 
clinically relevant 
change  
(Monticone et al., 
2011)	  
Good sensitivity to 
change over time as 
measured by a change 
reliability coefficients 
of  0.70  
(Hinz et al., 2009)	  
Not 
evaluated	  
 
 
Footnotes: Dartmouth CO-OP= Dartmouth Primary Care Cooperative Information Project; FABQ=fear avoidance beliefs questionnaire; FfBH=Funktionsfragebogen Hannover; 
HADS=hospital anxiety and depression scale; ICC=intra-class coefficient; PPSI=patient perceived satisfactory improvement; RMDQ=Roland-Morris disability questionnaire; SF-36=quality of 
life questionnaire with 36 items; VAS=visual analogue scale
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4.8	  Timing	  of	  assessments	  
 
4.8.1	  Primary	  endpoints	  	  
 
The trial was designed to investigate the effectiveness of tDCS alone and in 
combination with CBT. Two primary endpoints were defined to meet these objectives: 
24 hours after the final tDCS (post stimulation) and immediately after the CBT (post 
CBT). The implications of 2 primary endpoints for the trial sample size are discussed 
in Sections 4.3 and 4.13. 
 
4.8.2	  Follow-­‐up	  assessments	  
 
Participants were assessed immediately prior to the first tDCS (baseline), 24 hours 
after the final stimulation (immediate effect of tDCS), and on the last day of the CBT 
(immediate effect of tDCS & CBT). Follow-up assessments took place 4 weeks, 12 
weeks, and 24 weeks after the final day of the CBT to observe longer-term treatment 
effects. Follow-up time-points were chosen according to published research on tDCS 
and CBT for NSCLBP. tDCS trials generally used shorter follow-up periods ranging 
from 2 weeks (Fenton et al., 2009; Fregni et al., 2006b; Soler et al., 2010) to 60 days 
(Soler et al., 2010). Pain reduction following tDCS was statistically significant at all 
reported follow-up time-points. No research was published that indicated whether 
and after how many weeks the intervention effect would recede. CBT trials generally 
included longer-term follow-ups e.g. after 3 months (Dufour et al., 2010), 6 months 
(Dufour et al., 2010), 12 months (Dufour et al., 2010; Lamb et al., 2010), or 24 
months (Dufour et al., 2010). Follow-ups of more than 6 months post intervention 
were not feasible within the time-frame of a PhD, therefore, follow-up time-points 
were chosen that were comparable with tDCS trials and allowed comparison with 
results of published CBT trials.  
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Additionally, average pain intensity over the past 24 hours was assessed daily during 
the stimulation period to evaluate the number of stimulation sessions required to 
observe an effect. This was important since pain is a variable parameter (de Souza 
et al., 2008) and  previous researchers had reported pain reductions after 1 (Boggio 
et al., 2009a), 2 (Fenton et al., 2009) or 5 (Antal et al., 2010; Fregni et al., 2006a, 
2006b; Mori et al., 2009) consecutive days of stimulation.  
 
All measurement tools were questionnaires that participants were required to 
complete independently. The baseline questionnaires were completed at the clinic to 
allow participants to ask the researcher questions should they not understand the 
written instructions. All follow-up assessments were sent to the participant's home 
address and returned by post. If questionnaires were not returned within 5 working 
days, participants were contacted by telephone. This was repeated after 5 more days 
in those cases for which the questionnaires were still not returned. 
 
While postal questionnaires (compared to interviews or supervised questionnaires) 
might result in a higher number of non-responders (Hébert et al., 1996) and missing 
data (Addington-Hall et al., 1998), and might further introduce bias since it is not 
certain that questionnaires are filled-out by the participant himself, it is generally 
viewed as a reliable (Wilson et al., 2002) and cost-effective (Wolffsohn et al., 2000) 
method for data collection.  
 
4.9	  Determination	  of	  the	  required	  sample	  size	  
 
Based on the 2 primary outcome measures (VAS and ODI), n=135 participants were 
required (calculated using G*Power, Version 3.1.2). The sample size estimation was 
based on minimum clinically relevant change recommendations of 15 mm on a 0-100 
mm VAS (Ostelo et al., 2008) and 8 points on the ODI (Maughan and Lewis, 2010). 
Values for the standard deviations were taken from the baseline data from a previous 
trial (Kääpä, 2008) with a comparable study population, intervention and timing 
schedule for the measurements of the outcomes. The reported standard deviations 
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were 19 mm for VAS and 10.6 points for ODI. The sample size calculation was based 
on α= 0.0125 and 90% power (2-tailed). The α-value was determined by dividing the 
commonly accepted α= 0.05 by the number of primary endpoints (post stimulation 
and post CBT) and the number of primary outcome measures (VAS and ODI) 
(Bonferroni correction for multiple testing) (Cleophas and Zwinderman, 2006; 
Neuhäuser, 2006). The calculated effect sizes were 0.79 for VAS and 0.75 for ODI 
and were regarded as medium to large (Cohen, 1992). This resulted in a required 
sample size of n=96 for VAS and n=104 for ODI. Allowing for a loss to follow-up of 
12% up to the first primary endpoint (after the stimulation) as observed in a previous 
tDCS trial on spinal pain patients (Fregni et al., 2006a), and a further loss of 16% to 
the second primary endpoint (after the CBT) as observed in a recent large scale trial 
on CBT for CLBP patients (Lamb et al., 2010), the required sample size was n=125 
and n=135 for VAS and ODI, respectively, resulting in a trial sample size of n=135.  
	  
	  4.10	  Interim	  analyses	  and	  stopping	  guidelines	  
 
No interim analyses were planned during the data collection period. However, in the 
case of a serious adverse event or a serious side effect (defined as a participant 
requiring medical attention), the researcher would have been unblinded and the trial 
discontinued. This decision was made by the researcher. It was independent of the 
group allocation of the affected participant. Although safety studies had not identified 
any serious side effects (Kessler et al., 2012; Nitsche et al., 2003c; Poreisz et al., 
2007), participants were required to complete a safety questionnaire after each 
stimulation session. This comprised a range of potential side effects and allowed the 
participant to add any unpleasant effect they had perceived (Appendix 4.4). The 
questionnaire was used to compare published side effects with those observed in the 
trial population. 
	  
 	  
 93 
4.11	  Randomisation	  
 
4.11.1	  Sequence	  generation	  
 
The sequence was generated by an independent researcher using a computer 
randomisation of a list of 160 (80 programmed to trigger a verum stimulation and 80 
to trigger a sham stimulation) 5-digit stimulation codes that were used to set-off either 
the verum or the sham stimulation paradigm. More codes were produced than 
required according to the sample size calculation to allow for a block randomisation 
of 20 (Section 4.11.2). A 1:1 ratio was used to allocate equal numbers of participants 
to verum stimulation and sham stimulation. 
 
4.11.2	  Type	  of	  randomisation	  
 
Stratification based on pain intensity was required to achieve a minimum level of 
homogeneity in the verum and the sham stimulation group (Altman and Bland, 
1999a; Roberts and Torgerson, 1998). During the 3-months preliminary phase, 
baseline pain ratings ranged between 5 and 90 mm on a 0-100 mm VAS (Appendix 
4.1). ODI levels were more homogeneous with scores ranging between 3 and 25 
points on a 0 to 50 point scale. Higher pain levels allowed for a greater range of 
improvement and were, therefore, an important confounding factor that needed to be 
distributed evenly to both groups (Altman and Bland, 1999a). Stratification was 
achieved by randomising the 160 stimulation codes into 2 lists: one for participants 
with a VAS baseline score of 0-50 mm and 1 for participants with a VAS baseline 
score of 51-100 mm (Zelman et al., 2003). This resulted in 2 randomised lists, each 
comprising 40 verum codes, and 40 sham codes. 
 
During the computer randomisation procedure, block randomisation was conducted 
to ensure equal numbers of sham and verum stimulation at several time-points, e.g. if 
the trial had to be discontinued at any given time-point due to the stopping guidelines 
(Doig and Simpson, 2005). Permuted blocks of 20 were chosen to allow for adequate 
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allocation concealment despite the block randomisation (Altman and Bland, 1999a; 
Herbert, 2005; Meinert, 1986; Schulz and Grimes, 2002).  
 
4.11.3	  Allocation	  sequence	  concealment	  	  
 
The sequence generation and randomisation procedures described in Sections 
4.11.1 and 4.11.2 and the nature of the stimulation codes ensured an unbiased 
intervention allocation since neither the participant, nor the researcher who 
conducted the recruitment and intervention, was able to predict to which group the 
participant was allocated.  
 
4.11.4	  Implementation	  
 
The randomisation list was generated by an independent researcher and the list that 
identified number codes for verum and sham stimulation was kept in a locked cabinet 
until data analysis was completed. Participants were enrolled by telephone by the 
researcher as soon as they had been recommended (by the back pain clinic team) to 
participate in the CBT. If patients were willing to participate in the trial, an 
appointment for an informed consent meeting was made, during which patients 
received all information regarding the trial and had the opportunity to ask questions. 
Those who agreed to participate signed the informed consent form and completed 
the baseline set of questionnaires - including pain measurement on a 0-100 mm 
VAS. The level of pain indicated what code list (high or low pain intensity) was 
accessed for the stimulation code for this participant (Section 4.11.2 for details). 
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4.12.	  Blinding	  
 
The pre-programmed stimulation paradigms (corresponding with the 5 digit number 
codes) allowed blinding of both, the participant and researcher, applying the 
stimulation. As described in Section 4.5.2, the sham intervention was designed to 
mimic cutaneous perception of the verum condition by producing an initial 30 second 
stimulation phase identical to that of the verum condition but too short to result in 
neurophysiological changes. The success of blinding was assessed by asking the 
participant (after each stimulation) which mode of stimulation they believed they had 
received (Fergusson et al., 2004).  
 
Blinding of the researcher who provided the intervention was achieved by pre-
programming the stimulator to either deliver a verum or a sham stimulation according 
to a 5 digit number code. One code per participant was used according to a list of 
160 randomised codes (Section 4.11.2). The machine display was identical during 
verum and sham stimulation to further support successful participant and researcher 
blinding. 
 
Blinding during the statistical evaluation of the collected data was achieved by 
labelling participants as "Group A" and "Group B" after the data collection was 
completed. For this purpose, an independent researcher received the list of 
stimulation codes that triggered the sham or the verum procedure. The independent 
researcher identified the stimulation code for each participant and exchanged it for 
the labels "A" and "B". The researcher remained blinded until the final analyses had 
been conducted. 
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4.13	  Statistical	  methods	  
 
4.13.1	  Participant	  flow	  
 
Following the recommendations of the CONSORT statement, participant flow was 
documented as a flow diagram, indicating the numbers of potential participants who 
were assessed for eligibility, the numbers randomised and the numbers of 
participants analysed at each pre-specified time-point (Schulz et al., 2010).  
 
4.13.2	  Intention-­‐to-­‐treat	  (ITT)	  principle	  	  
 
Intention-to-treat analysis is important to evaluate the clinical effectiveness of an 
intervention because it a) maintains the random allocation to intervention groups; 
and b) allows for deviations from the protocol that might be typical for a clinical 
setting (Hollis and Campbell, 1999). Full ITT analyses can only be conducted when 
outcomes for all randomised participants (including those who withdrew from the 
trial) are available (Higgins et al., 2011a). Since this is rarely the case in clinical 
trials, following ITT principles were identified for the purpose of the planned RCT:  
 
• As recommended by the CONSORT 2010 statement (Schulz et al., 2010) as 
much information as possible was obtained on reasons for withdrawing from 
the trial.  
• The double-blinded trial design did not allow participants to switch intervention 
groups, fulfilling a main criterion of the ITT principle.  
• Statistical analysis was conducted on all available data from all participants.  
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4.13.3	  Missing	  data	  
 
To keep missing data to a minimum, participants were contacted twice if they did not 
return a set of questionnaires (Section 4.8.2). Following the ITT principle (Section  
4.13.2) participants who discontinued the trial were asked to provide follow-up data at 
the same time-points as participants who completed the trial.  
 
Data were considered to be missing at random if baseline data on primary outcome 
measures (VAS pain and ODI) were not significantly different (using 5% level of 
significance) between participants who continued the trial and participants who 
discontinued before the second primary endpoint (post CBT) was reached. A further 
criterion was that missing data on primary outcome measures had to be balanced 
across intervention groups (Herman et al., 2009; Hollis and Campbell, 1999; Polit 
and Gillespie, 2009). The number of missing data on primary outcome measures 
was compared with the drop-out allowance rate from the sample size calculation. If 
data were missing at random and did not exceed the drop-out allowance, a 
complete case analysis was conducted to avoid additional variance induced by 
missing data imputation (Groenwold et al., 2012; Wood et al., 2004). In the situation 
that one of these assumptions was not met, a worst-best-case-scenario was 
anticipated followed by a sensitivity analysis of both results (Lachin, 1999). 
 
4.13.4	  Analysis	  of	  baseline	  and	  demographic	  data	  
 
Number of participants, gender, medication taken within the past 24 hours, duration 
of back pain, first onset of back pain and baseline values for primary and secondary 
outcome measures were computed and presented as a table to allow comparison of 
the groups at baseline. Continuous data were calculated as group mean values with 
standard deviations and minimum / maximum values provided as an indicator for 
variability within the data (Howell, 2002, p.41-56). For the outcome measure 
bothersomeness, the median was calculated and upper / lower quartiles as well as 
minimum / maximum values were provided (Howell, 2002, p.41-56). Following the 
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CONSORT recommendations, baseline differences between the 2 groups (verum 
and sham stimulation) were not analysed statistically (Schulz et al., 2010).  
 
4.13.5	  Primary	  analyses	  
 
The main analyses were conducted at an alpha level of p<0.0125 (calculation 
reported in Section 4.9), to adjust for the 2 primary outcome measures (VAS and 
ODI) and the 2 endpoints of primary interest (post stimulation and post CBT) (Section 
4.8) (Turk et al., 2008). The outcome of the trial was regarded statistically significant 
if one of the primary outcome measures had a statistically significant result at one of 
the 2 primary endpoints. To assess the effectiveness of tDCS after the stimulation 
period and after the CBT, a general linear model was fitted for each of the 2 primary 
outcome measures (VAS and ODI) at each of the 2 primary endpoints (post 
stimulation and post CBT), using post intervention values as the dependent variable 
and pre-intervention values as covariates (ANCOVA) (Twisk and Proper, 2004; 
Vickers and Altman, 2001). Based on a recent systematic review of high 
methodological quality on prognostic factors for CLBP (Verkerk et al., 2012), no 
additional covariates were added to the statistical model. The authors identified a 
wide range of prognostic factors for pain and disability (and return to work as well as 
quality of life) in the literature but the methodological quality of the available evidence 
was low. No single factor showed consistent evidence that justified its inclusion into 
the statistical model (Adams et al., 1985; Verkerk et al., 2012).  
 
Normality, homogeneity, and Levene's test of equality of error variances were 
conducted to assess whether assumptions for ANCOVA testing were met (Hollis and 
Campbell, 1999, p.397). If the assumption of sphericity was violated (Mauchly's 
Test), Greenhouse-Geisser corrected values were reported (Field, 2009, p.476). It 
was pre-determined that multilevel models (Section 4.13.6.3) would be used as 
primary analyses for any outcome measures that did not satisfy the assumptions for 
ANCOVA testing. Results from ANCOVA analyses were reported as F-values 
(degrees of freedom) and p-values as well as 99% CI for between group differences 
with Sidak adjustment for multiple comparisons (Field, 2009, p.402 and 417). 
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4.13.6	  Secondary	  analyses	  
 
Secondary analyses were conducted at an exploratory level and did not require 
further adjustment of the alpha level for multiple testing (Turk et al., 2008). Any 
statistically significant and clinically meaningful results of ancillary analyses were 
presented and discussed as exploratory to inform future trial designs. 
 
4.13.6.1	  Effect	  of	  tDCS	  on	  secondary	  outcome	  measures	  at	  primary	  endpoints	  
 
To explore the effect of tDCS compared to sham stimulation on each of the 
secondary outcome measures, ANCOVA analyses were conducted using baseline 
values as covariates (Section 4.13.5). Despite the categorical nature of outcome 
measures (questionnaires with categories that participants were required to tick or 5-
point Likert scales) parametrical analyses were conducted. This approach had been 
justified based on the Central Limit Theorem, and by re-analysing data using various 
analysis approaches that indicated the robustness of parametric testing (Norman, 
2010). 
 
4.13.6.2	  VAS	  pain	  on	  each	  day	  of	  the	  stimulation	  
 
Following reported pain reducing effects after varying numbers of stimulation days 
(ranging from a single stimulation (Boggio et al., 2009a) to 10 days of stimulation 
(Soler et al., 2010; Valle et al., 2009)), mean values of VAS and standard deviations 
were calculated for each day of the stimulation. Between group differences were 
calculated for each stimulation day using t-tests (independent groups, 2-sided) to 
evaluate whether an effect can be observed after 1, 2 or more days of the 
stimulation. 
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4.13.6.3	  Effect	  of	  tDCS	  on	  VAS	  pain	  and	  ODI	  over	  time	  	  
 
To evaluate the intervention effect on the primary outcome measures over time, a 
separate, multilevel model was fitted for VAS and for ODI, including all assessment 
time-points. All secondary outcome measures (that were reported as prognostic 
factors for pain and disability in CLBP (Verkerk et al., 2012)) were entered into the 
statistical model in a stepwise manner (forward approach) and removed if not 
statistically significant (Draper and Smith, 1981). The order of the entry was based on 
a high quality systematic review of prognostic factors for CLBP (Verkerk et al., 2012). 
Factors that were identified by systematic review authors as consistently reported by 
2 or more trials were entered into the model first, followed by factors reported by 1 
high quality trial and, subsequently, factors reported by 1 low quality trial. These 
factors as well as group (verum / sham) were added to the model as fixed effect 
factors while time, time2 and time3 were entered as random factors to model a non-
linear trend over time (Twisk et al., 2013). Bonferroni corrected post-hoc t-tests were 
conducted if a significant interaction of group by time was identified for VAS or ODI 
(Field, 2009, p.372-374). 
	  
4.13.6.4	  Effect	  of	  tDCS	  on	  secondary	  outcome	  measures	  over	  time	  
 
The secondary outcome measures FfBH, the 2 domains of FABQ, RAND 36 
subscales, HADS (anxiety, depression), bothersomeness and PPSI were evaluated 
by building a multilevel model with time, time2 and time3 as random factors and group 
(verum / sham) as a fixed effect factor. No additional factors were entered into the 
model since no consistent evidence supported any specific covariate to strongly 
influence FfBH, FABQ, RAND 36, HADS, bothersomeness, and PPSI. Although a 
range of outcome measures had been used in the same trials, a correlation between 
factors was rarely conducted and causative influences of one outcome measure on 
another have not been reported (Bean et al., 2013; Kovacs et al., 2007b; Lang et al., 
2003). Bonferroni corrected post-hoc t-tests were conducted if a significant 
interaction of group by time was identified for any secondary outcome measure 
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(Field, 2009, p.372-374). All analyses were performed using SPSS 18 for Apple 
Macintosh (SPSS, Inc., Chicago, IL). 
	  
4.13.7	  Evaluation	  of	  side	  effects	  
 
To document any observed side effects, participants were required to complete a 
standardised questionnaire, routinely used for tDCS trials (Jurgens et al., 2012; 
Luedtke et al., 2012a), after each stimulation session. Answers were entered into a 
table. Observed side effects together with their intensities were presented as total 
numbers of observed side effects and percentages of observations in relation to the 
total number of available responses. 
 
	  4.14	  Ethical	  Considerations	  
 
Ethical approval was obtained from both the University of Birmingham (application 
number ERN_10-0863) and the Aerztekammer Hamburg (the local authority for 
medical trials in Hamburg, project number PV 3297). The trial was conducted 
according to the recommendations from the declaration of Helsinki 2008 (WMA, 
2008) and following the ICH good clinical practice guideline (ICH, 1996). Ethical 
approval documents are attached as an appendix (Appendix 4.5). 
 
4.14.1	  Participant	  information	  and	  consent	  	  
 
Eligible patients were given an information brochure designed according to the ICH 
GCP Chapter 7 (ICH, 1996) on the proposed study and contacted via telephone prior 
to the initial appointment. Patients who were willing to participate in the study were 
given an initial appointment. At the initial appointment, study procedures were 
explained and the patient received the Participant Information Sheet. The patient was 
given the opportunity to clarify any issues arising from the study before signing a 
consent form. A copy of the Participant Information Sheet and consent form is 
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attached as an appendix (Appendix 4.6). No information regarding the trial was 
concealed from the participants before or during the study period apart from the 
participant's group allocation (verum or sham tDCS). After the final follow-up 
assessment, participants were offered to be informed of their group allocation. Trial 
results were sent to participants following statistical analysis of the data. 
 
4.14.2	  Participant	  withdrawal	  
 
The consent form contained a section explaining that the participant could withdraw 
from the study at any given time, without having to give any reasons and without any 
consequences for their ongoing management. Participants who withdrew from the 
study continued their ongoing management and had the option that their personal 
data be removed from the project. Any data that had already been collected for 
research purposes was used for the statistical analysis only with the participant’s 
consent (ICH, 1996).  
	  
4.14.3	  Compensation	  
 
Participants were compensated for additional travel costs during the stimulation 
phase (funded by the Institute of Systems Neurosciences, Hamburg). Participants 
who withdrew from the trial were compensated for travel expenses that had arisen 
prior to the date of withdrawal.  
 
4.14.4	  Confidentiality	  
 
Participant data were pseudonymised by assigning an individual study number. The 
list that matched participant names and study numbers was kept in a locked cabinet 
in a locked research room. Only the researcher had access to these data.  
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4.14.5	  Storage	  access	  and	  disposal	  of	  data	  
 
Questionnaires and paper copies of assessment sheets were kept in a file in a locked 
cabinet in a locked research room to which only the researcher had access. 
Electronic data were kept on the password secured personal laptop of the 
researcher, regular backups were made and kept password secured. According to 
the ICH Good Clinical Practice Guidelines (ICH, 1996) and University of Birmingham 
requirements, essential data will be kept in the secure University Hospital storage 
facilities (in Germany) for 10 years after the publication of the trial results. 
 
4.15	  Trial	  protocol	  	  
 
To ensure complete transparency of trial procedures, a trial protocol was developed 
prior to the commencement of the data collection and published in an open access 
journal (Luedtke et al., 2011) (Appendix 4.7). The trial was registered with the 
current controlled trial register (ISRCTN8987487). This allowed a comparison 
between the proposed study protocol and the published results as the only reliable 
measure of a risk of bias induced by selective outcome reporting (DeAngelis et al., 
2004).  
 
Chapter summary  
 
This chapter detailed the trial methods and procedures as they were planned and 
published in the trial protocol. These included the trial design, eligibility criteria for 
participants, settings, location and standard care at the back pain clinic, intervention 
and sham intervention, the selection process of the primary and secondary outcome 
measures, type and implementation of randomisation, methods of blinding of 
participants and researcher, planned statistical analyses and ethical considerations. 
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5.	  CHAPTER	  	  
 
FEASIBILITY	  STUDY	  TO	  EVALUATE	  PRACTICAL	  ASPECTS	  OF	  
TRIAL	  PROCEDURES	  AND	  ACCEPTABILITY	  OF	  THE	  TDCS	  
INTERVENTION	   
 
The previous chapter detailed the methods and procedures for a RCT. A feasibility 
study was conducted as a precursor to the main trial to ensure that all procedures 
could be implemented as planned and to investigate how patients perceived tDCS as 
an intervention for pain. This chapter details the feasibility study and concludes by 
justifying any changes required to trial procedures. 
 
5.1	  Introduction	  and	  objectives	  
 
Electrotherapy including direct current stimulation is traditionally used by 
physiotherapists internationally. However, the motor cortex as a target tissue is not a 
standard physiotherapy approach. tDCS has only recently been introduced as a 
physiotherapy intervention in a pilot study of 8 participants (O’Connell et al., 2013). 
The authors did not report how participants perceived and whether they accepted 
tDCS as a physiotherapy intervention for NSCLP. To identify recruitment barriers and 
to assess the potential of tDCS as a future intervention for NSCLBP, it was important 
to evaluate patients' views on this new management approach before the 
commencement of the main trial. Additionally, trial design and procedures (detailed in 
Chapter 4 and  published in BMC Musculoskeletal (Luedtke et al., 2011)) required 
evaluation to ensure that it was feasible to conduct the main trial as planned within 
the available time frame.  
 
 105 
Although the terms pilot study and feasibility study are often used interchangeably 
(Thabane et al., 2010), the objectives listed below reflect common aims for feasibility 
studies (Lancaster et al., 2004; National Institute for Health Research, 2014). Pilot 
studies focus more on the evaluation of outcome measures to determine the required 
sample size or to test new treatment approaches for safety and effect, whilst 
feasibility studies focus on the practicability of procedures, the willingness of potential 
participants to be in the trial, the recruitment and retention rates and do not include a 
statistical analysis of outcome measures (Arain et al., 2010; Lancaster et al., 2004; 
www.netscc.ac.uk/glossary). A preliminary pilot study was not required as sufficient 
data from trials with similar interventions and trial populations (Fregni et al., 2006a; 
Kääpä, 2008), as well as minimum clinically relevant change recommendations for 
the primary outcome measures (Lauridsen et al., 2006) were available to calculate 
required sample size. Also, large safety trials and systematic reviews demonstrated 
that no side effects were likely to occur (Borckardt et al., 2011; Brunoni et al., 2011a; 
O’Connell et al., 2010; Poreisz et al., 2007).  
 
This feasibility study, therefore, focussed exclusively on the practicability of 
procedures for the main trial to ensure that data collection could be carried out as 
planned. It included patient interviews to evaluate how patients perceived and 
whether they accepted trial procedures and tDCS as a physiotherapy intervention. 
The following key objectives were identified for the feasibility study:  
 
Objective 1:  
To evaluate the practicability of trial procedures. 
 
 Objective 1 encompasses the following more specific objectives: 
a. Determine the number of patients meeting the inclusion / exclusion 
criteria.  
b. Assess the recruitment rate and thereby estimate the duration of the 
data collection period for the main trial. 
c. Evaluate whether allocation was successfully concealed and whether 
randomisation procedures were practicable. 
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d. Identify recruitment barriers for potential trial participants. 
e. Assess the patient information sheet and consent form for 
comprehensibility by potential trial participants. 
f. Assess the retention rate of trial participants up to the second primary 
endpoint of the main trial (after the CBT programme). 
 
Objective 2: 
Assess the participants’ views on the trial procedures and the intervention (tDCS) to 
determine acceptability. 
 
5.2	  Design	  of	  the	  Feasibility	  Study	  
 
The feasibility study was conducted using the methods for the planned RCT (Chapter 
4), including the use of defined inclusion / exclusion criteria, randomisation to verum 
or sham intervention, and blinded assessment of outcomes at 2 primary endpoints 
(post tDCS and post CBT). The realistic time frame for the feasibility study did not 
allow collection of long-term follow-up data. Consequently, drop-out rates for the 
long-term assessments were not estimated. This limitation was deemed acceptable 
since the feasibility study objectives focused exclusively on the practicability of trial 
procedures that were identical for the post CBT assessment and the longer-term 
follow-up time-points. Losses of longer-term follow-up data were anticipated to reflect 
those from published trials on CBT for CLBP that included trial populations and data 
collection methods comparable to those of the main trial (Kääpä, 2008; Lamb et al., 
2010).  
 
5.2.1	  Methods	  used	  to	  evaluate	  the	  practicability	  of	  trial	  procedures	  (objective	  1)	  
 
Although a minimum sample size of 12 per group has been recommended for pilot 
studies that aim to estimate effect sizes or standard deviations (Julious, 2005), no 
clear recommendations for feasibility studies were found in the literature. The 
objective of this feasibility study was to evaluate the practicality of the proposed 
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procedures. Hence, a realistic duration of 10 weeks was chosen –	   with 6 weeks 
being allocated to participant recruitment and a further 4 weeks added to allow the 
completion of the CBT programme following the tDCS intervention. All recruited 
participants were randomised and treated according to the planned procedures for 
the main data collection phase (Sections 4.5; 4.6; 4.11). To	  meet	  the	  objectives	  defined	  
in	  Section	  5.1	  pre-­‐specified	  data	  were	  recorded	  (Table	  5.1).	  
 
Table 5.1 Data recorded to meet objective 1 
Specific 
objectives 
 
Data recorded  
a. Number of contacted patients who fulfilled the eligibility criteria during the 6 weeks 
recruitment period.  
b. Number of patients who consented to participate in the study. 
c. The stimulation type that each individual participant believed they had received on each 
day. 
d. Questions asked and any concerns stated by patients during telephone recruitment and 
reasons provided by patients during telephone recruitment for not consenting to 
participate in the trial. 
e. Questions asked about the information brochure and the consent form. 
f. The number of participants who discontinued the study, the time-points at drop-out, and 
the reasons for withdrawing. 
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5.2.2	   Methods	   used	   to	   assess	   participants’	   views	   on	   trial	   procedures	   and	  
intervention	  (tDCS)	  to	  determine	  acceptability	  (objective	  2)	  
 
Semi-structured interviews (n=4) were conducted to gain detailed information 
regarding patients' views on tDCS and to evaluate their acceptance of the proposed 
trial procedures and of tDCS as an intervention for CNSLBP. This interview style was 
chosen to pre-specify questions on procedure and intervention acceptability while still 
allowing interviewees to determine the type and amount of information provided for 
each topic (Green et al., 2008).  
 
No literature was identified that indicated the number of interviews required for the 
evaluation of the acceptability of an intervention. Four interviews were considered 
adequate to provide this information due to the depth and richness of data generated 
through the open ended interview questions (Ogden and Cornwell, 2010). The 4 
participants (2 male / 2 female) were selected according to purposeful stratified 
sampling (Patton, 1990, p.168): Participants were selected who were evaluated as 
“good communicators” during recruitment and intervention. A 'good communicator' 
was defined as a person who asked questions and provided detailed information. 
Stratified sampling ensured that 2 participants had received verum stimulation and 2 
sham stimulation to include experiences of both stimulation types.  
 
The interview questions were designed after a literature search on acceptability of 
interventions (Ayala and Elder, 2011; Barnes et al., 2012; Cowley and Houston, 
2003) and according to the study objectives. The interviews followed a pre-designed 
interview guide (Appendix 5.2) specifying the topics of interests and with a series of 
prompts to encourage elaboration of any given answer. For convenience, interviews 
were conducted by the researcher immediately after a participant’s final day of the 
CBT within the CBT setting. Since this might reduce the credibility of the information 
provided (Al-Busaidi, 2008), participants were reminded that information from the 
interviews was exclusively used for this study and did not influence their future 
management.  
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Interviews were conducted and transcribed verbatim in German. They were recorded 
on a digital voice recorder, downloaded onto a personal computer, transcribed, and 
analysed by the researcher. A semantic level of transcription was chosen, since for 
the feasibility purpose of this study only the factual contents of the interviews and not 
the verbal expression and body language were analysed (Gibbs, 2008, p.14). 
 
5.2.3	  Data	  analysis	  
 
5.2.3.1	  Evaluation	  of	  practicability	  of	  trial	  procedures	  
 
Recorded data were analysed to meet the objectives defined in Section 5.1 (Table 
5.2). 
 
Table 5.2 Methods of data analyses to meet objective 1  
Specific 
objective 
 
Method used to address objective 
a. and b. The recorded number of eligible patients and the number of patients contacted during 
the 6 weeks recruitment period for the feasibility study were used to calculate the 
anticipated recruitment rate. This information was used to estimate the duration of the 
main trial that required a total sample size of 135 patients.  
c. Allocation concealment and blinding were assessed through the Kappa coefficient, 
after the researcher was unblinded following completion of the feasibility study (Landis 
and Koch, 1977; O’Connell et al., 2013).  
d. Questions asked and concerns stated during telephone recruitment, as well as 
reasons provided for not participating in the study, were used to adapt the wording 
and the aspects covered during telephone recruitment (Appendix 5.1.1). 
e. Questions asked about the information brochure and consent form were used to adapt 
the topics covered during the informed consent meeting (Appendix 5.1.2). 
f. The number of participants who discontinued the study was used to estimate the 
anticipated drop-out rate for the main trial. Reasons provided for discontinuing the 
study were documented and evaluated for possibilities to meet special requirements 
such as extended treatment hours and funding to cover travel costs.  
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5.2.3.2	  Evaluation	  of	  the	  data	  on	  acceptability	  of	  tDCS	  
 
Transcribed interviews were analysed thematically by coding the text line by line 
(Gibbs, 2008, p.52). An open coding approach was chosen to allow themes to 
develop from the data without fitting them into preset coding frames (Green and 
Thorogood, 2009, p.203). Consequently, the dominantly descriptive codes were 
transformed into more analytic concepts and collated across interviews. Each group 
of concepts was provided with a global title, and regarded as a key theme. 
Anonymous translated examples from the texts were provided for each theme to 
illustrate and compare patients’ views (Gibbs, 2008). All relevant data were included 
in this process to avoid selective reporting (Gibbs, 2008). 
 
5.2.4	  Ethical	  considerations	  and	  quality	  of	  qualitative	  research	  
 
All participants were informed of the procedures to be used in the feasibility study, 
had the opportunity to clarify questions with the researcher in an informed consent 
meeting, and signed an informed consent form if wishing to participate in the study. 
Privacy, confidentiality, and identity of participants were protected throughout the 
study. 
Quality of the data collection and analysis regarding validity, reliability, and 
generalisability (Gibbs, 2008, p.97-104) was supported by the following strategies:  
 
• Audio recordings and transcribed data were compared repeatedly to ensure 
that transcription did not introduce erroneous data.  
• Participant statements selected to support concepts and themes were 
interpreted in relation to the previous and following sentences to avoid 
misinterpretation of statements separated from the context.  
• To support the reliability of the data, variations of and opposing statements on 
the same topics were actively sought. 
• Although a sample size of n=4 is too small to allow a representativeness of 
findings, the sampling strategy of 2 male and 2 female participants as well as 
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2 participants from the sham and 2 participants from the verum group allowed 
for some variety of experiences and perceptions.  
• Participants were selected from the same population of NSCLBP patients as 
the participants from the main trial.  
 
5.3	  Results	  	  
 
5.3.1	  Practicability	  of	  trial	  procedures	  (objective	  1)	  
 
Six to 8 eligible patients attended the back pain clinic per fortnight. If all eligible 
patients were to participate in the main trial, the sample size of 135 could be reached 
within 34-45 weeks. Twenty participants were contacted, however only 8 patients 
agreed to participate in the feasibility study during the 6 week recruitment period. 
Hence, the data collection period for the main trial was estimated as 102 weeks. 
Whilst fulfilling all defined inclusion criteria, some participants scored very low on the 
2 primary outcomes at baseline, with 4 participants having pain scores below 15/100 
and 3 participants scoring below 8/50 for disability. Such low baseline scores allowed 
little room for improvement (Table 5.3). Hence minimum scores for pain and disability 
at baseline were required as inclusion criteria for the main trial.   
 
Using 5-digit number codes for the randomisation procedure achieved both allocation 
concealment and blinding in the feasibility study. The effectiveness of participant 
blinding was expressed as a Kappa value of agreement. The resultant Kappa= 0.19 
(with SE=0.16; and 95% CI -0.122 to 0.500) showed poor agreement between 
perceived group allocation and intervention received (Cohen, 1960), indicating 
effective participant blinding (Table 5.4).  
 
Recruitment barriers for potential participants were expressed by the questions 
asked during telephone recruitment. These included: 
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• Are there any known side-effects of tDCS? (n=11) 
• How flexible are the available intervention times? (n=9) 
• Does the intervention hurt? (n=6) 
• How likely is it that I will perceive a positive effect? (n=5) 
 
Further barriers and reasons stated for not participating were:  
 
• time (n=7) 
• travel costs (n=2) 
• distance to the study location (n=1) 
• fear of electrical currents (n=1)  
• no interest in research (n=1) 
 
Based on the reasons provided (during telephone recruitment) for not participating in 
the trial, time seemed to be the most important factor for not participating (n=7): 
Some patients had arranged appointments with their own doctor, work meetings or 
other commitments for the week during which they should have been receiving tDCS. 
The costs for train tickets or fuel for the 5 additional tDCS days deterred 2 patients 
from participating. A further patient lived in a different city and was planning to stay in 
a hotel for the duration of the CBT and could not afford to arrive 5 days earlier for the 
tDCS. 
 
The information brochure and consent form prompted patients to ask questions such 
as: 
 
• Why do some participants receive sham stimulation? 
• Will you tell me afterwards whether I had the real stimulation? 
• Can I have the overall trial results once the trial is completed? 
 
The retention rate at the second primary endpoint after the CBT was 7 out of 8 
participants. The 1 withdrawal occurred after the first stimulation and was due to 
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conflicting appointments. If 1 in 8 participants were to drop-out in the main trial, this 
would result in 16.9 out of 135 drop-outs after the CBT or a 12.5% drop-out rate.  
 
Table 5.3 Participant data at baseline  
Participant 
number 
 
 
Male/ 
Female 
Age (years) 
at study entry 
Duration of 
back pain 
(months) 
Oswestry 
Disability Index 
(0-50 points) 
 
Pain intensity 
(0-100 mm) 
 
 
P01 f 38 156 22 21 
P02 m 38 7 14 10 
P03 f 51 6 4 3 
P04 m 37 24 0 0 
P05 m 44 120 7 75 
P06 f 45 6 9 12 
P07 f 63 240 20 77 
P08 f 32 6 21 52 
 
   Footnotes: f=female; m=male 
 
 
 
Table 5.4 Assessment of the success of blinding. Table for kappa statistics.  
 
 Number of verum 
stimulations 
Number of sham 
stimulations 
Number of verum ratings  18 8 
Number of sham ratings  7 7 
 
 
 
5.3.2	  Patient	  acceptability	  of	  trial	  procedures	  and	  tDCS	  (objective	  2)	  
 
All 4 selected participants agreed to be interviewed. Baseline characteristics of the 
interviewees are presented in Table 5.5. 
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    Table 5.5 Interview participants’ data at baseline  
 
Participant 
number 
 
 
Male/ 
Female 
Age (years) 
at study entry 
Duration of 
back pain 
(months) 
Oswestry 
Disability Index 
(0-50 points) 
 
Pain intensity  
(0-100 mm) 
 
 
I01 f 44 24 25 80 
I02 m 48 6 11 55 
I03 f 28 42 7 35 
I04 m 54 10 9 38 
 
  Footnotes: f=female; m=male. 
 
Two key themes were identified from the interview data (Table 5.6): 
 
• Attitudes towards tDCS (positive, neutral, negative) as a therapy for NSCLBP. 
• Feedback on information received during telephone recruitment and informed 
consent meeting. 
 
Participants used different concepts to illustrate their attitudes towards tDCS. These 
included hope, curiosity, trust, open-mindedness, acknowledgement of the 
importance of research and acceptance of side effects. When asked whether there 
was anything else that they would like to communicate regarding trial procedures, a 
second theme emerged as participant feedback on the information received during 
telephone recruitment and at the informed consent meeting. Concepts included 
perceived intelligibility, comprehensiveness, and volume of information. 
 
Overall participants showed mainly positive attitudes towards tDCS as an 
intervention for pain reduction and were willing to accept mild side effects, such as a 
sensation of burning under the electrodes. The information provided was perceived 
as comprehensive and intelligible, however, the volume of information was regarded 
as overwhelming by 2 participants. Participants were satisfied with the therapy 
setting despite some discomfort associated either with the stimulation itself (e.g. 
itching or sensation of burning under the electrode) or with the position during the 
stimulation (e.g. back pain increased in lying position) (Table 5.6). 
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Table 5.6 Findings from participant interviews 
Key themes Concepts Examples from text 
Positive attitude 
towards tDCS 
Hope "....a new chance" (I01) 
 
"I was glad that I was asked to participate. It is an 
additional module to my therapy that may have a 
positive effect on my complaints" (I03) 
 curiosity "....one can always try, can't I" (I02) 
 
"I was curious..., excited by what you told me on the 
phone" (I03) 
 
"I wanted to find out whether it would show a result" 
(I04) 
 trust "I think you wouldn't do anything that would harm my 
back...therefore...I totally trust you" (I02) 
 acknowledging importance 
of health research 
"Research is important for all of us, I want to make 
new therapies public, want to make therapy 
accessible for everybody" (I01) 
 pleasantness of stimulation 
and therapy setting 
"In the beginning there was always a prickly itchy 
sensation that stopped after a few seconds, at least 
that is what I felt. After that it was simply relaxing" 
(I04) 
 
"...no, that was perfect, couldn't have been any 
better" (I02) 
 
"good atmosphere, totally ok" (I03) 
Neutral attitudes 
towards tDCS 
open-mindedness 
 
"I was completely laid-back and without any 
expectations because I find it important to approach 
things without any reservations" (I01) 
 
"I would honestly try anything that is not dangerous 
and that my back may benefit from" (I03) 
 
"It doesn’t hurt to try something new" (I04) 
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Table 5.6 - continued 1 
Key themes Concepts Examples from text 
Negative aspects 
of tDCS 
acceptance of 
uncomfortable aspects 
"It wasn't pleasant, not really unpleasant, it didn't hurt, 
but it wasn't nice. But as you said in the beginning, the 
unpleasantness got less and less over time, this itching, 
tingling, pricking.....somehow...but it wasn't a problem" 
(I03)  
 
"yes, lying hurts, sitting hurts, too, but somehow we had 
to find a position, it was ok, you couldn't do anything else 
than those blankets and pillows to make me more 
comfortable, it's me...nobody can influence that" (I01) 
Comments on 
verbal and written 
information 
received 
 "... knew in advance what would happen after what you 
told me on the phone" (I01) 
 
"clearly written" (I01) 
 
"that was comprehensible, no problems with that"(I02) 
 
"had to read some passages  a bit more slowly, 
somehow, but that was ok" (I03) 
 comprehensiveness "Maybe, if I could have wished for anything, I would have 
liked to hear some experiences from other patients who 
had tried the intervention, whether it worked for them or 
not" (I04) 
 
"...it didn't say whether 5 interventions can do anything at 
all" (I04) 
 
"Before the procedure when you tried to find the right 
spot on my head, I would have liked to know more, like, 
what is going to happen..it would make some people 
more relaxed about what you are doing" (I04) 
 volume "too much paper....read it all...just got on with filling out 
the forms" (I01) 
 
"I didn't think it was too much with the questionnaires at 
all. It was just ticking boxes, more than reasonable for 
something that might help me in the end" (I03) 
 
"well, I didn't go into depths with reading all the 
information....I know where I put the documents and...I 
scanned them on Sunday" (I04)   
 
 
Footnotes: The number in brackets under “Example” refers to the number of the individual participant: I01=interviewee 1; 
I02=interviewee 2; I03=interviewee 3; I04=interviewee 4. 
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5.4	  Discussion	  of	  the	  results	  and	  consequences	  for	  the	  main	  trial	  	  
 
5.4.1	  Practicability	  of	  trial	  procedures	  (objective	  1)	  
 
The results of this feasibility study indicated that minor changes were required to the 
planned procedures for the main trial. Low levels of pain and / or disability at baseline 
in some participants required the introduction of minimum levels of pain and disability 
as inclusion criteria. Setting the minimum levels for participant inclusion in the trial as 
15 mm on the 0-100 mm VAS pain scale and 8 points on the 0-50 points ODI scale 
would provide the potential to detect change that was clinically relevant in all 
participants (Maughan and Lewis, 2010; Ostelo et al., 2008). 
 
With 6-8 eligible patients every fortnight and a recruitment rate of approximately 35%, 
the required total sample size of 135 patients for the main trial would be recruited 
within 96-128 weeks. The final follow-up would be at 24 weeks after the 4-week 
group programme, resulting in a total data collection period of 125-157 weeks.  
 
Allocation concealment and blinding could not be differentiated in this study and were 
expressed as 1 kappa value for all intervention days, to gain an overall impression of 
the success of blinding. Individual kappa values for each day showed that agreement 
varied (day 1 kappa=-0.429; day 2 kappa=0.25; day 3 kappa=0.467; day 4 
kappa=0.75; day 5 kappa=-0.429) without indicating a systematic pattern; most 
importantly participants did not learn to distinguish sham and verum stimulation over 
time. However, daily agreement rates were based on 8 ratings per stimulation day. 
Larger sample sizes might provide different results.  
 
Funding was obtained for participant travel costs to cover the 5 days of stimulation, to 
reduce recruitment barriers for potential trial participants. Furthermore, a research 
assistant was employed to increase available intervention hours. Wording on known 
side-effects of tDCS, flexibility of available intervention times and research results on 
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the effect of tDCS for pain reduction were adapted to meet participant questions in 
the standard operating procedures (SOP) for the telephone recruitment (Appendix 
5.1.1). Explanations about the necessity of a sham stimulation group were added to 
the SOPs for the informed consent meeting (Appendix 5.1.2), as well as the option 
for participants to provide an email address to be informed of their group allocation 
and the overall trial results upon completion of the trial. The drop-out rate of 12.5% 
across groups after the CBT was lower than the drop-out rate used for the sample 
size calculation (Section 4.9) for the main trial. The longer duration of the main trial is 
likely to result in more drop-outs and missing data than the brief feasibility phase. A 
systematic review of drug trials reported that the drop-out rate increased with the 
duration of the trial (Wahlbeck et al., 2001). To ensure sufficient statistical power for 
the effectiveness of tDCS on pain and disability reduction in NSCLBP, the original 
sample size calculation based on large trials with long-term follow-ups was 
maintained. 
 
5.4.2	  Acceptability	  of	  trial	  procedures	  and	  tDCS	  (objective	  2)	  
 
None of the trials on tDCS had evaluated participant acceptability of the intervention 
(Antal et al., 2010; Boggio et al., 2009a; Fenton et al., 2009; Fregni et al., 2006a, 
2006b; Mori et al., 2009; Soler et al., 2010; Valle et al., 2009). However, the low rate 
of reported side effects and the low drop-out rates reported in tDCS trials provided an 
indicator that participants generally accepted tDCS as an intervention for the 
reduction of pain (Boggio et al., 2009a; Fenton et al., 2009; Fregni et al., 2006a, 
2006b; Mori et al., 2009; Soler et al., 2010; Valle et al., 2009). However, for the 
feasibility of the planned main trial it was important to evaluate how participants 
perceived trial procedures and tDCS as an intervention. Overall, participants stated a 
positive attitude towards all study procedures and tDCS as a intervention for 
NSCLBP within a physiotherapy setting. The concepts of hope, curiosity, and trust, 
and the more neutral concept of open-mindedness, emerged from participants’ 
statements. Hence, results indicated that attitudes towards tDCS as an intervention 
for NSCLBP will not limit the recruitment of participants for the main trial.  
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5.4.3	  Limitations	  of	  the	  feasibility	  study	  
 
The small sample size, use of a single centre, and 1 interviewer limited the 
transferability of study findings. Furthermore, no long-term data could be collected 
within the short time-frame for the feasibility study. However, responses on 
intervention acceptability were consistent across the 4 interviewees.  
 
Chapter summary: 
 
This feasibility study was conducted to evaluate whether patients at the back pain 
clinic would accept tDCS as an intervention and participate in the main trial. In 
addition, it was designed to test the proposed trial design and procedures before 
commencement of the full trial. The observed low levels of pain and disability at 
baseline informed the incorporation of additional inclusion criteria on minimum levels 
of pain and disability for the main trial. All other procedures from the research 
protocol fulfilled practicability and feasibility criteria. Participants accepted trial 
procedures and tDCS as an intervention for NSCLBP. 
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6.	  CHAPTER	  	  	  	  	  	  	  	  	  	  	  	  
	  
RESULTS	  FROM	  THE	  RCT	  
 
This chapter details the participant flow through the RCT, states numbers and 
reasons for losses and exclusions, reports summaries of data collected on participant 
characteristics and all outcome measures at each time-point, and presents the 
results of the statistical analyses of primary and secondary outcome measures. It 
also states the frequency and type of side effects. The presentation of trial results 
followed the recommendations and format of the CONSORT Statement (Moher et al., 
2010; Schulz et al., 2010). 
 
6.1	  Recruitment	  period	  and	  participant	  flow	  
 
Recruitment took place over 26 months (01.01.2011 to 01.03.2013). Two hundred 
and fifty five NSCLBP patients were telephoned and assessed for eligibility (Section 
4.3) to recruit the required 135 participants. Of 232 eligible patients (ineligibility was 
due to recent spinal surgery and pain intensities lower than 15 mm on a 0-100 mm 
VAS), 97 declined to participate due to the additional time and travel required for the 
extra 5 visits to the back pain clinic (Figure 6.1). Two participants in each group 
discontinued the intervention during the stimulation phase. Reasons provided were 
skin reactions (n=1), conflicting appointments (n=2) and spinal surgery (n=1). None 
of the participants from the verum group and 3 participants from the sham group 
discontinued the CBT (reasons: acute sciatica, influenza, spinal surgery). Eighty nine 
participants (47 in the verum group and 42 in the sham group) completed 
assessments at all time-points (Figure 6.1). Telephone calls to participants who did 
not return questionnaires at follow-ups elicited reasons for non-intervention related 
health issues, and, did not want to complete any further questionnaires.  
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Excluded (n=120) 
♦   Not meeting inclusion criteria (n=23) 
• pain<15 VAS and ODI <8 at 
baseline (n=12) 
• surgery <6 months ago (n=11) 
♦   Declined to participate (n=97) 
Analysed (VAS n=61; ODI n=61) 
♦ Excluded from analysis (n=0) 
Lost to follow-up (missing data):                 
(VAS n=4; ODI n=4) 
 
Discontinued intervention (n=2)                  
(skin reaction, conflicting appointments) 
Allocated to verum stimulation (n=67) 
♦ Received allocated intervention (n=67) 
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(surgery, conflicting appointments) 
Allocated to sham stimulation (n=68) 
♦ Received allocated intervention (n=68) 
Analysed (VAS n=62; ODI n=61) 
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Figure 6.1 CONSORT 2010 Flow Diagram of patient inclusion and numbers of participants      
available for analysis at each pre-specified time-point for both primary outcome measures  
       (Moher et al., 2010)  
          Footnotes: ODI=Oswestry Disability Index; VAS= visual analogue scale for pain 	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6.2	  Baseline	  participant	  characteristics	  
 
6.2.1	  Participant	  demographic	  and	  clinical	  characteristics	  	  
 
Sixty three (47%) of the 135 participants were female. The mean age of all 
participants was 45 years (SD 9 years; range 26-64 years). The mean duration of the 
current episode of LBP across all participants was 21 months (SD 40 months; range 
6-240 months) and the mean first onset of LBP was 95 months ago (SD 115 months; 
range 6-600 months). Participant characteristics for each intervention group are 
given in Table 6.1 
 
Table 6.1 Participant demographic and clinical characteristics at baseline 
Participant characteristics 
Intervention group 
verum (n=67) sham (n=68) 
Females  n (%)  33 (49) 30 (44) 
Age at study entry 
(years) 
Mean (SD) Minm, Maxm  45 (9) 26, 64 44 (10) 27, 62 
First onset of back 
pain  
(months ago) 
Mean (SD) Minm, Maxm  98 (106) 6, 600 93 (125) 6, 384 
This episode of 
back pain  
(months) 
Mean (SD) Minm, Maxm  23 (49) 6, 156 19 (29) 6, 240 
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Medication  Pain medication: n (%)  
   NSAIDS 
   Week opioids   
   Strong opioids  
 
Adjuvant medication n (%)  
   Antidepressants   
   Muscle relaxants   
   Anticonvulsiva 
   Glucocorticoids 
 
Other medication: n (%)  
   Cardiovascular 
   Asthma 
   Thyroid 
   Restless legs 
   Hormone replacement 
   Malaria 
 
43 (64) 
  6 (9) 
  7 (10) 
 
 
  3 (4) 
  1 (1) 
  3 (4) 
  1 (1) 
 
 
  9 (13) 
  3 (4) 
  1 (1) 
  1 (1) 
  3 (4) 
  1 (1) 
 
34 (50) 
  4 (6) 
  6 (9) 
 
 
  3 (4) 
  1 (1) 
  0 (0) 
  0 (0) 
 
 
  9 (13) 
  2 (3) 
  1 (1) 
  0 (0) 
  1 (1) 
  0 (0) 
 
 
Footnotes: Maxm = maximum value; Minm= minimum value; n=number; NSAIDS=Non-Steroid Anti-Inflammatory Drugs; 
SD=Standard Deviation.  
	  
6.2.2	  Baseline	  data	  on	  primary	  and	  secondary	  outcome	  measures	  
 
The mean VAS pain intensity across groups at baseline was 48 mm (SD 19 mm). 
The mean disability across all participants was 16 points on the ODI (SD 6 points).  
Baseline characteristics by intervention group are shown in Table 6.2.  
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Table 6.2 Baseline data on primary and secondary outcome measures by intervention group 
Baseline data on primary and secondary 
outcome measures 
Intervention group 
verum (n=67) sham (n=68) 
Primary outcome measures  Mean (SD) Minm, Maxm  Mean (SD) Minm, Maxm  
VAS     
(0-100 mm) 
 
48 (21) 15, 89 
 
48 (18) 15, 84 
 
ODI    
(0-50 points) 
 
 
17 (6) 8, 32 
 
 
15 (5) 8, 29 
Secondary outcome measures  Mean (SD) Minm, Maxm  Mean (SD) Minm, Maxm  
FABQ   Physical activity 
             (0-24 points) 
 
14 (4) 7, 20 
 
15 (7) 2, 24 
             Work 
             (0-42 points) 
 
21 (11) 2, 42 
 
23 (10) 9, 40 
 
FfBH    (12-36 points) 
            
 
22 (4) 12, 29 
 
21 (4) 12, 33 
 
HADS  Anxiety 
            (0-21 points) 
 
 
 7 (4) 0, 15 
 
 
 6 (4) 0, 18 
             
            Depression 
            (0-21 points) 
 
 
 6 (4) 0, 15 
 
 
 6 (4) 0, 14 
 
RAND-36 (0-100%) 
            Physical functioning 
 
 
54 (19) 0, 90 
 
 
58 (23) 10, 100 
            Role limitations due to physical health 19 (28) 0, 100 15 (28) 0, 100 
            Pain 31 (16) 0, 74 32 (12) 0, 52 
            General Health 50 (17) 15, 92 54 (19) 20, 100 
            Energy / fatigue 38 (19) 0, 85 44 (18) 10, 85 
            Social functioning 56 (26) 0, 100 61 (26) 0, 100 
             
            Role limitations due to emotional    51 (43) 0, 100 49 (43) 0, 100 
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            problems 
            Emotional well-being 58 (19) 20, 96 60 (18) 24, 92 
 
Median (Minm, Maxm ) 
lower; upper quartile 
Median (Minm, Maxm ) 
lower; upper quartile 
Bothersomeness 
(0-4 points) 
 
 3 (2, 4) 3; 4 
 
 3 (2, 4) 3;4 
   
 
Footnotes: FABQ= Fear Avoidance Beliefs Questionnaire; FfBH=Funktionsfragebogen Hannover; HADS=Hospital Anxiety and 
Depression Scale; ODI=Oswestry Disability Index; RAND-36=The RAND 36-Item Health Survey; SD=Standard Deviation; VAS= 
Visual Analogue Scale for Pain. 
 
6.3	  Intention-­‐to-­‐treat-­‐principle	  and	  missing	  data	  
 
Numbers analysed at each time-point were detailed in the CONSORT Flow Diagram 
(Figure 6.1). At the second primary endpoint (post CBT), 5 complete data sets were 
missing and an additional 13 ODI questionnaires were either not returned or left 
blank. Withdrawal reasons provided by participants who discontinued the trial were 
not related to the interventions and did not differ between groups (Section 6.1). 
Exploration of participant characteristics indicated no statistically significant 
difference of baseline pain and baseline ODI values for participants who discontinued 
and participants who continued the trial up to the second primary endpoint (post 
CBT) (Table 6.3). Hence, according to the definitions in Section 4.13.2, data were 
considered to be missing at random and ITT principles were met. 
 
Missing data at the 2 primary endpoints (post stimulation and post CBT) were 
balanced across groups (Figure 6.1). The total amount of missing data was 10%  
post stimulation and 13% post CBT. This amount was within the anticipated drop-out 
rate for the sample size calculation (Section 4.9). Hence, according to the missing 
data strategy in the trial protocol (Section 4.13.3), no data imputation was required. 
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Table 6.3 Baseline VAS and ODI scores of participants who continued and who discontinued the trial  
 Participants continued  
Mean (SD); n 
Participants discontinued 
Mean (SD); n 
Differences between 
groups  
(p-value) 
VAS 
baseline 49 (25); 121 
48 (19); 14 
0.9 
ODI 
baseline 16 (6); 120 18 (6); 15 0.3 
 
 
Footnotes: ODI=Oswestry Disability Index; SD=Standard Deviation; VAS=Visual Analogue Scale for Pain. P-value for between 
group differences according to two-tailed t-tests. 
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6.4	  Primary	  Analyses	  
 
6.4.1	  Analyses	  of	  primary	  outcome	  measures	  at	  primary	  endpoints	  
 
All assumptions for ANCOVA analysis as defined in Section 4.13.5 were met. 
 
6.4.2	  Effect	  of	  tDCS	  on	  VAS	  pain	  
 
Mean VAS pain post tDCS was 42 mm (SD 24; n=61) in the verum group and 41 mm 
(SD 23; n=62) in the sham group. There was no statistically significant effect of tDCS 
on mean VAS pain post tDCS: F(1,119)=0.18, p=0.68 (99% CI for the between group 
difference -8.69 to 6.3) (Table 6.4 Figure 6.3).  
 
6.4.3	  Effect	  of	  tDCS	  on	  ODI	  
 
Mean ODI post tDCS was 15 points (SD 7; n=61) in the verum group and 14 points 
(SD 6; n=61) in the sham group. There was no statistically significant effect of tDCS 
on mean ODI post tDCS: F(1,119)=0.31, p=0.86 (99% CI for the between group 
difference  -1.73 to 1.98) (Table 6.4, Figure 6.4).  
 
 
6.4.4	  Effect	  of	  tDCS	  &	  CBT	  on	  VAS	  pain	  	  
 
Mean VAS pain post CBT was 26 mm (SD 23; n=66) in the verum group and 23 mm 
(SD 18; n=64) in the sham group. There was no statistically significant effect of tDCS 
on mean VAS pain post CBT: F(1,127)=0.30, p=0.58 (99% CI for between group 
difference -10.32 to 6.73) (Table 6.4, Figure 6.3).  
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6.4.5	  Effect	  of	  tDCS	  &	  CBT	  on	  disability	  
 
Mean ODI post CBT was 7 points (SD 6; n=58) in the verum group and 7 points (SD 
5; n=59) in the sham group. There was no statistically significant effect of tDCS on 
mean ODI post CBT: F(1,114)=0.01, p=0.92 (99% CI for between group difference  -
2.45 to 2.62) (Table 6.4, Figure 6.4).  
 
 
Table 6.4 Mean scores for VAS pain and ODI at the primary endpoints post tDCS and post CBT 
 
 Post tDCS 
Mean (SD); n 
p-values post CBT 
Mean (SD); n 
p-values 
 Sham Verum  Sham Verum  
VAS 
pain 
41(23); 62 42(24); 61  0.68  23(18); 64 26(23); 66 0.58 
ODI  14(6); 61 15(7); 61 0.86   7(5); 59   7(6); 58 0.86  
 
Footnotes: CBT=cognitive behavioural therapy; ODI=Oswestry Disability Index; SD=standard deviation; tDCS=transcranial 
direct current stimulation; VAS=visual analogue scale for pain. P-values for between group differences according to ANCOVA 
results. 
 
 
 
 
 
 
 
 
 
  
Figure 6.3 Box plot of VAS pain values at baseline and primary endpoints  
n=68       n=67                       n=62        n=61                        n=64          n=66 
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6.5	  Secondary	  analyses	  
 
6.5.1	  Analyses	  of	  secondary	  outcome	  measures	  at	  primary	  endpoints	  
 
Data for all secondary outcome measures met the requirements for ANCOVA 
analysis detailed in Section 4.13.5. There was no statistically significant effect of 
tDCS on any secondary outcome measure at either the post tDCS or the post CBT 
endpoint when assessed by ANCOVA analyses (Table 6.5). 
Figure 6.4 Box plot of ODI values at baseline and primary endpoints 
   n=68       n=67                     n=61        n=61                    n=59          n=58 
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Table 6.5 Mean values, standard deviations and results from ANCOVA for all secondary outcome measures post stimulation and post CBT 
 
 Post stimulation Post CBT 
 verum 
Mean (SD); n 
sham 
Mean  
(SD); n 
95% CI 
(lower to 
upper) 
F-values 
(degrees of 
freedom) 
p-
values 
 
verum 
Mean  
(SD); n 
sham 
Mean  
(SD); n 
95% CI 
(lower to 
upper) 
F-values  
(degrees of 
freedom) 
p-
values 
 
FABQ 
     Physical activity 
 
15 (4); 62 
 
15 (4); 61 
 
-3.24 to 3.14 
 
(1,22) 0.00 
 
0.98 
 
9 (4); 54 
 
10 (7); 55 
 
-4.75 to 5.32 
 
(1,20) 0.01 
 
0.91 
     Work 21 (12); 62 21 (12); 61 -5.92 to 4.74 (1,22) 0.05 0.82 16 (9); 54 14 (11); 55 -8.47 to 5.96 (1,20) 0.13 0.72 
FfBH 21 (4); 62 20 (5); 61 -0.70 to 1.39 (1, 120) 0.43 0.51 16 (4); 54 16 (4); 55 -1.58 to1.11 (1,106) 0.12 0.73 
HADS  
     Anxiety 
 
7 (4); 59 
 
6 (4); 58 
 
-0.95 to 0.51 
 
(1,114) 0.35 
 
0.56 
 
5 (4); 52 
 
4 (3); 52 
 
-1.10 to 0.88 
 
(1,101) 0.05 
 
0.83 
     Depression 6 (4); 59 6 (4); 57 -1.10 to 0.69 (1,113) 0.21 0.65 4 (4); 52 4 (3); 51 -0.85 to 1.15 (1,100) 0.09 0.77 
Bothersomeness 3 (1); 61 3 (1); 61 -0.18 to 0.30 (1,119) 0.23 0.63 2 (1); 54 2 (1); 55 -0.47 to 0.30 (1,106) 0.19 0.67 
PPSI 1 (1); 61 2 (1); 61 -0.29 to 0.55 (1,97) 0.38 0.54 3 (1); 54 3 (1); 55 -0.57 to 0.21 (1,81) 0.85 0.36 
RAND-36  
     Physical Activity 
 
57 (19); 62 
 
62 (21); 61 
 
-2.64 to 8.45 
 
(1,120) 1.07 
 
0.30 
 
81 (19); 58 
 
85 (18); 59 
 
-3.51 to 8.64 
 
(1,114) 0.70 
 
0.41 
     Role limitations due  
     to physical health 
23 (32); 61 21 (32); 61 -5.90 to 11.53 (1,119) 0.41 0.52 53 (46); 53 59 (44); 54 -7.09 to 23.71 (1,104) 1.15 0.29 
     Pain 33 (13); 61 33 (14); 61 -3.12 to 4.35 (1,119) 0.11 0.77 49 (18); 53 53 (17); 55 -1.44 to 11.31 (1,105) 2.36 0.13 
     General Health 52 (19); 58 55 (19); 61 -5.52 to 4.37 (1,116) 0.05 0.82 60 (20); 53 63 (21); 55 -5.36 to 5.54 (1,105) 0.00 0.97 
     Energy / Fatigue 43 (20); 59 47 (18); 61 -7.02 to 2.87 (1,117) 0.69 0.41 56 (16); 54 58 (19); 54 -4.59 to 6.87 (1,105) 0.16 0.69 
     Social Functioning 59 (26); 62 64 (28); 59 -3.82 to 7.24 (1,118) 0.38 0.54 77 (22); 54 75 (22); 53 -13.25 to 0.88 (1,104) 3.01 0.09 
     Role limitations due to      
     emotional problems 
     
47 (45); 62 52 (46); 61 -3.62 to 21.13 (1,120) 1.96 0.16 70 (42); 54 78 (37); 54 -5.78 to 19.53 (1,105) 1.11 0.28 
     Emotional well-being 60 (19); 60 63 (17); 60 -1.83 to 5.83 (1,117) 1.07 0.30 73 (18); 53 73 (16); 53 -7.89 to 2.03 (1,103) 1.38 0.24 
 
Footnotes: CI=Confidence Interval; FABQ=Fear Avoidance Beliefs Questionnaire; FfBH=Funktionsfragebogen Hannover; HADS=Hospital Anxiety and Depression Scale; PPSI=Patient 
Perceived Satisfactory Improvement.
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6.5.2	  VAS	  pain	  on	  each	  day	  of	  the	  stimulation	  
 
Mean VAS pain was reduced over time during the stimulation for participants in each 
group. There was a trend towards a lowest mean value on day 4 of the stimulation. 
The reduction in mean VAS pain on day 4 compared to baseline was statistically 
significant (F(129)=4.187 p<0.05) in both groups (verum and sham). There was no 
statistically significant difference between mean VAS pain for the 2 groups on any 
specific day (Table 6.6, Figure 6.5). 
 
Table 6.6 Mean VAS pain for both groups on each day of the stimulation  
                   Time 
Group 
Baseline Day 1 Day 2 Day 3 Day 4 Day 5 
Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) Mean(SD) 
sham 48(18) 49(22) 45(22) 43(23) 40(23) 41(23) 
verum  47(21) 46(21) 42(22) 41(22) 33(22) 42(24) 
       
p-values for 
differences 
between groups 
0.82 0.55 0.56 0.52 0.66 0.86 
95% CI for 
differences 
between groups 
-5.99 to 
7.36 
-5.16 to 
9.16 
-5.33 to 
9.86 
-5.25 to 10.33 -6.07 to 
9.62 
-9.05 to 7.68 
 
 
Footnotes: CI=Confidence Interval; SD=Standard Deviation; P-values and CIs indicate between group differences according to 
two-tailed t-tests. 
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Figure 6.5: Mean VAS pain for both groups on each day of the stimulation period 
 
 
6.5.3	  Exploratory	  analysis	  of	  VAS	  pain	  and	  ODI	  	  	  
 
The graphical illustration of mean VAS pain and mean ODI over the period of the 
trial, indicated an improvement for both groups after the CBT that seemed to remain 
stable at all follow-up time-points (Figures 6.6 and 6.7). No statistically significant 
interaction of the factors group and time was found using a multilevel model analysis 
on VAS pain (CI 95% for the estimates of group*time as a fixed effect -0.84 to 0.20; 
p=0.23) or on ODI (95% CI for the estimates of group*time as a fixed effect -0.16 to 
0.11; p=0.72) (Table 6.7). The final model for VAS pain included the fixed effects 
Time + Time2 + Time3 + FABQ_PA + FABQ_W + gender + VAS_pre + FfBH + 
RAND36_EWB + ODI_pre + group*time. The final model for ODI included the fixed 
effects Time + Time2 + Time3 + FABQ_PA + FABQ_W + VAS_pre + FfBH + 
group*time. Stepwise building of the multilevel models for VAS and ODI are reported 
in Appendices 6.1 and 6.2.  
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Figure 6.6 Graphical illustration of mean VAS scores over time for each group 
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Figure 6.7 Graphical illustration of mean ODI over time for both groups 
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C
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Table 6.7 Primary outcome measures at 4, 12, and 24 weeks follow-up and results of multilevel model 
analysis 
 
  Weeks post CBT   
Outcome 
measure 
 
 
Group 4   
Mean  
(SD); n 
12  
Mean  
(SD); n 
24  
Mean  
(SD); n 
95% CI 
estimates of 
group*time 
 
(lower to upper) 
p-value  
group*time 
interaction 
VAS pain sham 
verum 
23 (23); 56 
26 (26); 54 
22 (22); 48 
27 (26); 53 
22 (21); 42 
29 (26); 47 
-0.84; 0.20 0.23 
ODI sham 
verum 
7 (6); 56 
8 (7); 56 
6 (6); 49 
9 (7); 52 
7 (6); 42 
9 (7); 48 
-0.16; 0.11  0.72 
 
 
Footnotes: CBT=Cognitive Behavioural Therapy; CI=Confidence Interval; ODI=Oswestry Disability Index; SD= Standard 
Deviation; VAS=Visual Analogue Scale for Pain. 
 
 
6.5.4	  Exploratory	  analyses	  of	  secondary	  outcome	  measures	  	  
 
Graphical illustration of secondary outcome measures over time showed results 
similar to VAS pain and ODI: both groups improved slightly during the stimulation 
period and significantly after the CBT. Differences between post stimulation and post 
CBT values for all secondary outcome measures within groups were statistically 
significant with p<0.05. Improvements were maintained throughout follow-up (Figure 
6.6). Multilevel models for all secondary outcome measures showed that there was a 
statistically significant interaction of group*time for the RAND36 subscales physical 
functioning, general health and emotional well-being (Table 6.8). Post-hoc testing 
indicated no significant differences between groups at any time-point. The significant 
interaction was caused by statistically significant reductions in the RAND36 
subscales physical functioning, general health and emotional well-being (p<0.001 for 
each subscale) after the CBT observed in both groups. 
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Table 6.8 Secondary outcome measures at 4, 12, and 24 weeks follow-up time-points  
 
 
  
Weeks post CBT 
  
Outcome measure Group 
4  
Mean (SD); 
n 
12  
Mean  
(SD); n 
24  
Mean  
(SD); n 
95% CI 
estimates of 
group*time 
lower to upper 
p-value  
group*time 
interaction 
FFBH 
sham 
verum 
15 (4); 56 
16 (4); 55 
15 (4); 49 
17 (4); 52 
15 (4); 42 
17 (5); 49 
-0.11 to 0.01 0.09 
FABQ 
    Physical Activity 
sham 
verum 
12(7); 52 
12 (5); 54 
9 (9); 46 
12 (4): 52 
24 (8); 38 
12 (5); 48 
-0.37 to 0.01 0.06 
    Work 
sham 
verum 
15 (12); 52 
14 (11); 54 
16 (14); 46 
17 (12); 52 
16 (15); 38 
18 (13); 48 
-0.52 to 0.22 0.41 
HADS 
    Anxiety 
sham 
verum 
4 (3); 56 
5 (5); 55 
4 (3); 49 
5 (4); 52 
3 (3); 42 
5 (4); 49 
-0.07 to 0.00 0.06 
    Depression 
sham 
verum 
3 (3); 56 
4 (4); 55 
3 (3); 49 
4 (4); 52 
3 (3); 42 
4 (4); 49 
-0.77 to 0.01 0.87 
RAND-36 
     Physical   
     functioning 
sham 
verum 
84 (20); 55 
78 (21); 55 
83 (22); 49 
75 (24); 53 
86 (18); 42 
75 (25); 49 
0.03 to 0.64 0.03* 
     Role limitations  
     due to physical   
     health 
sham 
verum 
70 (38); 55 
63 (39); 55 
74 (35); 49 
70 (37); 53 
78 (35); 42 
66 (40); 49 
-0.00 to 1.21 0.05 
     Pain 
sham 
verum 
59 (23); 56 
58 (27); 55 
63 (22); 49 
59 (25); 52 
64 (21); 42 
58 (25); 49 
-0.11 to 0.69 0.15 
     General health 
sham 
verum 
66 (22); 56 
61 (23); 55 
67 (20); 49 
62 (21); 53 
69 (20); 41 
59 (24); 48 
0.07 to 0.57 0.01* 
     Energy / fatigue 
sham 
verum 
64 (20); 56 
57 (22); 54 
62 (19); 49 
57 (19); 52 
63 (17); 41 
56 (21); 49 
-0.10 to 0.41 0.24 
     Social functioning 
sham 
verum 
84 (18); 55 
77 (25); 55 
85 (20); 49 
82 (24); 52 
84 (20); 41 
81 (27); 49 
-0.23 to 0.48 0.49 
     Role limitations  
     due to emotional    
     problems 
sham 
verum 
79 (38); 56 
72 (40); 55 
80 (33); 49 
82 (36); 51 
83 (29); 42 
81 (37); 49 
-0.41 to 0.61 0.69 
     Emotional well- sham 77 (14); 56 74 (13); 49 77 (15); 42 
0.01 to 0.45 0.04* 
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     being verum 71 (20); 55 71 (19); 52 69 (20); 49 
Patient perceived  
     satisfactory  
     improvement  
sham 
verum 
3 (1); 46 
2 (1); 52 
3 (1); 47 
2 (1); 51 
2 (1); 35 
2 (1); 45 
-0.01 to 0.03 0.17 
Bothersomeness 
sham 
verum 
2 (1); 55 
2 (1); 53 
2 (1); 49 
2 (1); 52 
2 (1); 41 
2 (1); 49 
-0.03 to 0.01 0.16 
 
Footnotes: FABQ=Fear Avoidane Beliefs Questionnaire; FFBH=Funktionsfragebogen Hannover; HADS=Hospital Anxiety         
and Depression Scale; p-values and 95% CI for group differences according to multilevel models for all outcome measures 
across time. * indicates statistically significant results at p<0.05.
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6.6	  Side	  effects	  of	  tDCS	  
 
A total of 587 side-effect evaluation questionnaires from the 135 participants over 5 
days of stimulation were evaluated. Participants observed sensory perceptions 
during and after the majority (75% in the sham group and 89% in the verum group) of 
the stimulation sessions (Table 6.9). The most frequently observed sensations were 
Figure 6.6 Secondary outcome measures by group at each time-point.  
 
Footnotes: Higher ratings for all RAND subscales and PPSI indicate a positive outcome, while lower levels of FABQ, 
FfBH, bothersomeness and HADS indicate improved results. The CBT was conducted from week 2 to week 5. The 
round markers indicate the measurement time-points.  
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tingling (53% of the sessions in the verum group and 50% of the sessions in the 
sham group) and a sensation of burning (35% of the sessions in the verum group 
and 17% of the sessions in the sham group) underneath the electrodes during the 
stimulation. Further side effects included itching and pain under the electrodes during 
the stimulation, tiredness during and after the stimulation and headaches after the 
stimulation (Table 6.9). All of these reported side effects were rated as "mild to 
moderate" by participants and none of the participants asked for the stimulation to be 
discontinued.  
 
Table 6.9 Frequencies of participant-reported side effects 
 
 
Type of side-effect Group 
 sham  
(n=290) 
verum  
(n=297) 
During the stimulation n (%) n (%) 
Light flashes 27 (9) 18 (6) 
Pain under the electrodes 21 (7) 87 (29) 
Tingling under the electrodes 144 (50) 158 (53) 
Itching under the electrodes 26 (9) 98 (33) 
Burning under the electrodes 48 (17) 104 (35) 
Tiredness 21 (7) 32 (11) 
Nervousness 4 (1) 3 (1) 
Reduced concentration 7 (2) 0 (0) 
Impaired vision 12 (4) 12 (4) 
Headaches 14 (5) 21 (7) 
Other perception 10 (3) 9 (3) 
Anything else 11 (4) 10 (3) 
Unpleasantness 7 (2) 21 (7) 
After the stimulation n (%) n (%) 
Pain at stimulation site 6 (2) 10 (3) 
Tingling under the electrodes 33 (11) 29 (10) 
Itching under the electrodes 14 (5) 34 (11) 
Burning under the electrodes 4 (1) 35 (12) 
Tiredness 29 (10) 41 (14) 
Nervousness 4 (1) 2 (1) 
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Reduced concentration 11 (4) 6 (2) 
Impaired vision 8 (3) 16 (5) 
Headaches 35 (12) 31 (10) 
Nausea 0 (0) 3  (1) 
Vomiting 0 (0) 3  (1) 
Impaired sleep 11 (4) 18 (6) 
Lifted mood 1 (0) 19 (6) 
Cold feeling 9 (3) 17 (6) 
Hot flushes 8 (3) 14 (5) 
Other sensations 5 (2) 6  (2) 
Anything else 9 (3) 9 (3) 
 
 
 
Chapter summary: 
 
This chapter has presented the results from statistical analyses conducted on trial 
data. tDCS alone or in combination with a CBT did not significantly influence VAS 
pain or ODI when compared to sham stimulation. None of the secondary outcome 
measures were significantly influenced by the stimulation type (verum or sham) at 
either of the 2 primary endpoints. The most frequently observed side effects were 
skin sensations underneath the electrodes. These were observed in the majority of 
stimulation sessions but rated as mild or moderate. 
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7.	  CHAPTER	  	  	  
 
EVALUATION	  OF	  LITERATURE	  PUBLISHED	  AFTER	  THE	  
SYSTEMATIC	  REVIEW	  (SEPTEMBER	  2010)	  TO	  INFORM	  
DISCUSSION	  
 
tDCS is still of high scientific interest as indicated by numerous research articles 
evaluating the effectiveness of tDCS for the reduction of clinical and experimental 
pain, published since the cut-off date for trial inclusion into the systematic review 
(Chapter 3). In order to provide an overview of current research in this field and to 
evaluate how results from the current trial (Chapter 6) will compare with recent 
evidence, this chapter will present an updated systematic review of the published 
evidence on tDCS for the reduction of clinical and experimental pain.  
 
7.1	  Introduction	  
 
The published systematic review of trials on tDCS for the reduction of clinical and 
experimental pain (Chapter 3 and (Luedtke et al., 2012b)) had a cut-off date for the 
literature search as Sept 30th 2010. Research interest in non-invasive brain 
stimulation is still high. An updated version of the 2010 Cochrane Review on non-
invasive brain stimulation for the management of chronic pain included 6 new trials 
on tDCS (O’Connell et al., 2014). The combined effect size from 5 old and 6 new 
trials was smaller (SMD -0.18 [95% CI -0.46, 0.09]) than the 2010 publication (SMD -
0.37 [95% CI -1.01, 0.28]) (O’Connell et al., 2010). The updated review, as in the 
2010 review, focused on all types of non-invasive brain stimulation for the reduction 
of chronic pain but did not include trials on experimental pain. 
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An updated systematic review was required:  
 
1) To provide a comprehensive overview of current tDCS research, by including and 
comparing all trials on tDCS for the reduction of clinical and experimental pain;   
 
2) To enable this thesis to discuss the results from the current trial within the context 
of recent research. For the purpose of facilitating the discussion it was important:  
 
 - To identify whether a new stimulation paradigm had emerged as the most 
    efficient for pain reduction; 
 - To evaluate how results from the current trial compared with the results of  
             recent trials; 
 - To assess how results from the current trial would influence the combined   
             mean effect for tDCS as an intervention to reduce clinical pain.  
 
7.2	  Methods	  
 
The methods of this updated review followed those defined for the original systematic  
review (Chapter 3). Limits for publication dates were set as 2010 to 6th Nov 2013. 
The search was conducted on 6th November 2013. As suggested by an updated 
version of the Cochrane Risk of Bias Tool (Higgins et al., 2011b) the risk of bias 
assessment was revised: One additional column was added to the risk of bias 
assessment table headed "Assessor blinding" to distinguish between the person who 
applied the stimulation (therapist) and the person who evaluated the results 
(assessor). As an accepted limitation, for practicability reasons and time restrictions, 
the literature search, screening against inclusion / exclusion criteria, risk of bias 
evaluation and data extraction were conducted by 1 researcher.  
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Results from trials on clinical pain with no high risk of bias were combined in a meta-
analysis to compare the combined mean effect of the 2010 meta-analysis with the 
combined mean effect of all published clinical trials including those published 
between 2010 and Nov 2013. A sensitivity analysis was conducted that also included 
trials with a high risk of bias (in 1 or more domains). Results from the 2 meta-
analyses with and without exclusion of high risk of bias trials were compared to 
evaluate the influence of methodological quality on trial results. In order to evaluate 
the influence of results from the current trial (Chapter 6) on the combined mean effect 
of published trials on tDCS for the reduction of clinical pain, a further sensitivity 
analysis was conducted: a subgroup meta-analysis of all trials that applied anodal 
tDCS to the M1 to reduce clinical pain was performed with and without entering data 
from the current trial.  
 
7.3.	  Results	  
 
7.3.1	  Search	  results	  
 
The search in Medline (PubMed) resulted in 40 new eligible articles. The same 
search strategy for OVID added 4 eligible articles and hand searching of reference 
lists and journal contents added 1 further publication. Title / abstract screening of 
these 45 articles excluded 18 articles that did not focus on pain as an outcome 
measure, were not a clinical trial, did not use tDCS as an intervention, were not 
conducted on humans, or were already included in the last systematic review (Figure 
7.1). Full text screening excluded 8 trials: one did not include a control group for 
tDCS (Vigano et al., 2013); 2 did not assess pain intensity as a primary or secondary 
outcome (Maeoka et al., 2012; Tadini et al., 2011); 2 trials were excluded since no 
group received tDCS alone (Moloney and Witney, 2013; Riberto et al., 2011); 2 were 
excluded because analgesic use was the main outcome measure and varying levels 
of analgesics made pain as an outcome measure unreliable (Borckardt et al., 2011, 
2013), and 1 publication was the abstract for a conference with no full-text available 
(despite email request) (Lee et al., 2013). This procedure resulted in 19 included new 
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trials, 10 on clinical pain (Antal et al., 2011; Auvichayapat et al., 2012; Bolognini et 
al., 2013; DaSilva et al., 2012; Dubois et al., 2013; Jensen et al., 2013; Mendonca et 
al., 2011; O’Connell et al., 2013; Villamar et al., 2013; Wrigley et al., 2013) and 9 on 
experimental pain (Borckardt et al., 2012; Grundmann et al., 2011; Hansen et al., 
2010; Jurgens et al., 2012; Luedtke et al., 2012a; Mancini et al., 2012; Mylius et al., 
2012; Reidler et al., 2012; Zandieh et al., 2013) (Figure 7.1) (Appendix 7.1).  
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Figure 7.1: Flowchart for study selection process (Moher et al., 2009) 
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- tDCS only in combination  
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- 9 trials on experimental pain 
- 10 trials on clinical pain 
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7.4	  Risk	  of	  bias	  assessment	  
 
The majority of trials used a tDCS machine that had to be actively switched off for the 
sham stimulation. This resulted in a "high risk of bias" in the column focused to 
therapist blinding (Table 7.1). None of the included trials had a published research 
protocol resulting in the rating "unclear" for the domain of selective outcome 
reporting. Allocation concealment was also rated as unclear in all trials since no 
methods to conceal participant allocation were described. Further high or unclear risk 
of bias ratings referred to crossover trials with an unclear carry-over effect. 
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Table 7.1:  Summary assessment of risk of bias for each trial 
Author, year 
country 
1 2 3 
a 
3 
b 
3 
c 
4 5 6 Comments 
Antal et al. 2011 
(Germany) 
H U L L U L U L Order of entry as randomisation method; 
allocation concealment not reported; assessor 
blinding not reported; no study protocol published. 
Auvichayapat et 
al. 2012 
(Thailand) 
L U L H L L U L Allocation concealment not reported; therapist had 
to switch off machine for sham stimulation; no 
study protocol published. 
Bolognini et al. 
2013  
(Italy, USA) 
L U L H U L U H Crossover trial; allocation concealment not 
reported; therapist had to switch off machine for 
sham stimulation; assessor blinding not reported; 
no study protocol published; parametric tests 
conducted on small sample size. 
  
Borckardt et al.     
2012  
(USA) 
L U L H U L U L Allocation concealment not reported; therapist had 
to switch off machine for sham stimulation; 
assessor blinding not reported; no study protocol 
published. 
DaSilva et al. 
2012  
(USA) 
L U L U U U U H Allocation concealment not reported; therapist had 
to switch off machine for sham stimulation; 
assessor blinding not reported; last observation 
carried forward; no study protocol published. 
ANOVA on 13 subjects; no correction for multiple 
comparisons. 
Dubois et al. 
2013  
(Belgium) 
L U L L L L U L Allocation concealment not reported; no study 
protocol published.  
Grundmann et 
al. 2011 
(Germany) 
L U L U U L U L Crossover trial; allocation concealment not 
reported; unclear whether therapist had to switch 
off machine and who evaluated the data; no study 
protocol published. 
Hansen et al. 
2010 
(Germany) 
H U L H U L U L Crossover trial; randomised according to order of 
study entry; allocation concealment not reported; 
therapist had to switch off machine for sham 
stimulation; assessor blinding not reported; no 
study protocol published. 
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Jensen et al. 
2013  
(USA) 
L U L H U L U U Crossover trial; allocation concealment not 
reported; unclear whether therapist had to switch 
off machine and who evaluated the data; no study 
protocol published; carry-over effects unclear. 
Jürgens et al. 
2012 
(Germany) 
U U L L U L U L Crossover trial; randomisation unclear and 
allocation concealment not reported; unclear who 
evaluated the data; no study protocol published.  
Luedtke et al. 
2012  
(Germany)* 
L U L L U L U L Crossover trial; allocation concealment not 
reported; unclear who evaluated the data; no 
study protocol published.  
Mancini et al. 
2012 
(Italy) 
U U L H U L U L Crossover trial; counterbalanced order but how 
randomised? Allocation concealment not reported; 
therapist had to switch off machine; unclear who 
evaluated the data; no study protocol published.  
Mendonca et al. 
2011  
(Brazil, USA) 
L U L H L L U H Allocation concealment not reported; therapist had 
to switch off machine; no study protocol 
published; 6 participants per group. 
Mylius et al. 
2012 
(Germany) 
L U L H U L U L Crossover trial; allocation concealment not 
reported; therapist had to switch off machine; 
unclear who evaluated the data; no study protocol 
published. 
O'Connell et al. 
2013  
(UK) 
L L L H L L U H Therapist had to switch off machine; no study 
protocol published; statistical tests conducted on 
small sample size. 
Reidler et al. 
2012 
(USA, Brazil, 
Canada) 
L U L U L L U L Crossover trial; allocation concealment not 
reported; unclear whether therapist had to switch 
off machine; no study protocol published. 
Villamar et al. 
2013  
(USA, Ecuador, 
Thailand) 
L U L H L L U L Crossover trial; allocation concealment not 
reported; therapist had to switch off machine; no 
study protocol published. 
Wrigley et al. 
2013  
(Australia) 
U U L U L L U H Crossover trial; allocation concealment not 
reported; unclear whether therapist had to switch 
off machine; no study protocol published; multiple 
t-Tests, no correction for multiple testing, small 
sample size (n=10); no primary outcome defined. 
Zandieh et al. 
2012  
(Iran) 
L U L H U L U L Crossover trial; allocation concealment not 
reported; therapist had to switch off machine; 
unclear who evaluated the data; no study protocol 
published. 
 
Footnotes: Components of risk of bias: 1 Sequence generation; 2 Allocation concealment; 3a Blinding of participants; 3b 
Blinding of therapist; 3c Blinding of outcome assessor; 4 Incomplete outcome data; 5 Selective outcome reporting; 6 Other 
sources of bias. Levels of risk of bias: H= high risk of bias; U=unclear risk of bias; L= low risk of bias.   
* pilot study conducted prior to PhD on tDCS for the reduction of experimental pain in chronic low back pain patients 
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7.5	  Risk	  of	  bias	  assessment	  of	  current	  trial	  
 
The current trial has a low risk of bias in all domains of the Cochrane Risk of Bias 
Tool (Higgins et al., 2011b). 
 
7.5.1	  Random	  sequence	  generation	  
 
Computer randomisation was used to generate lists of stimulation codes that 
automatically triggered either a sham or a verum stimulation. Two lists were 
produced: one for participants with baseline levels of pain between 20 mm and 50 
mm on a 0-100 mm VAS and the second for baseline VAS pain between 51 mm and 
100 mm (Section 4.11.2). This randomisation approach allowed for balanced 
baseline pain levels in the 2 intervention groups. This random sequence generation 
resulted in a low risk of bias to correctly guess the order of interventions. 
 
7.5.2	  Allocation	  concealment	  
 
Participants were allocated to an intervention group by receiving the next unused 
stimulation code from the randomisation list pertinent to their baseline level of pain 
intensity (Section 4.11.2). Neither participants nor researchers could identify the 
stimulation mode  triggered by the code. This procedure resulted in a low risk of bias 
to correctly guess the group allocation. 
 
7.5.3	  Blinding	  
 
The study mode of the tDCS machine used in the current trial allowed for participant 
and researcher blinding by delivering a pre-programmed verum or sham stimulation 
triggered by a 5-digit number code (Section 4.12). Blinding was evaluated after every 
stimulation by asking participants which stimulation mode they thought they had 
received (Section 4.12). Groups were coded A and B by an independent researcher 
 152 
to ensure assessor blinding during the statistical analysis of the data (Section 4.12). 
Consequently blinding of participants, researchers and assessors was regarded as of 
low risk of bias. 
 
7.5.4	  Incomplete	  outcome	  data	  
 
Evaluation of the number of participants who discontinued the trial showed that the 
number of drop-outs was within the range used for the sample size calculation 
(Section 6.3). Participant did not switch intervention groups. Reasons for withdrawal 
and evaluation of baseline data indicated no systematic loss of data due to factors 
directly associated with the intervention (Sections 6.1 and 6.3). Hence, there was a 
low risk of bias due to incomplete outcome data in the current trial. 
 
7.5.5	  Selective	  outcome	  reporting	  
 
A trial protocol was developed and published in an open access (Luedtke et al., 
2011) (Appendix 4.7). The protocol pre-specified all trial procedures including primary 
and secondary outcome measures. No alterations were made to the protocol. This 
category was therefore rated as low risk of bias.  
 
7.5.6	  Other	  sources	  of	  bias	  
 
There were no relevant differences at baseline between groups, all assumptions for 
statistical testing were met, and there were no conflicts of interest or other potential 
sources of bias. This category was therefore rated as low risk of bias. 
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7.6	  Study	  characteristics	  
 
7.6.1	  Experimental	  pain	  
 
All trials on experimental pain evaluated the effect of a single session of tDCS (Table 
7.2). Stimulation paradigms varied regarding the stimulation site (M1, S1, DLPFC, 
centroparietal and occipital cortex), the stimulation intensity (1 mA or 2 mA), the 
duration (10, 15, 20 minutes), and the stimulation mode (anodal, cathodal). Pain 
related outcomes included pain thresholds (thermal, mechanical, electrical), ratings 
to an experimental pain paradigm and pain evoked potentials. Most trials applied 
tDCS to healthy participants, while 1 trial investigated the effect of tDCS on 
experimental pain intensity in patients already experiencing chronic pain (Luedtke et 
al., 2012a). 
 
7.6.2	  Clinical	  pain	  
 
Trials evaluated either a single session or repeated sessions (up to a maximum of 20 
sessions) of tDCS for the reduction of clinical pain. The most frequently used 
stimulation paradigm was 2 mA for 20 minutes over M1 (DaSilva et al., 2012; Jensen 
et al., 2013; Mendonca et al., 2011; O’Connell et al., 2013; Villamar et al., 2013; 
Wrigley et al., 2013) (Table 7.3). Three trials applied an intensity of 1 mA (Antal et al., 
2011; Auvichayapat et al., 2012; Dubois et al., 2013), 4 trials additionally or 
exclusively targeted a different cortical area (visual cortex, S1, DLPFC) (Antal et al., 
2011; Bolognini et al., 2013; Dubois et al., 2013; Mendonca et al., 2011), and 2 trials 
applied tDCS for a duration of 15 min (Antal et al., 2011; Bolognini et al., 2013). One 
trial used a new type of tDCS (HD-tDCS) (Villamar et al., 2013) and 1 trial exclusively 
used the cathodal stimulation mode (Antal et al., 2011). Four trials applied both 
anodal and cathodal stimulation (Bolognini et al., 2013; Dubois et al., 2013; 
Mendonca et al., 2011; Villamar et al., 2013). Trial participants were diagnosed with 
migraine, phantom limb pain, post-operative pain, spinal cord injury, fibromyalgia, 
and CNSLBP.  
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Table 7.2: Characteristics of trials on experimental pain 
Authors,	  	  
Year	  
(Country)	   
	  Type	  of	  	  
	  pain	   
Number	  
of	  	  	  	  
partici-­‐
pants 
	  Mean	  
age	  	  
(SD)	  or	  
range	  	  	  	  	  
(years) 
	  Mode	  of	  	  	  	  
	  active	  	  
stimulation	  	   
Control	   	  Site	   
Intensity	  
	  (mA)	   
Duration	  	  	  
	  (min) 
	  Side	  effects 	  Pain	  related	  	  	  
	  outcome	  	  	  
	  measures 
Borckardt	  et	  al.	  2012	  
(USA) 
thermal,	  
mechanical 
24 
27	  (6)	  
HD	  tDCS sham M1 2 20 none 
cold	  pain	  thresholds,	  heat	  pain	  thresholds,	  
thermal	  wind	  up	  pain,	  mechanical	  thresholds 
Grundmann	  et	  al.	  
2011	  (Germany) 
thermal,	  
mechanical	   
12 
30	  
(22-­‐42) 
anodal	  
cathodal 
sham S1 1 15 not	  reported 
heat	  pain	  thresholds,	  	  
cold	  pain	  thresholds,	  mechanical	  thresholds 
Hansen	  et	  al.	  	  
2010	  (Germany) 
pain	  related	  
EPs	   
19 30	  (7) 
anodal	  
cathodal 
sham 
M1	  
1 20 initial	  itching	   Pain	  related	  evoked	  potentials:	  latency	  of	  N2	  and	  
peak-­‐to-­‐peak	  amplitude	   
Jürgens	  et	  al.	  	  
2012	  (Germany) 
thermal,	  
mechanical	   
17 25	  (3) 
anodal	  
cathodal 
sham 
M1	  	  	  
1 15 
 heat	  pain	  thresholds,	  cold	  pain	  thresholds,	  
mechanical	  pain	  thresholds,	  VAS	  ratings	   
Luedtke	  et	  al.	  2012	  
(Germany) 
thermal,	  
electrical 
15 
49	  
(30-­‐70) 
anodal	  
cathodal 
sham M1 1 15 not	  reported thermal	  pain	  thresholds,	  VAS	  ratings	  to	  pain	  
paradigm 
Mancini	  et	  al.	  2012	  
(UK,	  Italy) 
electrical 24 23	  (4) 
anodal,	  
cathodal 
sham 
cp,	  	  
Occ	   2 10 not	  reported experimental	  pain	  intensity	  while	  viewing	  own	  
hand	   
Mylius	  et	  al.	  2012	  
(Germany)	   thermal 26 
25	  (3)	  
and	  
24	  (4) 
anodal,	  
cathodal 
sham DLPFC 2 20 headaches	   thermal	  pain	  thresholds 
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Reidler	  et	  al.	  2012	  
(USA,	  Brazil,	  Canada) 
mechanical 15 37	  (11)	   anodal sham M1 2 20 itching,	  
tingling,	  skin	  
redness,	  scalp	  
pain,	  scalp	  
burning,	  
headache,	  pins	  
and	  needles	   
pressure	  pain	  threshold 
Zandieh	  et	  al.	  2012	  
(Iran) 
thermal	  
(cold) 
22 23	  (5) anodal,	  
cathodal 
sham M1 2 max.15	   tingling	   cold	  pain	  thresholds	  and	  cold	  tolerance	  /	  
intensity 
 
  
Footnotes: cp= centro-parietal; DLPFC= dorsolateral prefrontal cortex; EPs=evoked potentials; LEPs= laser-evoked potentials; M1= primary motor cortex; NRS= Numerical Analogue Scale; 
Occ=occipital; S1=  primary somatosensory cortex; SD=standard deviation; VAS=visual analogue scale. 
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Table 7.3 Characteristics of trials on chronic clinical pain 
Author,	  year	  
(Country) 
Type	  of	  	  
pain	   
Number	  of	  
participants	   
Mean	  
age	  (SD)	  
or	  range	   
Mode	   Control	   Site	   
Intensity	  	  
(mA) 
Duration Side	  effects Pain	  related	  outcome	  
measures 
Antal	  et	  al.	  2011	  	  
(Germany) 
migraine 30 
33	  (10)	  	  
32	  (12) 
cath. sham V1 1 
15	  min	  
3	  per	  week	  for	  3	  
weeks	   
tingling,	  itching,	  fatigue,	  
headache 
Pain	  intensity	  during	  migraine	  
attack 
Auvichayapat	  et	  al.	  2012	  
(Thailand) 
migraine 37 23	  (8) anodal sham M1 1 
	  
20	  min,	  
20	  days 
first	  degree	  burn,	  skin	  rash	   VAS 
	  
Bolognini	  et	  al.	  	  
2013	  (Italy,	  USA) 
Phantom	  
limb	  pain 
8 59	  (19) 
	  
anodal	  
cath. 
sham 
	  
M1	  
PPC 
2 15	  min assessed	  but	  not	  reported VAS	  for	  phantom	  limb	  pain,	  
VAS	  for	  stump	  pain 
	  
DaSilva	  et	  al.	  	  
2012	  (USA) 
migraine 13 46	  (6) anodal sham M1 2 
	  
20	  min	  	  
4	  weeks,	  every	  
2nd	  day 
headache,	  neck	  pain,	  
tingling,	  skin	  redness,	  
sleepiness,	  scalp	  pain 
Pain	  intensity	  during	  migraine	  
attack 
	  
Dubois	  et	  al.	  	  
2013	  (Belgium) 
post	  OP	  
pain	   
59 50	  (16) anodal,	  
cath. 
sham DLPFC 1 
	  
20	  min	   itching,	  visual	  flash 
	  
VAS,	  
morphine	  consumption 
	  
Jensen	  et	  al.	  	  
2013	  (USA) 
SCI	   
	  
30 
	  
49	  
(22-­‐77) 
anodal 
	  
sham	   M1 2 20	  min not	  reported NRS 
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Mendonca	  et	  al.	  2011	  
(Brazil,	  USA) 
fibro-­‐
myalgia 
30 43 anodal,	  
cath. 
sham	   
	  
M1	  
supra-­‐
orbital 
2 20	  min no	  adverse	  reactions VNS,	  pressure	  pain	  thresholds 
O'Connell	  et	  al.	  2013	  (UK) 
	  
CNSLBP 
8 45	  (10) anodal sham M1 2 
	  
20	  min	  
3-­‐15	  days 
dizziness,	  headaches,	  ear	  
ache,	  less	  cravings	  for	  
high-­‐fat	  content	  food 
VAS 
Villamar	  et	  al.	  2013	  	  (USA,	  
Ecuador,	  Thail.) 
fibro-­‐
myalgia 
18 50	  (9) anodal,	  
cath. 
	  
sham	   M1 2 20	  min tingling,	  itching VNS	  overall	  pain,	  pressure	  pain	  
thresholds 
	  
Wrigley	  et	  al.	  	  
2013	  (Australia) 
SCI 10 56	  (15) anodal sham 
	  
M1	   2 
	  
20min,	  
5	  days 
redness,	  tingling,	  fatigue,	  
light-­‐headedness,	  
headache 
Neuropathic	  Pain	  Scale	  (Pain	  
intensity	  and	  unpleasantness) 
 
Footnotes: BPI= brief pain inventory;  cath=cathodal; DLPFC= dorsolateral prefrontal cortex; M1= primary motor cortex; NRS= numerical rating scale; PPC=posterior parietal cortex; 
S1=primary somato-sensory cortex; SD=standard deviation; Thail=Thailand; V1= visual cortex; VAS= visual analogue scale: VNS=visual numerical scale
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7.7	  Syntheses	  of	  results	  
 
7.7.1	  Experimental	  pain	  
 
Although most trials on experimental pain used pain thresholds as a primary or 
secondary outcome measure, a meta-analysis of the results was not possible. Pain 
thresholds referred to different modalities (mechanical, thermal or electrical) that 
used different scales. Furthermore, publications reported percentage of change, 
normalised or standardised values that could not be entered into a meta-analysis. An 
email response from the research group that published the majority of trials stated 
that data could not be provided due to limited time and limited access to stored study 
files.  
 
 
7.7.2	  Clinical	  Pain	  
 
To compare the results from current evidence with the combined mean effect 
reported by the 2010 systematic review, a meta-analysis was conducted that 
included all (previously included and new trials) published trials with a low risk of bias 
on clinical pain, independent of localisation and mode of stimulation. The result 
indicated a small favourable effect of tDCS of -0.82 [95% CI -1.10 to -0.53] on a 0-10 
VAS (Figure 7.2). Including trials with a high risk of bias in 1 or more domains 
resulted in a combined mean effect of -0.68 [95% CI -0.96 to -0.40] on a 0-10 VAS 
(Figure 7.3). 
 
The subgroup analysis of trials that applied anodal tDCS to M1 indicated a 
comparable combined mean effect of -0.82 [95% CI -1.44 to -0.20] (Figure 7.4). 
When results from the current trial were entered into the subgroup analysis of trials 
on anodal tDCS over M1, this result was reduced to a combined mean effect of -0.72 
[95% CI -1.28 to -0.16] (Figure 7.5). 
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Table 7.4 Main results of trials on experimental pain 
 
Author, year 
(Country) 
Between group differences  (verum vs. sham) 
Statistical significance at p<0.05 
Borckardt et al. 
2012 
(USA) 
Heat / cold pain thresholds & mechanical pain not statistically significant.  
Statistically significant difference in thermal pain wind-up slope 
Grundmann et al. 
2011  
(Germany) 
Thermal pain and mechanical pain thresholds not significantly altered by tDCS  
Hansen et al.  
2010 
(Germany) 
Cathodal: significantly decreased PPA, anodal significantly increased PPA 
(trigeminal and extracranial nociceptive system); latencies unaltered 
Jürgens et al.  
2012 
(Germany) 
No statistically significant response to suprathreshold heat pain paradigm; no 
statistically significant increase in pain thresholds 
Luedtke et al.  
2012  
(Germany) 
No statistically significant change of pain thresholds or of an experimentally 
induced suprathreshold pain paradigm 
Mancini et al.  
2012 
(UK, Italy) 
Occipital tDCS resulted in statistically significant enhanced visually induced 
analgesia 
Mylius et al.  
2012 
(Germany) 
Anodal tDCS over right DLPFC significantly increased pain heat thresholds; 
cathodal tDCS over left DLPFC significantly increased cold pain thresholds  
Reidler et al.  
2012 
(USA, Brazil, 
Canada) 
Anodal tDCS significantly increased pressure pain threshold  
Zandieh et al.  
2012 
(Iran) 
Anodal stimulation significantly increased pain threshold and tolerance 
(seconds of cold water immersion) 
Footnotes: DLPFC=Dorsolateral Prefrontal Cortex; PPA= Peak-to-Peak Amplitude; tDCS=transcranial Direct Current 
Stimulation. 
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Figure 7.2: Meta-analysis of all trials on clinical pain with an unclear or low risk of bias  
independent of stimulation paradigm  
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Figure 7.2: Meta-analysis of all trials on clinical pain independent of stimulation paradigm  
and risk of bias 
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Figure 7.4: Subgroup analysis of trials that used anodal stimulation over M1 (excluding current trial) 
 
 
 
 
 
 
 
Figure 7.5 Meta-analysis of subgroup anodal stimulation over M1 including results of current trial 
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7.8	  Discussion	  
 
The number of included trials indicated the ongoing scientific interest in tDCS as an 
intervention for pain reduction in clinical and experimental pain trials. The risk of bias 
analysis showed that the methodological quality of published trials and the quality of 
reporting had not improved since the 2010 systematic review. In particular, allocation 
concealment and randomisation procedures were rarely reported in detail and no trial 
protocols pre-specifying planned procedures were available for any included trial. 
Sample sizes were still too small to provide adequate statistical power. Moreover, 
mean values and standard deviations were rarely reported but were substituted by 
percentage of change or by data reported graphically. The analysis of the stimulation 
parameters of new trials on experimental pain indicated that higher intensities had 
been applied to healthy participants than in the earlier trials. Research on tDCS for 
the reduction of experimental pain was not conducted with a homogenous stimulation 
paradigm. Furthermore, outcomes on pain thresholds or responses to a 
suprathreshold stimulation paradigm showed mixed and conflicting results. An 
emerging area of research was the investigation of experimental pain in patients 
already experiencing chronic pain. Such investigations might be useful to assess the 
effect of tDCS in patients with altered pain processing due to a clinical pain condition. 
By applying an experimental pain paradigm rather than investigating the clinical pain 
itself, the type and intensity of pain is easier to standardise. In the only experimental 
pain trial that included chronic pain patients, tDCS failed to influence experimental 
pain thresholds and suprathreshold perception (Luedtke et al., 2012a).  
 
Trials on clinical pain indicated that research had been conducted on new pain 
syndromes such as migraine, CLBP, and phantom limb pain. A new area of scientific 
interest had emerged that applied tDCS for the reduction of acute clinical pain. The 
stimulation paradigm used by most researchers on clinical pain was still the paradigm 
that had been used for the current trial. The meta-analysis of all trials on clinical pain 
showed that the combined mean effect was lower than in the meta-analysis 
conducted in 2010. This indicated that recent trials had reported neutral or negative 
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results for tDCS on pain reduction while early research had exclusively reported 
statistically significant pain reduction. The sensitivity analysis that included trials 
independent of risk of bias did not alter this result. A subgroup analysis on anodal 
tDCS over M1 resulted in a comparable combined mean pain reduction. It was the 
stimulation paradigm applied in the majority of trials. The combined mean effect of 
anodal tDCS over M1 was slightly reduced when data from the current trial were 
included. Combined mean effect sizes from all meta-analyses did not reach minimum 
clinically relevant change levels of 1.5 points for VAS pain (0-10 mm scale) (Ostelo et 
al., 2008).   
 
The overall level of published evidence was still regarded as "low" according to  
GRADE (Schunemann et al., 2008) (Section 3.2.11) since all published trials had to 
be downgraded by 2 levels due to limitations in design, imprecision of results (wide 
confidence intervals), unexplained inconsistency of results and a high possibility of 
publication bias. Hence, current evidence is based on publications of an overall low 
methodological quality. The current trial had a low risk of bias in all domains. 
Following GRADE no downgrading was required. If the current trial were added to 
the systematic review, the GRADE approach would be based on 1 RCT with a low 
risk of bias. According to GRADE this is defined as a high level of evidence and can 
be interpreted as "further research is very unlikely to change the confidence in the 
estimate of effect" (Guyatt et al., 2008, p.926). However, this high level of evidence, 
since it is based on a single RCT, can only apply to the stimulation paradigm used 
and to NSCLBP. 
 
 
 
 
 
 
 
 
 
 165 
Chapter summary 
 
This chapter provided a systematic review of the methodological quality and 
characteristics of recent trials on tDCS for the reduction of clinical and experimental 
pain. tDCS had been applied to new areas of research (experimental pain reduction 
in patients with chronic pain and acute clinical pain) and intensities in experimental 
pain trials had increased from 1 mA to 2 mA. The meta-analysis of trials on clinical 
pain resulted in a lower combined mean effect than in the 2010 systematic review 
and meta-analysis. Results from the current trial further reduced the combined mean 
effect size. The overall level of published evidence for tDCS as an intervention for 
pain reduction was still regarded as low but upgraded to "high" if the current trial was 
added to the body of evidence. This level of evidence is based on 1 RCT only, hence 
future research is unlikely to show a pain reducing effect of tDCS in patients with 
NSCLBP, but may report pain reductions in other pain syndromes or by using 
different stimulation parameters. 
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8.	  CHAPTER	  	  	  
	  
	  DISCUSSION	  
 
Chapter 6 presented the results from a randomised controlled trial that investigated 
the effectiveness of tDCS alone and in combination with CBT on pain and disability of 
patients with NSCLBP. Results indicated no effect of tDCS on either pain or disability 
immediately after the stimulation, after the CBT, or at any of the long-term follow-up 
time-points at 4, 12, and 24 weeks after the CBT. Participants perceived transient 
side effects during most stimulation sessions, however, these were of mild to 
moderate intensity and did not cause participants to discontinue the intervention. This 
chapter discusses the findings from the current trial within the context of the 
systematic review (Chapter 3) and the updated systematic review (Chapter 7). It 
further discusses the limitations of the current trial and outlines research priorities for 
the future. 
 
8.1	  Participant	  group	  characteristics	  at	  baseline	  
 
Following CONSORT recommendations, between group differences at baseline were 
not evaluated for statistical significance. However, Table 6.1 and 6.2 indicated that 
patient characteristics and baseline data were largely comparable between groups. 
Importantly there were no differences in the primary outcome measures VAS pain 
and ODI. However, the range in duration since the first onset of back pain was larger 
in the verum group (maximum value of 600 months) than in the sham group 
(maximum value of 384 months). This value, however, only referred to a single 
participant and is therefore unlikely to introduce bias to the data. The same applies to 
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the duration of this episode of back pain where the sham group showed a larger 
value (240 months) than the verum group (156 months).  
 
11 more patients in the verum group (compared to the sham group) received NSAIDs 
for pain relief. This is a large difference and might cause concern if the verum group 
had shown better results than the sham group. Figure 6.6 visualises that the sham 
group showed overall better results than the verum group therefore NSAIDs did not 
seem to influence the data towards a better effectiveness in the verum group. That 
the sham group consistently showed better results than the verum group might be 
explained by marginally better baseline values in most RAND36 subscales. However, 
all other primary and secondary outcome measures did not support this notion that 
the sham group had been generally less affected than the verum group. 
 
8.2	  Effectiveness	  of	  tDCS	  for	  the	  reduction	  of	  pain	  
 
Five days of  verum tDCS compared to sham stimulation did not result in a reduction 
of the intensity of pain in participants with NSCLBP. Hence, results from the trial did 
not support the pain reducing effect of tDCS on chronic pain as reported by the 
majority of previously published trials and, consequently, reduced the small 
combined effect size identified in the updated systematic review and meta-analysis  
(-0.82 [95% CI -1.44 to -0.20]) to -0.72 [95% CI -1.28 to -0.16] (Chapter 7). Differing 
results on pain between the current trial and previously published trials could be due 
to issues concerning the stimulation paradigm, trial participants, sample size, or 
statistical analyses. Disability had not been used as a primary outcome measure in 
any previous tDCS trial.   
 
8.2.1	  Differences	  regarding	  the	  stimulation	  paradigm	  
 
The stimulation paradigm (20 min, 2 mA, 5 consecutive days, anodal, M1) was 
selected based on the systematic review that indicated this particular paradigm as 
the most frequently applied and most effective paradigm in trials that reported a pain 
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reducing effect of tDCS in chronic clinical pain to date (Chapter 3). This allowed a 
direct comparison of trial results with evidence from the literature but did not exclude 
the possibility that more intense stimulation paradigms might result in a pain reducing 
effect. No previous trial used higher stimulation intensities on patients with chronic 
pain, but 5 trials reported more repetitions (10 stimulation days) (Antal et al., 2011;  
Auvichayapat et al., 2012; DaSilva et al., 2012; Soler et al., 2010; Valle et al., 2009) 
and 1 trial used a longer duration of 30 minutes (Boggio et al., 2009).  
 
Neurophysiological studies reported that the duration of the stimulation (Furubayashi 
et al., 2008; Nitsche et al., 2002) and repetitions of the stimulation (Monte-Silva et al., 
2013) increased the duration of the intervention effect. However, without an observed 
immediate effect, longevity of the results is arbitrary. Only 1 study has compared 
varying numbers of consecutive intervention sessions on chronic pain patients 
applied 3-14 sessions to NSCLBP patients, but with no indication that a higher 
number of stimulation sessions increased the intervention effect (O’Connell et al., 
2013). However, only 8 participants were included and 6 participants received more 
than 5 days of tDCS, therefore, the study can only serve as an indication that a more 
intense stimulation paradigm is not very likely to result in a pain reducing effect in 
NSCLBP. 
 
DLPFC and S1 are further accessible brain areas associated with pain processing 
(Nir et al., 2008; Ringler et al., 2003). Experimental pain trials reported an increased 
heat tolerance (Mylius et al., 2012) and heat pain thresholds (Boggio et al., 2008), as 
well as reduced unpleasantness when exposed to images of human pain after 
DLPFC stimulation (Boggio et al., 2009b). S1 stimulation increased cold detection 
thresholds in healthy participants (Grundmann et al., 2011). However, clinical pain 
trials reported no effect of DLPFC stimulation on acute post-operative pain (Dubois et 
al., 2013) and pain reductions in fibromyalgia patients after DLPFC stimulation were 
significantly lower than pain reductions after M1 stimulation (Fregni et al., 2006b; 
Valle et al., 2009). S1 had not been used  as a stimulation target in trials on clinical 
pain. These results indicate that DLPFC and S1 as alternative intervention targets 
are unlikely to result in more effective pain reduction than M1 stimulation. 
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8.2.2	  Inter-­‐study	  differences	  in	  trial	  participants	  	  
 
The current trial is the first RCT to exclusively investigate the effect of tDCS on 
NSCLBP. Only 2 previous publications on tDCS for the reduction of chronic pain 
included participants with CLBP. Antal et al. (2010) investigated a mixed population 
of CLBP (n=8) and other chronic pain (n=23) and patients. Results indicated a 
statistically significant pain reducing effect in the group that received anodal 
stimulation. However, the CLBP subgroup was too small to draw statistically 
significant conclusions. Furthermore, patients were not analysed separately, 
therefore the effect of anodal tDCS on CLBP could not be distinguished from the 
overall effect (Antal et al., 2010).  
 
A second trial focussed on the reduction of NSCLBP and found no effect of anodal 
tDCS compared with sham stimulation (O'Connell et al., 2013). The trial used an 
interrupted time series design, with 8 participants, who received sham stimulation 
until a randomly allocated day when the stimulation changed to verum mode. This 
approach resulted in a minimum of 3 and a maximum of 15 stimulation sessions per 
patient. The design did not allow the evaluation of a specific stimulation paradigm, as 
stimulation was applied with varying gaps (up to 6 days) between sessions. The 
small sample size was a further limitation of the trial, hence the effectiveness of tDCS 
on NSCLBP could not be evaluated. 
 
The current trial was specifically designed to assess the effectiveness of tDCS on 
pain and disability in NSCLBP. Consequently, the study population was carefully 
selected by defining clear eligibility criteria to achieve a level of homogeneity that 
reflected typical participants of a CBT programme and, thereby allowed transferability 
of the trial results to other CBT settings. This is therefore the first trial that allows 
clinically relevant conclusions to be drawn regarding the effectiveness of tDCS for the 
reduction of pain (and disability) in patients with NSCLBP. 
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8.2.3	  Differences	  regarding	  assessment	  of	  sample	  size	  	  
 
The current trial is the only tDCS trial to date that was adequately powered (based on 
a well justified sample size calculation (Section 4.9) to demonstrate a clinically 
meaningful effect on pain and disability. As critiqued in the systematic review and its 
update (Chapters 3 and 7) all published trials have been conducted using small and 
inadequate sample sizes. Sample size calculations (if reported) were based on TMS 
studies with large effect sizes and small standard deviations (Fregni et al., 2006b), or 
on previous publications of equally underpowered studies (Boggio et al., 2009a). 
Small sample sizes generally increase the Type II error (failure to reject a false null 
hypothesis) (Schulz and Grimes, 2005; Vickers, 2003), but can also lead to false-
positive results by inducing chance.  
 
8.2.4	  Differences	  regarding	  statistical	  analyses	  
 
Methodological problems in previous trials included inappropriate use of parametric 
statistical tests (e.g. repeated measures ANOVA) on small sample sizes and 
reported statistically significant results without consideration of the validity of 
assumptions underlying the use of the statistical tests. Repeated measures ANOVA 
conducted on small samples can inflate the Type I error (incorrect rejection of the 
assumption of no difference between groups), indicating a false-positive effect 
(Vasey and Thayer, 1987). In the current trial, all assumptions for the primary 
analysis of covariance (ANCOVA) were met (Section 6.4), thereby minimising 
chances for a Type I error within the limits pre-defined in the sample size calculation 
(Section 4.9). 
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8.3	  Effectiveness	  of	  tDCS	  on	  the	  disability	  associated	  with	  NSCLBP	  
 
Five days of anodal stimulation did not result in a statistically significant reduction of 
disability associated with NSCLBP. Disability was chosen as a primary outcome 
measure for the current trial to meet the requirements for a clinically relevant 
indicator of change in NSCLBP following outcome recommendations for trials in 
CLBP (Section 4.7). Although disability is correlated with pain intensity in patients 
with LBP (Hout et al., 2001; Kovacs et al., 2004), the effect of tDCS on disability is 
unknown: Disability has not been previously selected as a primary outcome measure 
in any published trial on tDCS. Two trials on tDCS for the reduction of pain did 
evaluate disability measured with the RMDQ as a secondary outcome measure. In a 
crossover trial on 7 participants with chronic pelvic pain, Fenton et al. (2009) found a 
reduction of 0.83 out of 24 points that was statistically significant but not clinically 
relevant. A second trial on 8 participants resulted in a reduction of 0.5 points in the 
sham group and 1.7 points in the anodal stimulation group (O'Connell et al., 2013). 
Results were not analysed for statistical significance between groups and 
recommended minimum clinically relevant change levels for the RMDQ of 4-5 points  
(Maughan and Lewis, 2010; Ostelo et al., 2008) were not achieved. Similar to these 
results, a small reduction of ODI of 1 point out of 50 (SD 3) in the sham group and 2 
points (SD 4) in the verum group were identified in the current trial, and did not reach 
statistical significance or clinical relevance (Section 6.4.3).  
 
8.4	  Effectiveness	  of	  tDCS	  in	  combination	  with	  CBT	  (on	  VAS	  and	  ODI)	  
 
Although both groups improved significantly after the CBT, there were no statistically 
significant differences between verum and sham stimulation (p=0.62 for pain and 
p=0.86 for disability). One previous trial applied tDCS in combination with a 
multidisciplinary intervention for the reduction of fibromyalgia pain (Riberto et al., 
2011). Twenty three patients were randomly assigned to weekly verum and sham 
stimulation sessions for 10 weeks during a multidisciplinary intervention. No effect for 
VAS was found, and disability was not measured. However, the SF-36 subscale for 
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pain showed a statistically significant effect of anodal stimulation compared to the 
sham group. This effect, however, should be interpreted with caution since the 
sample size calculation was based on a large effect size of 3 cm on a 0-10 cm VAS 
and SDs of 2.5. Furthermore, 2 outcome measures were presented (but not defined 
a priori) in the results section at an alpha level of 0.05 and a power of 80%. No 
adjustments for multiple testing were made, hence, reported results were based on 
an underpowered trial (Bender and Lange, 2001). The stimulation was applied once 
a week and patients received a total of 10 stimulation sessions. This stimulation 
paradigm is different from the paradigm used for the current trial, and therefore 
results are not directly comparable.  
 
Further research was published that combined tDCS with a second intervention, such 
as TENS for the reduction of chronic pain (Boggio et al., 2009a), motor learning 
exercises in stroke patients (case report) (Hummel and Cohen, 2005) and healthy 
participants (Kidgell et al., 2013), working memory training (Fregni et al., 2005), and 
tDCS as a preconditioning technique for TMS (Lang et al., 2004b; Moloney and 
Witney, 2013). All trials reported a statistically significant enhancing effect of tDCS on 
the subsequent intervention. However, a risk of bias assessment identified an 
unclear risk of bias for the domains sequence generation, allocation concealment, 
therapist blinding, assessor blinding, and incomplete outcome data for all trials. 
Sample sizes ranged from 1 to 15 participants. Fregni et al. (2005) applied tDCS to 
the DLPFC rather than M1; Lang et al. (2004) used a stimulation duration of 10 
minutes; and Moloney and Witney (2013) only found a pain reducing effect after 
cathodal tDCS. A further difference between the above trials and the current trial is 
that they performed tDCS during or minutes prior to the second intervention and the 
second intervention was of brief duration. In the current trial the second intervention 
(CBT) started a minimum of 24 hours after the stimulation and continued for 4 weeks. 
Based on the results of the current trial and on the results and methodological quality 
of trials combining tDCS with a second intervention, it is unlikely that tDCS applied 
immediately prior or during the CBT would change trial results. 
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8.5	  Exploratory	  analyses	  of	  secondary	  outcome	  measures	  
 
The RAND36 subscales physical functioning, general health, and emotional well-
being were the only secondary outcome measures to have a statistically significant 
time*group interaction. Post-hoc tests did not identify a statistically significant 
difference between groups at any time-point. The interaction was driven by a 
tendency towards better physical functioning, general health and emotional well-
being in the sham group at 24-weeks follow-up.  
 
8.6	  Side	  effects	  
 
No adverse events occurred in the current trial. However, during the majority of 
stimulation sessions (group sham: 89%; group verum: 75%) participants reported 
some type of sensory perception such as tingling, burning, or itching underneath the 
electrodes. These perceptions were rated as mild or moderate in intensity and no 
participant discontinued the stimulation. An overview of side effects and frequencies 
was reported (Table 6.9). All side effects reflected those published in previous trials 
investigating chronic pain populations (Antal et al., 2010; Boggio et al., 2009a; 
Fenton et al., 2009; Fregni et al., 2006a; Fregni et al., 2006b; Mori et al., 2009; Soler 
et al., 2010; Valle et al., 2009) but only 1 publication on chronic pain patients 
reported a similarly high incidence (Antal et al., 2010). A high incidence of sensory 
side effects was also found in a large trial on healthy participants (Kessler et al., 
2012). Both research groups that reported a high incidence of side effects used the 
same questionnaire as that used for the evaluation of side effects in the current trial. 
All other publications reported only verbally asking participants about side effects. 
The questionnaire listed a range of potential side effects, thereby directing a 
participant's attention to potential side effects including unspecific perceptions such 
as tiredness or feeling cold. The expectation of side effects increases the likelihood 
for participants to experience such perceptions (Faasse and Petrie, 2013). This effect 
is known as the nocebo response (Benedetti et al., 2007; van Laarhoven et al., 
2011). Side effects were less frequent but had the same quality and intensity in the 
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sham stimulation group. In particular, sensory effects under the electrode were 
perceived in the sham stimulation group because the machine was programmed to 
intentionally provoke these perceptions in the initial 30 seconds of the stimulation. 
This indicates the effectiveness of participant blinding in the sham condition. 
 
8.7	  Blinding	  of	  patients	  and	  researchers	  
 
Sham stimulation as used in the current trial is regarded as a reliable placebo 
condition (Gandiga et al, 2006) and has been used by all authors that evaluated the 
effect of tDCS on chronic or experimental pain (Tables 3.3 and 3.4). Towards the end 
of the data collection for the current trial, a discussion on the effectiveness of blinding 
of participants and researchers was triggered by a publication that raised doubt about 
the reliability of the sham stimulation, mainly due to a higher rate of skin redness 
underneath the electrodes after the verum stimulation (O'Connell et al., 2012). Some 
authors further reported that trial participants, who had experienced tDCS before,  
might be able to distinguish between verum and sham stimulation even at a low 
intensity of 1 mA, due to skin perceptions (Ambrus et al., 2012); others confirmed 
effective participant (but not researcher) blinding at 2 mA (Palm et al., 2013).  
 
The effectiveness of therapist blinding was addressed by documenting (for the 
remaining data collection period) what type of stimulation researchers believed the 
participant had received. One rating per patient was obtained for the stimulation type 
that the researcher believed they had applied. Researchers also rated whether they 
had observed skin redness after the stimulation. Participants rated on each day of 
the stimulation which stimulation type they believed they had received. To evaluate 
whether participants and researcher could guess the stimulation type on a greater 
number of occasions than would be expected by chance and to evaluate skin 
redness after the stimulation, the answers were analysed by calculating the kappa 
coefficient of agreement for each day of the stimulation (O'Connell et al., 2012; 
Landis and Koch, 1977). 
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Five hundred and eighty seven participant ratings (1 rating per participant per day of 
stimulation) were available, and indicated what stimulation type participants believed 
they had received. Seventy five percent of the participant ratings (n=442) indicated 
that participants believed they had received verum stimulation. Agreement for 
guessed and received stimulation type was poor to slight, indicating effective 
participant blinding in the current trial (Table 8.1). 
 
 
Table 8.1 Effectiveness of participant blinding  
 Day 1 
(n=112) 
Day 2 
(n=120) 
Day 3 
(n=124) 
Day 4 
(n=118) 
Day 5 
(n=120) 
Agreement between 
guessed and received 
stimulation 
κ=0.111 κ=0.000 κ=-0.014 κ=-0.007 κ=-0.120 
Interpretation 
(Landis and Koch, 
1977) 
slight  
agreement 
slight  
agreement 
poor 
agreement 
poor 
agreement 
poor 
agreement 
 
Footnotes: κ=kappa coefficient 
 
 
Thirty one researcher ratings were available (1 researcher rating per participant). The 
kappa coefficient for correctly guessed intervention groups was κ= 0.103. This result 
is interpreted as slight agreement indicating effective researcher blinding (Landis and 
Koch, 1977). The kappa coefficient for skin reactions observed after the verum 
stimulation was κ= 0.671 (p= 0.003), which was considered as "substantial 
agreement" and indicated more skin reactions in the verum group compared to the 
sham group (Landis and Koch, 1977). Participant and researcher blinding in the 
current trial was therefore effective despite the higher rate of skin redness 
underneath the electrodes after verum stimulation. Participants did not guess the 
stimulation mode more correctly towards the end of the stimulation period. This 
indicated that participants did not "learn" to detect the stimulation mode during the 5 
day tDCS period (Table 8.1).  
 
The literature reporting the reliability of the sham condition referred to different tDCS 
machines. The machines that applied a brief period of stimulation and had to be 
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manually switched off by the researchers for the sham condition (Ambrus et al., 
2012; O'Connell et al., 2012; O'Connell et al., 2013) were less effective in blinding 
participants than the machine used by Palm et al. (2013) and for the current trial. 
This newer machine provided a study mode that for sham stimulation automatically 
switched off after a ramping up and a brief stimulation phase, while continuing to 
indicate the time elapsed and impedance on the display. This had the benefit that 
participants could not detect the "switching-off action" and continued to watch an 
active display. The study mode further allowed blinding of the person who applied the 
stimulation. The current trial indicated slight agreement between researcher rating 
and stimulation type, due to observed reddening of the skin under the electrodes that 
occurred more frequently in the anodal stimulation group. Other authors reported 
insufficient blinding due to such skin reactions (O'Connell et al., 2012; Palm et al., 
2013) or recommended that the stimulation sites should be covered after the 
intervention (Palm et al., 2013). In the current trial blinding of the researcher was 
more effective since the decision whether verum or sham stimulation had been 
applied was based not only on redness of the skin but also on other issues including 
tingling and itching reported by the participant.  
 
There was also a difference in the attachment technique between the 2 trials and the 
current trial that highlighted skin reactions as a risk to researcher blinding (O'Connell 
et al., 2012; Palm et al., 2013). The 2 trials that reported reddening of the skin only in 
the verum group used soft elastic straps or rubber bands to secure the electrodes. 
This had resulted in a large number of automatically terminated stimulations due to 
impedance levels exceeding the permitted range and automatically switching off the 
machine in pilot experiments preceding the current trial. To reduce the number of 
automatically terminated stimulations, elastic bandages were used that allowed for a 
closer contact of the electrodes to the skin and thereby better impedance levels. The 
elastic bandages had to be attached very tightly to the head. The compression to the 
skin left red marks on most participants and made it less likely for researchers to 
distinguish these from redness due to the stimulation mode.  
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8.8	  Reduction	  of	  pain	  and	  disability	  in	  the	  sham	  stimulation	  group	  
 
In the current trial, an improvement of 7 mm (SD 16) on the 0-100 mm VAS pain was 
found in the sham group immediately after the stimulation, corresponding to a 15% 
reduction of pain intensity from baseline. Disability improved by a mean difference of 
1 point (SD 3) on the 0-50 ODI, corresponding to a reduction of 9% from baseline. 
This is an interesting finding not attributable to the stimulation itself. Authors have 
attributed this effect to natural pain fluctuation, regression to the mean, or other 
influences such as responses influenced by politeness or gratefulness for the chance 
to try a new treatment approach or to receive extra attention (Ernst and Resch, 1995; 
Kienle and Kiene, 1997). These influences have previously been referred to as "the 
healing situation" (Papakostas et al., 2001). The healing situation in the current trial 
was identical for both groups. Previous trials found a pain reduction after sham tDCS 
of 18.9% (Antal et al., 2010) and 23.7% (Mori et al., 2009) while O'Connell et al. 
(2013) reported a negligible reduction in a trial on NSCLBP patients. The negligible 
reduction in the trial by O’Connell et al. (2013) was explained by the authors through 
questioning participant blinding.  
 
8.9	  Neurophysiological	  working	  mechanisms	  and	  explanations	  for	  the	  
lack	  of	  a	  stimulation	  effect	  	  
 
Working mechanisms for anodal tDCS over the M1 are still not fully understood 
(Knotkova et al., 2013; Medeiros et al., 2012). Previous research has identified local 
and referred working mechanisms, and the resulting pain control mechanisms are 
hypothetical or inferred from investigations on invasive MCS.  
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8.9.1	  Local	  working	  mechanisms	  
 
It is generally acknowledged that anodal tDCS results in an excitatory effect on 
cortical structures underneath the electrode, partially spreading to surrounding tissue 
(Antal et al., 2010; Lang et al., 2004a; Nitsche and Paulus, 2000; Suzuki et al., 2012). 
Cortical responses to tDCS have been well documented using various techniques. 
MEP studies consistently showed altered cortical activation as summarised in a 
recent systematic review (Bastani and Jaberzadeh, 2012). PET studies indicated an 
altered regional blood flow (Zheng et al., 2011) that was mainly observed during a 
task specific for the stimulated region (e.g. motor task during M1 stimulation) 
(Paquette et al., 2011). Only fMRI studies found conflicting results regarding the 
measured response in regional brain activation during and after anodal stimulation 
(Antal et al., 2011; Baudewig et al., 2001; Kwon et al., 2008). Inconsistencies 
between fMRI and MEP studies were explained by the differences in 
neurophysiological activity measured by the techniques: MEP measures the synaptic 
excitability of the pyramidal tract neurones (Rothwell et al., 1991) while fMRI 
measures the activity within the cortical network (Ogawa et al., 1990).  
 
8.9.2	  Referred	  working	  mechanisms	  
 
Evidence suggested that the application of tDCS influenced neurotransmitter 
systems, important for the communication within and descending from the brain, 
including dopamine, acetylcholine, and serotonin (Kuo et al., 2007; Monte-Silva et al., 
2009; Nitsche et al., 2009). It was further reported to affect sodium and calcium 
channels and to interfere with the synaptic modulation (Medeiros et al., 2012). 
Studies that combined tDCS with pharmacological interventions identified a 
modifying influence on the neurotransmitter GABA and on NMDA receptors 
(Liebetanz et al., 2002; Nitsche et al., 2004; Tremblay et al., 2013); both closely 
linked to pain transmission (Cao et al., 2011).  
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8.9.3	  Hypotheses	  for	  pain	  control	  mechanisms	  
 
8.9.3.1	  Activation	  of	  the	  endogenous	  opioid	  system	  	  
 
Invasive MCS enhanced the activity of the endogenous opioid system in animal 
studies (Fonoff et al., 2009). Researchers attributed the effect to the opioid system by 
abolishing the stimulation induced pain reduction with opioid receptor blocking 
medication (naloxone). The effect of invasive MCS on the opioid system in humans 
was hypothesised, based on post stimulation changes of the periaqueductal grey, an 
area associated with endogenous opioid system observed in PET studies (Chiou et 
al., 2013; Maarrawi et al., 2007). One case study replicated this effect for tDCS in a 
PET study using an opioid receptor selective radiotracer. Authors reported changes 
in the periaqueductal grey and an immediate increase in opioid release post 
stimulation (DosSantos et al., 2012). Larger studies are required to further investigate 
the endogenous opioid system as a working mechanism for pain reduction following 
tDCS. 
 
8.9.3.2	  Modulation	  of	  the	  emotional	  appraisal	  of	  pain	  	  
 
Modulation of the emotional appraisal of pain was proposed as a working mechanism 
based on PET studies that showed a correlation between the level of pain relief 
during invasive MCS and an activation of the cingulate and orbitofrontal regions 
(Garcia-Larrea et al., 1999; Garcia-Larrea and Peyron, 2007). The proposed 
mechanism of action was an activation of these regions due to MCS resulting in a 
reduction of pain caused by a modulation of the emotional appraisal of pain. 
However, the cingulate and prefrontal regions have previously been shown to also 
correlate also with perceived control over pain (Wiech et al., 2006). Reported results, 
therefore might have been the consequence of the perceived pain reduction and not 
the effect of the stimulation. Furthermore, it has not been investigated whether tDCS 
also activates the cingulate and orbitofrontal regions. Further research is required to 
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clarify the role of specific brain areas for the emotional appraisal of pain and the 
capacity of brain stimulation techniques to influence activities. 
 
8.9.3.3	  Activation	  of	  the	  descending	  pain	  inhibiting	  network	  	  
 
Descending inhibition is the most described working mechanism for invasive MCS 
and tDCS (Knotkova et al., 2013; Medeiros et al., 2012; Garcia-Larrea and Peyron, 
2007). It is also known as central pain modulation and relies on the concept that 
altered cortical activity leads to a descending cascade of events, consequently 
resulting in pain relief (Ossipov et al., 2010). M1 is the origin of the descending 
cortico-thalamic pathway. Polania et al. found an increased functional coupling of M1 
and the thalamus after anodal tDCS over M1 (Polania et al., 2011) and further 
evidence suggested a spreading of electrical currents to subcortical areas distant 
from the stimulation site (Lang et al., 2005; Reidler et al., 2012). Modulation of the H-
reflex in the quadriceps muscle indicated that the cascade of effects from tDCS 
descended as far down as the leg via the spinal pathway in healthy participants 
(Roche et al., 2011). However, evidence that these remote neurophysiological effects 
lead to pain reduction relied on studies with controversial results using experimental 
pain or pain thresholds (Luedtke et al., 2012; Jurgens et al., 2012; Grundmann et al., 
2011; Bachmann et al., 2011; Csifcsak et al., 2009; Boggio et al., 2008; Antal et al., 
2008). Recent data showed that healthy participants responded to tDCS during fMRI 
scanning with distinct cortical activations but did not show a reduction of the 
perceived intensity of experimental pain measured by a quantitative sensory testing 
protocol (including pain and perception thresholds and thermal and cold pain) (Ihle et 
al., 2014). In participants with spinal cord injury, EEG data indicated altered brain 
activity following tDCS that was not correlated with changes in clinical pain 
perception (Jensen et al., 2013). In summary, there is sufficient evidence to support a 
reliable cortical and subcortical neurophysiological response to tDCS, but alterations 
in pain perception were absent or inconsistent. Consequently, descending 
mechanisms can be activated by tDCS, but do not consistently result in the 
modulation of pain perception. 
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8.10	  Implications	  for	  the	  use	  of	  tDCS	  in	  chronic	  clinical	  pain	  	  
 
Chronic pain is associated with multidimensional central and peripheral changes 
(Apkarian et al., 2010; Baliki et al., 2006, 2011; Cedraschi and Allaz, 2005; 
Heneweer et al., 2007; Linton, 2000; Martelli et al., 2004; May, 2008). Specific brain 
areas associated with chronic pain were identified by investigating anatomical 
changes (e.g. loss of grey matter) (Apkarian et al., 2004; Baliki et al., 2011; May, 
2008) and functional changes (activity of brain regions as a response to a painful 
stimulus) (Baliki et al., 2006; Kobayashi et al., 2009; May, 2007). Both techniques 
demonstrated a distinct pattern of altered brain regions in chronic pain including the 
spino-thalamic tract, the lateral thalamus, somatosensory areas and the posterior 
insula (Moisset and Bouhassira, 2007) that only partially overlapped with those 
affected by anodal tDCS over M1. Other regions involved in sensory-discriminative 
pain processing, such as the S1 and secondary somatosensory cortex (Gustin et al., 
2013; Kong et al., 2013; Vartiainen et al., 2009), have never been shown to be 
modulated by anodal tDCS over M1. A simple explanation why tDCS cannot 
consistently reduce pain is, therefore, that the stimulation cannot alter all brain 
regions associated with sensory-discriminative pain processing. Depending on the 
individual's cognitions, emotions and alterations in central pain processing, regions 
other than M1 (and associated cortico-thalamic tract) might support ongoing pain 
perception. Secondly, there is no evidence regarding how and to what extent tDCS 
passes through the thalamus, the brainstem, and the spinal cord, regions known to 
be important for the processing of pain.  
 
Additionally, a range of psychological factors have been described to be predictive 
for the transition from acute to chronic pain, such as depression and maladaptive 
cognitions or work related factors (Carragee et al., 2005; Cedraschi and Allaz, 2005; 
Heneweer et al., 2007; Linton, 2000; Martelli et al., 2004; Melloh et al., 2009). M1 
tDCS does not alter cognitive and affective brain networks: While shown to improve 
clinical depression when applied to the DLPFC (Berlim et al., 2013), no published 
research has reported an influence of M1 tDCS on psychological aspects. 
Consequently, tDCS results in measurable neurophysiological changes within the 
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brain and in remote areas of the nervous system but does not influence pain 
perception or disability due to the multi-layered factors that result in and maintain a 
chronic pain condition. 
 
8.11	  Limitations	  	  
 
8.11.1	  Limitations	  of	  the	  trial	  
 
All care was taken to design and conduct a RCT of high methodological standard. 
However, the RCT was conducted within a clinical and not a laboratory environment, 
resulting in practicability issues that limited the trial design but had the advantage of 
a direct transferability of trial results to clinical practice. Feasibility and ethical 
considerations required that all participants received CBT after the stimulation. CBT 
was the standard management for patients at the study site and it was neither 
feasible nor ethical to deprive patients of this management or to postpone the CBT. 
Consequently, no long-term effects of tDCS alone were evaluated.  
 
A key limitation is that the trial was conducted at only 1 study centre. This might 
reduce the generalisability of the results despite the clear definition and description of 
the inclusion and exclusion criteria and trial procedures. The back pain clinic and the 
CBT programme were developed following international and national examples of 
chronic pain management programmes. It can be viewed, therefore, as a 
representative example of a back pain clinic applying CBT. A final limitation is that 
cost-effectiveness could not be evaluated due to the German data protection act that 
does not allow access to patients’ health files to evaluate doctor visits and further 
health care use. Data collected for medication use and number of physician visits 
based on patient recall have previously been evaluated as unreliable. 
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8.12.	  Recommendations	  for	  future	  research	  
	  
Based on the results of the RCT reported in this thesis and on the systematic review 
of the currently available literature on tDCS for pain reductions, tDCS is not effective 
for the treatment of clinical pain and does not consistently reduce experimentally 
induced pain. It is highly unlikely that altered stimulation paradigms, such as longer 
duration, higher intensities or a different stimulation target will increase its 
effectiveness. Future research on tDCS should therefore focus on different clinical 
conditions such as stroke, Parkinson’s disease or dementia. Research in these areas 
is in its preliminary phase with few small scale trials indicating clinical improvements 
of the conditions. However, without a low risk of bias and adequately powered RCT, 
there is only a low level of evidence for its effectiveness. 
 
Regarding chronic pain research, future research should further attempt to identify 
interventions that might improve the outcomes of CBT. These should continue to 
target pain processing within the central nervous system and effects of the 
intervention on pain processing within the brain should be monitored. A range of 
interventions has been proposed such as graded motor imagery, including left/right 
recognition and mirror therapy as well as sensory perception interventions.  
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Chapter Summary 
 
This was the first adequately powered and low risk of bias trial to investigate the 
effectiveness of anodal tDCS over M1 for the reduction of pain and disability in a 
population of NSCLBP patients. Trial results indicated that tDCS compared to sham 
stimulation was ineffective to change both primary outcome measures and did not 
influence the outcome of a CBT. Participants perceived a range of side effects but 
these were of mild to moderate intensity. Blinding of participants and researchers 
was evaluated following a recent discussion on the reliability of sham stimulation. 
Participants and researchers were effectively blinded in the current trial. 
Neurophysiological hypotheses as to why tDCS did not effectively reduce pain in 
NSCLBP patients were based on the multidimensional nature of the pain experience. 
While the literature reported a measurable response to tDCS in brain regions 
underneath the electrodes, it was not sufficient to alter the perception of pain or to 
change perceived disability. Trial results did not support the use of tDCS for the 
reduction of pain and disability in NSCLBP.  
 
	   	  
 185 
9.	  CHAPTER	  	  	  
 
CONCLUSIONS	  
 
This PhD aimed to evaluate the effectiveness of tDCS on pain and disability in 
patients with NSCLBP. It provided an overview of the published literature (overview 
of reviews and a systematic review of clinical trials) on the effectiveness of tDCS for 
the reduction of pain. Findings from the systematic review informed the design and 
methods for a RCT investigating the effectiveness of tDCS for pain and disability in a 
NSCLBP population. The trial was preceded by a feasibility study that evaluated 
practical aspects of trial procedures and the acceptability of tDCS as an intervention 
for NSCLBP. The results of the main trial were presented. The systematic review was 
updated. Trial results and limitations were discussed within the context of the 
updated systematic review, representing current evidence. Possible explanations for 
the non-significant effect of tDCS were explored from a neurophysiological 
perspective.    
   
The initial systematic review (Chapter 3) revealed a high scientific interest in tDCS as 
a pain reducing intervention, as indicated by the large number of trials being 
published each year. Preliminary evidence was provided for a pain reducing effect for 
a variety of chronic pain disorders that raised hope for a new and effective tool in the 
management of chronic pain. However, the systematic review and meta-analysis of 
published trials revealed an unclear or high risk of bias in most trials due to 
methodological issues such as non-randomised sequence generation or 
unconcealed allocation to intervention groups. The external validity of reviewed trials 
was also unclear owing to small sample sizes based on unknown effect sizes of 
tDCS for the reduction of pain. The meta-analysis of trials on clinical pain showed a 
small pain reducing effect that was lower than minimum clinically relevant change 
recommendations. The overall level of evidence was rated as "low" according to 
GRADE (Guyatt et al., 2008). The systematic review of trials on the reduction of 
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experimental pain in healthy participants showed that trials could not be combined in 
a meta-analysis because stimulation paradigms, experimental pain conditions, and 
outcome measures were too diverse. Based on these results and on doubts about 
the transferability of data produced by experimental pain studies into clinically 
meaningful results, a RCT on tDCS for the reduction of NSCLBP was designed 
(Chapter 4). It was the first RCT that focussed exclusively on NSCLBP and the first 
clinical trial that showed a low risk of bias. Furthermore, it was the first adequately 
powered clinical trial on tDCS for the reduction of pain using a sample size 
calculation that was based on clinically relevant change recommendations and on 
previous trials on tDCS as well as on NSCLBP.  
 
A feasibility study indicated that planned trial procedures were feasible to conduct in 
practice and showed good patient acceptability for tDCS as an intervention for 
NSCLBP (Chapter 5). It further detected that potential trial participants had pain and 
disability values that were lower than anticipated and that they did not allow for an 
improvement that satisfied minimum clinically relevant change recommendations. 
Subsequently, the inclusion criteria for the trial were amended to include a minimum 
level of VAS pain of 15 mm and a minimum ODI score of 8 points.  
 
The results of the main trial (Chapter 6) indicated that tDCS was not effective to 
reduce pain or disability in patients with NSCLBP and that tDCS in combination with 
a CBT did not improve the outcome of the CBT. No adverse events were observed 
(defined as the participant requiring medical attention) but mild side effects were 
reported during / after most stimulation sessions. Participant, researcher, and 
assessor blinding was effective throughout the trial contrary to recently published 
doubts on the validity of the sham stimulation paradigm in tDCS research (O'Connell 
et al., 2012). 
 
The systematic review of recent clinical trials on tDCS (Chapter 7) showed that 
results differed widely regarding the effectiveness of tDCS for pain reduction. Since 
the cut off date for the initial systematic review, negative results on the effectiveness 
of tDCS had been published, but the level of evidence was still low due to an unclear 
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or high risk of bias in all trials. The updated meta-analysis of published trials showed 
a combined mean effect of tDCS for the reduction of pain that was below 1 mm on a 
0-10 mm VAS. Including the results of the current trial into the meta-analysis resulted 
in an even smaller effect size. Interestingly, all recent positive results were reported 
by 1 research team, an issue that compromises the credibility of the results in the 
light of the negative results published by other research teams. The systematic 
review of recent trials further indicated that experimental pain trials still have not 
agreed on a stimulation mode, duration, location or intensity that can be regarded as 
consistently effective for the reduction of experimental pain perception or the 
increase of pain thresholds. Owing to the diversity in outcome measures it was  
impossible to combine experimental pain trial results in a meta-analysis. 
  
Trial results clearly indicated that anodal tDCS, applied over M1 with an intensity of 2 
mA on 5 consecutive days for 20 min each day, was ineffective for the reduction of 
the pain intensity and disability in participants with NSCLBP and did not improve the 
outcome of CBT. Results from the updated meta-analysis additionally showed that 
the combined effect of anodal tDCS over M1 for the reduction of clinical pain, 
independent of the intensity, duration and frequency of the stimulation was smaller 
than 1 mm on a 0-10 mm VAS (Chapter 7). The current trial raised the level of the 
current evidence from "low" to "high" using the GRADE approach, since evidence 
was now based on 1 low risk of bias RCT. This can be interpreted as confidence that 
future research is unlikely to change the combined mean effect of tDCS for the 
reduction of clinical pain. The clinical use of tDCS can therefore not be 
recommended. 
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APPENDICES	  
 
Appendix 2.1 Search history for Ovid  
 
 
Search History  (8 searches)  
 
Searches Results 
1 pain.mp. [mp=ab, ti, ot, bt, hw, sh, tn, dm, mf, dv, kw, ps, 
rs, nm, an, ui, tx, ct, tc, id, tm] 
1224640 
2 brain.mp. [mp=ab, ti, ot, bt, hw, sh, tn, dm, mf, dv, kw, ps, 
rs, nm, an, ui, tx, ct, tc, id, tm] 
2597630 
3 (tDCS or transcranial direct current or direct current).mp. 
[mp=ab, ti, ot, bt, hw, sh, tn, dm, mf, dv, kw, ps, rs, nm, an, 
ui, tx, ct, tc, id, tm] 
12784 
4 (noninvasive or non-invasive).mp. [mp=ab, ti, ot, bt, hw, sh, 
tn, dm, mf, dv, kw, ps, rs, nm, an, ui, tx, ct, tc, id, tm] 
246025 
5 1 and 2 and 3 and 4 177 
6 review.mp. [mp=ab, ti, ot, bt, hw, sh, tn, dm, mf, dv, kw, ps, 
rs, nm, an, ui, tx, ct, tc, id, tm] 
4984586 
7 5 and 6 117 
8 remove duplicates from 8 101 
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Appendix 2.2 Critical appraisal tool for the assessment of the methodological quality of systematic 
reviews (AMSTAR) 
 
 
1. Was an ‘a priori’ design provided? 
The research question and inclusion criteria should be established before the 
conduct of the review.    
Yes 
No 
Can’t answer 
Not applicable 
2. Was there duplicate study selection and data extraction? 
There should be at least 2 independent data extractors and a consensus 
procedure for disagreements should be in place. 
Yes 
No 
Can’t answer 
Not applicable 
3. Was a comprehensive literature search performed? 
At least 2 electronic sources should be searched. The report must include 
years and databases used (e.g. Central, EMBASE, and MEDLINE). Key 
words and/or MESH terms must be stated and where feasible the search 
strategy should be provided. All searches should be supplemented by 
consulting current contents, reviews, textbooks, specialized registers, or 
experts in the particular field of study, and by reviewing the references in the 
studies found. 
Yes 
No 
Can’t answer 
Not applicable 
4. Was the status of publication (i.e. grey literature) used as an inclusion 
criterion? 
The authors should state that they searched for reports regardless of their 
publication type. The authors should state whether or not they excluded any 
reports (from the systematic review), based on their publication status, 
language etc. 
Yes 
No 
Can’t answer 
Not applicable 
5. Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. 
Yes 
No 
Can’t answer 
Not applicable 
 6. Were the characteristics of the included studies provided? 
In an aggregated form such as a table, data from the original studies should 
be provided on the participants, interventions and outcomes. The ranges of 
characteristics in all the studies analyzed e.g. age, race, sex, relevant 
socioeconomic data, disease status, duration, severity, or other diseases 
should be reported.  
Yes 
No 
Can’t answer 
Not applicable 
 
7. Was the scientific quality of the included studies assessed and 
documented? 
‘A priori’ methods of assessment should be provided (e.g., for effectiveness 
studies if the author(s) chose to include only randomized, double-blind, 
placebo controlled studies, or allocation concealment as inclusion criteria); for 
other types of studies alternative items will be relevant. 
 
Yes 
No 
Can’t answer 
Not applicable 
  III 
 
8. Was the scientific quality of the included studies used appropriately in 
formulating conclusions? 
 The results of the methodological rigor and scientific quality should be 
considered in the analysis and the conclusions of the review, and explicitly 
stated in formulating recommendations. 
 
Yes 
No 
Can’t answer 
Not applicable 
9. Were the methods used to combine the findings of studies 
appropriate? 
For the pooled results, a test should be done to ensure the studies were 
combinable, to assess their homogeneity (i.e. Chi-squared test for 
homogeneity, I²). If heterogeneity exists a random effects model should be 
used and/or the clinical appropriateness of combining should be taken into 
consideration (i.e. is it sensible to combine?). 
Yes 
No 
Can’t answer 
Not applicable 
10. Was the likelihood of publication bias assessed? 
An assessment of publication bias should include a combination of graphical 
aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger 
regression test).   
Yes 
No 
Can’t answer 
Not applicable 
 
11. Was the conflict of interest stated? 
Potential sources of support should be clearly acknowledged in both the 
systematic review and the included studies. 
 
Yes 
No 
Can’t answer 
Not applicable 
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Appendix 2.3 List of included and excluded reviews 
 
 
Included: 
Antal, A and Paulus, W. Transkranielle Gleichstromstimulation: Neues Werkzeug in der 
Schmerztherapie? Transcranial Direct Current Stimulation: A New Method in the Therapy of 
Pain? 2007; 34: 530-533. 
 
Antal, A and Paulus, W. [Transcranial magnetic and direct current stimulation in the therapy of pain]. 
Schmerz 2010; 24: 161-166. 
 
Arul-Anandam, AP, Loo, C and Sachdev, P. Transcranial direct current stimulation - what is the 
evidence for its efficacy and safety? F1000 Med Rep 2009; 1. 
 
Been, G, Ngo, TT, Miller, SM and Fitzgerald, PB. The use of tDCS and CVS as methods of non-
invasive brain stimulation. Brain Res Rev 2007; 56: 346-361. 
 
Fregni, F, Freedman, S and Pascual-Leone, A. Recent advances in the treatment of chronic pain with 
non-invasive brain stimulation techniques. Lancet Neurol 2007; 6: 188-191. 
 
Fregni, F and Pascual-Leone, A. Technology insight: noninvasive brain stimulation in neurology-
perspectives on the therapeutic potential of rTMS and tDCS. Nat Clin Pract Neurol 2007; 3: 
383-393. 
 
Jensen, MP, Hakimian, S, Sherlin, LH and Fregni, F. New insights into neuromodulatory approaches 
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